Targeting MicroRNAs for Metabolic Disorders

ABSTRACT

Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing inelectronic format. The Sequence Listing is provided as a file entitledETHZ0001WOSEQ.txt, created on May 19, 2010 which is 4 Kb in size. Theinformation in the electronic format of the sequence listing isincorporated herein by reference in its entirety.

FIELD OF INVENTION

Provided herein are methods and compositions for the treatment ofmetabolic disorders.

DESCRIPTION OF RELATED ART

MicroRNAs (miRNAs), also known as “mature miRNA” are small(approximately 18-24 nucleotides in length), non-coding RNA moleculesencoded in the genomes of plants and animals. In certain instances,highly conserved, endogenously expressed miRNAs regulate the expressionof genes by binding to the 3′-untranslated regions (3′-UTR) of specificmRNAs. More than 1000 different miRNAs have been identified in plantsand animals. Certain mature miRNAs appear to originate from longendogenous primary miRNA transcripts (also known as pri-miRNAs,pri-mirs, pri-miRs or pri-pre-miRNAs) that are often hundreds ofnucleotides in length (Lee, et al., EMBO J., 2002, 21(17), 4663-4670).

Functional analyses of miRNAs have revealed that these small non-codingRNAs contribute to different physiological processes in animals,including developmental timing, organogenesis, differentiation,patterning, embryogenesis, growth control and programmed cell death.Examples of particular processes in which miRNAs participate includestem cell differentiation, neurogenesis, angiogenesis, hematopoiesis,and exocytosis (reviewed by Alvarez-Garcia and Miska, Development, 2005,132, 4653-4662).

Families of miRNAs can be characterized by nucleotide identity atpositions 2-8 of the miRNA, a region known as the seed sequence. Lewiset al. describe several miRNA families, as well as miRNA superfamilies,which are characterized by related seed sequences (Lewis et al. Cell.2005, 120(1):15-20). MicroRNAs miR-103 and miR-107 are family members,as they have identical seed regions. Thus these two microRNAs willregulate similar, if not identical, sets of target genes.

SUMMARY OF INVENTION

Provided herein are methods for treating metabolic disorders, andconditions associated with metabolic disorders, comprising administeringa compound comprising an oligonucleotide targeted to a microRNA. Incertain embodiments, the microRNA is miR-103. In certain embodiments,the microRNA is miR-107.

Provided herein are methods for reducing a blood glucose level of asubject comprising administering to the subject a compound comprising anoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence complementary to miR-103, miR-107 or to a precursorof miR-103 or miR-107; and thereby reducing the blood glucose level ofthe subject.

Provided herein are methods for reducing blood glucose level of asubject comprising administering to the subject a compound comprising anoligonucleotide consisting of 7 to 12 linked nucleosides and having anucleobase sequence complementary to miR-103 and miR-107, therebyreducing the blood glucose level of the subject.

In certain embodiments, the subject has an elevated blood glucose level.In certain embodiments, the methods comprise measuring the blood glucoselevel of the subject. In certain embodiments, the methods compriseselecting a subject having an elevated blood glucose level. In certainembodiments, the blood glucose level is a fasted blood glucose level. Incertain embodiments, the blood glucose level is a post-prandial bloodglucose level. In certain embodiments, the blood glucose level is awhole blood glucose level. In certain embodiments, the blood glucoselevel is a plasma blood glucose level.

In certain embodiments, the blood glucose level is reduced to below 200mg/dL. In certain embodiments, the blood glucose level is reduced tobelow 175 mg/dL. In certain embodiments, the blood glucose level isreduced to below 150 mg/dL. In certain embodiments, the blood glucoselevel is reduced to below 125 mg/dL. In certain embodiments, the bloodglucose level is reduced to below 120 mg/dL. In certain embodiments, theblood glucose level is reduced to below 115 mg/dL. In certainembodiments, the blood glucose level is reduced to below 110 mg/dL. Incertain embodiments, the blood glucose level is reduced to below 105mg/dL. In certain embodiments, the blood glucose level is reduced tobelow 100 mg/dL. In certain embodiments, the blood glucose level isreduced to below 110 mg/dL.

Provided herein are methods for preventing or delaying the onset of anelevated blood glucose level in a subject at risk for developing anelevated glucose level comprising administering to the subject acompound comprising an oligonucleotide consisting of 12 to 30 linkednucleosides and having a nucleobase sequence complementary to miR-103,miR-107, or a precursor of miR-103 or miR-107; and, thereby preventingor delaying the onset of an elevated blood glucose level in the subject.

Provided herein are methods for preventing or delaying the onset of anelevated blood glucose level in a subject at risk for developing anelevated glucose level comprising administering to the subject acompound comprising an oligonucleotide consisting of 7 to 12 linkednucleosides and having a nucleobase sequence complementary to miR-103and miR-107, thereby preventing or delaying the onset of an elevatedblood glucose level in the subject.

Provided herein are methods for reducing gluconeogenesis in a subjectcomprising administering to the subject a compound comprising anoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence complementary to miR-103, miR-107 or a precursor ofmiR-103 or miR-107; and thereby reducing gluconeogenesis in the subject.In certain embodiments, the subject has elevated gluconeogenesis.

Provided herein are methods for reducing gluconeogenesis in a subjectcomprising administering to the subject a compound comprisingadministering to the subject a compound comprising an oligonucleotideconsisting of 7 to 12 linked nucleosides and having a nucleobasesequence complementary to miR-103 and miR-107; and thereby reducinggluconeogenesis in the subject.

Provided herein are methods for improving insulin sensitivity in asubject comprising administering to the subject a compound comprising anoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence complementary to miR-103, miR-107 or a precursor ofmiR-103 or miR-107; and thereby improving insulin sensitivity in thesubject. In certain embodiments, the subject has insulin resistance. Incertain embodiments, the methods comprise selecting a subject havinginsulin resistance.

Provided herein are methods for improving insulin sensitivity in asubject comprising administering to the subject a compound comprisingadministering to the subject a compound comprising an oligonucleotideconsisting of 7 to 12 linked nucleosides and having a nucleobasesequence complementary to miR-103 and miR-107; and thereby improvinginsulin sensitivity in the subject.

Provided herein are methods for preventing or delaying the onset ofinsulin resistance in a subject at risk for developing insulinresistance comprising administering to the subject a compound comprisingan oligonucleotide consisting of 12 to 30 linked nucleosides and havinga nucleobase sequence complementary to miR-103, miR-107 or a precursorof miR-103 or miR-107; and thereby preventing or delaying the onset ofinsulin resistance in the subject. In certain embodiments, the methodscomprise selecting a subject at risk for developing insulin resistance.

Provided herein are methods for preventing or delaying the onset ofinsulin resistance in a subject at risk for developing insulinresistance comprising administering to the subject a compound comprisingadministering to the subject a compound comprising an oligonucleotideconsisting of 7 to 12 linked nucleosides and having a nucleobasesequence complementary to miR-103 and miR-107; and thereby preventing ordelaying the onset of insulin resistance in the subject.

Provided herein are methods for improving glucose tolerance in a subjectcomprising administering to the subject a compound comprising anoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence complementary to miR-103, miR-107 or a precursor ofmiR-103 or miR-107; and thereby improving glucose tolerance. In certainembodiments, the subject has impaired glucose tolerance. In certainembodiments, the methods comprise selecting a subject having impairedglucose tolerance.

Provided herein are methods for improving glucose tolerance in a subjectcomprising administering to the subject a compound comprisingadministering to the subject a compound comprising an oligonucleotideconsisting of 7 to 12 linked nucleosides and having a nucleobasesequence complementary to miR-103 and miR-107; and thereby improvingglucose tolerance.

Provided herein are methods for decreasing the plasma cholesterol levelin a subject comprising administering to the subject a compoundcomprising an oligonucleotide consisting of 12 to 30 linked nucleosidesand having a nucleobase sequence complementary to miR-103, miR-107 or aprecursor of miR-103 or miR-107; and thereby decreasing plasmacholesterol in the subject. In certain embodiments, the subject has anelevated plasma cholesterol level. In certain embodiments, the methodscomprise selecting a subject having an elevated plasma cholesterollevel. In certain embodiments, the plasma cholesterol isLDL-cholesterol. In certain embodiments, the plasma cholesterol isVLDL-cholesterol.

In any of the methods provided herein, the subject may have a metabolicdisorder.

Provided herein are methods for treating at least one metabolic disorderin a subject, comprising administering to the subject having a metabolicdisorder a compound comprising an oligonucleotide consisting of 12 to 30linked nucleosides and having a nucleobase sequence complementary tomiR-103, miR-107 or a precursor miR-103 or miR-107; and thereby treatingthe metabolic disorder.

Provided herein are methods for treating at least one metabolic disorderin a subject, comprising administering to the subject having a metabolicdisorder a compound comprising administering to the subject a compoundcomprising an oligonucleotide consisting of 7 to 12 linked nucleosidesand having a nucleobase sequence complementary to miR-103 and miR-107;and thereby treating the metabolic disorder.

Provided herein are methods for preventing or delaying the onset of atleast one metabolic disorder in a subject at risk for developing ametabolic disorder, comprising administering to the subject a compoundcomprising modified oligonucleotide consisting of 12 to 30 linkednucleosides and having a nucleobase sequence complementary to miR-103,miR-107 or a precursor miR-103 or miR-107; and thereby preventing ordelaying the onset of a metabolic disorder in the subject.

Provided herein are methods for preventing or delaying the onset of atleast one metabolic disorder in a subject at risk for developing ametabolic disorder, comprising administering to the subject a compoundcomprising administering to the subject a compound comprising anoligonucleotide consisting of 7 to 12 linked nucleosides and having anucleobase sequence complementary to miR-103 and miR-107; and therebypreventing or delaying the onset of a metabolic disorder in the subject.

In certain embodiments, the at least one metabolic disorder is selectedfrom among pre-diabetes, diabetes, metabolic syndrome, obesity, diabeticdyslipidemia, hyperlipdemia, hypertension, hypertriglyceridemia,hyperfattyacidemia, hypercholesterolemia, and hyperinsulinemia.

In certain embodiments, the administering comprises parenteraladministration. In certain embodiments, the parenteral administrationcomprises intravenous administration or subcutaneous administration. Incertain embodiments, the administering comprises oral administration.

In certain embodiments, the administering comprises administering atleast one additional therapy. In certain embodiments, the at least oneadditional therapy is a glucose-lowering agent. In certain embodiments,the glucose-lowering agent is selected from among a PPAR agonist (gamma,dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a GLP-I analog,insulin or an insulin analog, an insulin secretagogue, a SGLT2inhibitor, a human amylin analog, a biguanide, an alpha-glucosidaseinhibitor, a meglitinide, a thiazolidinedione, and sulfonylurea. Incertain embodiments, the at least one additional therapy is alipid-lowering agent. In certain embodiments, the at least oneadditional therapy is administered at the same time as the compound. Incertain embodiments, the at least one additional therapy is administeredless frequently than the compound. In certain embodiments, the at leastone additional therapy is administered more frequently than thecompound. In certain embodiments, the at least one additional therapy isadministered prior to administration of the compound. In certainembodiments, the at least one additional therapy is administered afteradministration of the compound. In certain embodiments, the at least oneadditional therapy and the compound are co-administered.

In certain embodiments, the compound is administered in the form of apharmaceutical composition.

Provided herein are methods for improving insulin resistance in a cellor tissue comprising contacting the cell or tissue with a compoundcomprising an oligonucleotide consisting of 12 to 30 linked nucleosidesand having a nucleobase sequence complementary to the nucleobasesequence of SEQ ID NO: 1, 2, 3, 4, or 5. In certain embodiments, thecell or tissue is a liver, fat, or skeletal muscle cell or tissue. Incertain embodiments, the cell or tissue is a fat cell or tissue. Incertain embodiments, the cell or tissue is contacted in vivo.

Provided herein are methods for increasing adipocyte differentiation ina subject comprising administering to the subject a compound comprisingmodified oligonucleotide consisting of 12 to 30 linked nucleosides andhaving a nucleobase sequence complementary to miR-103, miR-107 or aprecursor miR-103 or miR-107, thereby increasing adipocytedifferentiation in the subject. In certain embodiments, the subject hasexcess body fat. In certain embodiments, the administration reduces thebody weight of the subject. In certain embodiments, the administeringreduces body fat in the subject.

Provided herein are methods for increasing adipocyte differentiation ina subject comprising administering to the subject a compound comprisingan oligonucleotide consisting of 7 to 12 linked nucleosides and having anucleobase sequence complementary to miR-103 and miR-107, therebyincreasing adipocyte differentiation in the subject.

Provided herein are methods for increasing insulin sensitivity in a cellcomprising contacting the cell with a compound comprising anoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence complementary to the nucleobase sequence of SEQ IDNO: 1, 2, 3, 4, or 5. In certain embodiments, the cell has a decreasedsensitivity to insulin. In certain embodiments, the cell is an adipocytecell.

Provided herein are methods for inducing adipocyte differentiationcomprising contacting an undifferentiated adipocyte with a compoundcomprising an oligonucleotide consisting of 12 to 30 linked nucleosidesand having a nucleobase sequence complementary to the nucleobasesequence of SEQ ID NO: 1, 2, 3, 4, or 5.

In certain embodiments, the compound consists of the oligonucleotide.

In certain embodiments, the nucleobase sequence of the oligonucleotideis at least 85% complementary to the nucleobase sequence of SEQ ID NO:1, 2, 3, 4, or 5. In certain embodiments, the nucleobase sequence of theoligonucleotide is at least 90% complementary to the nucleobase sequenceof SEQ ID NO: 1, 2, 3, 4, or 5. In certain embodiments, the nucleobasesequence of the oligonucleotide is at least 95% complementary to thenucleobase sequence of SEQ ID NO: 1, 2, 3, 4, or 5. In certainembodiments, the nucleobase sequence of the oligonucleotide is fullycomplementary to the nucleobase sequence of SEQ ID NO: 1, 2, 3, 4, or 5.In certain embodiments, the nucleobase sequence of the oligonucleotidehas no more than two mismatches to a nucleobase sequence selected fromSEQ ID NO: 1, 2, 3, 4, or 5. In certain embodiments, the nucleobasesequence of the oligonucleotide has no more than one mismatch to anucleobase sequence selected from SEQ ID NO: 1, 2, 3, 4, or 5. Incertain embodiments, the nucleobase sequence of the oligonucleotide hasone mismatch to a nucleobase sequence selected from SEQ ID NO: 1, 2, 3,4, or 5. In certain embodiments, the nucleobase sequence of theoligonucleotide has no mismatches to a nucleobase sequence selected fromSEQ ID NO: 1, 2, 3, 4, or 5.

In certain embodiments, the oligonucleotide is a modifiedoligonucleotide. In certain embodiments, the oligonucleotide comprisesat least one modified internucleoside linkage. In certain embodiments,the oligonucleotide comprises at least two modified internucleosidelinkages. In certain embodiments, the oligonucleotide comprises at leastthree modified internucleoside linkages. In certain embodiments, thefirst and last internucleoside linkages of the oligonucleotide aremodified internucleoside linkages. In certain embodiments, eachinternucleoside linkage of the oligonucleotide is a modifiedinternucleoside linkage. In certain embodiments, at least one modifiedinternucleoside linkage is a phosphorothioate internucleoside linkage.In certain embodiments, the oligonucleotide comprises at least onenucleoside comprising a modified sugar. In certain embodiments, theoligonucleotide comprises at least two nucleosides comprising a modifiedsugar. In certain embodiments, the oligonucleotide comprises at leastthree nucleosides comprising a modified sugar. In certain embodiments,each nucleoside the oligonucleotide comprises a modified sugar. Incertain embodiments, each nucleoside the oligonucleotide comprises a2′-O-methoxyethyl sugar. In certain embodiments, the oligonucleotidecomprises a plurality of nucleosides comprising a 2′-O-methoxyethylsugar and a plurality of nucleosides comprising a 2′-fluoro sugarmodification. In certain embodiments, each modified sugar isindependently selected from a 2′-O-methoxyethyl sugar, a 2′-fluorosugar, 2′-O-methyl sugar, and a bicyclic sugar moiety. In certainembodiments, the bicyclic sugar moiety is LNA. In certain embodiments,the compound comprises a conjugate linked to the oligonucleotide. Incertain embodiments, the conjugate is cholesterol.

In certain embodiments, the modified oligonucleotide has the followingmodifications: each nucleoside is a 2′-O-methyl nucleoside, each of thefirst two 5′ internucleoside linkages are phosphorothioate, each of thefour 3′ terminal internucleoside linkages are phosphorothioate, each ofthe remaining internucleoside linkages is phosphodiester, and the 3′terminal nucleoside is linked to cholesterol through a hydroxyprolinollinkage.

In certain embodiments, the oligonucleotide consists of 7 linkednucleosides. In certain embodiments, the oligonucleotide consists of 8linked nucleosides. In certain embodiments, the oligonucleotide consistsof 9 linked nucleosides. In certain embodiments, the oligonucleotideconsists of 10 linked nucleosides. In certain embodiments, theoligonucleotide consists of 11 linked nucleosides. In certainembodiments, the oligonucleotide consists of 12 linked nucleosides. Incertain embodiments, the oligonucleotide consists of 13 linkednucleosides. In certain embodiments, the oligonucleotide consists of 14linked nucleosides. In certain embodiments, the oligonucleotide consistsof 15 linked nucleosides. In certain embodiments, the oligonucleotideconsists of 16 linked nucleosides. In certain embodiments, theoligonucleotide consists of 17 linked nucleosides. In certainembodiments, the oligonucleotide consists of 18 linked nucleosides. Incertain embodiments, the oligonucleotide consists of 19 linkednucleosides. In certain embodiments, the oligonucleotide consists of 20linked nucleosides. In certain embodiments, the oligonucleotide consistsof 21 linked nucleosides. In certain embodiments, the oligonucleotideconsists of 22 linked nucleosides. In certain embodiments, theoligonucleotide consists of 23 linked nucleosides. In certainembodiments, the oligonucleotide consists of 24 linked nucleosides.

In certain embodiments, the nucleobase sequence of the oligonucleotidecomprises the nucleobase sequence of SEQ ID NO: 6, 7, or 8. In certainembodiments, the nucleobase sequence of the oligonucleotide consists ofthe nucleobase sequence of SEQ ID NO: 6, 7, or 8.

In certain embodiments, the oligonucleotide comprises the nucleobasesequence of any of SEQ ID NOs 10, 11, 12, 13, 14, 15, and 16. In certainembodiments, oligonucleotide comprises the nucleobase sequence of SEQ IDNO: 10. In certain embodiments, the oligonucleotide comprises thenucleobase sequence of SEQ ID NO: 11.

In certain embodiments, the oligonucleotide consists of the nucleobasesequence of any of SEQ ID NOs 10, 11, 12, 13, 14, 15, and 16. In certainembodiments, oligonucleotide consists of the nucleobase sequence of SEQID NO: 10. In certain embodiments, the oligonucleotide consists of thenucleobase sequence of SEQ ID NO: 11. In certain such embodiments, eachnucleoside comprises a sugar modification.

Provided herein are methods for identifying a subject in need oftreatment comprising comparing the amount of a microRNA in a sampleobtained from the subject with the amount of negative control, whereinthe microRNA is miR-103 or miR-107 and wherein a greater amount ofmicroRNA in the sample obtained from the subject indicates that thesubject is in need of treatment with a compound comprising a modifiedoligonucleotide complementary to miR-103/107. In certain embodiments,the sample is a liver sample. In certain embodiments, the sample is anadipose sample. In certain embodiments, the subject is at risk fordeveloping a metabolic disorder. In certain embodiments, the subject issuspected of having a metabolic disorder. In certain embodiments, thesubject is treated with a compound comprising a modified oligonucleotidehaving nucleobase complementarity to miR-103 and/or miR-107, or aprecursor thereof.

These and other embodiments of the present invention will becomeapparent in conjunction with the figures, description and claims thatfollow.

BRIEF DESCRIPTION OF DRAWINGS

Unless otherwise specified, wildtype male C57Bl/6 mice (≈20 g) wereinjected with either PBS, anti-miR-107 (1×15 mg/kg), anti-miR103 (2×15mg/kg), anti-mm-107 (2×15 μg/kg), or anti-miR-124 (2×15 μg/kg), whilemale ob/ob (45 g) with either PBS, anti-miR-107 (1×15 mg/kg),anti-miR-103 (2×15 mg/kg), or anti-miR-124 (2×15 mg/kg). Throughout theFigures, the labeling of anti-miR treatment is as described in thefollowing table.

TABLE 1 Description of Modified Oligonucleotides Descriptionof Figures & Figure Label Examples Sequence and Chemistry Ant.103 oranti-miR-103 UCAUAGCCCUGUACAAUGCUGCU (SEQ ID NO: 6) Ant-1032′-O-methyl modification at each sugarPhosphorothioate linkages at each of the first 4 and last 2internucleoside linkages; remaining linkages are phosphodiesterCholesterol at the 3′ end linked through hydroxyprolinol Ant.107 oranti-miR-107 UGAUAGCCCUGUACAAUGCUGCU (SEQ ID NO: 7) Ant-1072′-O-methyl modification at each sugarPhosphorothioate linkages at each of the first 4 and last 2internucleoside linkages; remaining linkages are phosphodiesterCholesterol at the 3′ end linked through hydroxyprolinol Ant.scr oranti-mm-107 TCATTGGCATGTACCATGCAGCT (SEQ ID NO: 9) Ant-scr or2′-O-methyl modification at each sugar Ant.MM107 orPhosphorothioate linkages at each of the first 4 and last 2Anti-MM107 orinternucleoside linkages; remaining linkages are phosphodiesterAnt.MM103 or Cholesterol at the 3′ end linked through hydroxyprolinolAnt-MM103 Ant.124 or anti-miR-124 Full complement of miR-124 Ant-124TGGCATTCACCGCGTGCCTTAA (SEQ ID NO: 19)2′-O-methyl modification at each sugarPhosphorothioate linkages at each of the first 4 and last 2internucleoside linkages; remaining linkages are phosphodiesterCholesterol at the 3′ end linked through hydroxyprolinol

FIG. 1. miR-103 and miR-107 are up-regulated in models of diabetes andobesity. (A) Northern blotting for miR-103 and miR-107 on 25 μg totalRNA from livers of wildtype (wt), ob/ob, normal chow-fed (Chow) or DIOmice as indicated (n=3). Ethidium bromide staining of total RNA is shownas control. (B) Northern blotting for miR-103 on 0, 10, or 100 nMsynthetic miR-103 or miR-107. (C) Northern blotting for miR-103,miR-107, or miR-16 on 35 ug total RNA from livers of ob/ob mice injectedeither with anti-miR-103 and anti-miR-107, or PBS as control. (D)Northern blotting for miR-107 or miR-16 on 35 ug total RNA from fat ofob/ob or C57bl/6 mice injected with either anti-miR-103, anti-miR-107,or PBS as control. (E) Northern blotting for miR-103, miR-16 or U6 on35, 10, or 5 ug of total RNA from different organs of C57Bl/6, with orwithout anti-miR-103 treatment. (F) Northern blotting for miR-103 on 35ug of total RNA from livers and fat of C57Bl/6 mice.

FIG. 2. Adenoviral-mediated overexpression of miR-107 increases miR-107expression and down-regulates miR-103/107 targets. (A) Northern blotanalysis of miR-107 from liver in adenovirus-injected C57Bl/6, or PBSinjected ob/ob mice. All experiments shown are from n=5. (B) mRNAshaving a seed match to miR-107 in the 3′ UTR were significantlydownregulated compared to mRNAs without a seed match to miR-107 in the3′ UTR; the down-regulation is more pronounces for the subset of mRNAsharboring seed matches inferred to be under evolutionary selectivepressure.

FIG. 3. Anti-miR inhibition of miR-103/107 decreases cholesterol. (A)Western blotting of the fractions as indicated, immunoblotted withanti-apoB, or anti-apoA1 antibodies as markers of LDL, or HDLrespectively. (B) Western blotting of the fractions as indicated,immunoblotted with anti-apoE, anti-apoB, or anti-apoA1 antibodies asmarkers of VLDL, LDL, or HDL respectively. (C) Major lipoproteinfractions separated by FPLC gel filtration from 150 ul of plasma of 8week old female LDLR−/− mice injected with either PBS or anti-miR-103,assayed for triglycerides.

FIG. 4. Anti-miR inhibition of miR-103/107 decreases gene targets. (A)Real-time PCR of target genes using liver RNA from ob/ob mice uponsilencing of miR-103/107. (B) Real-time PCR of target genes using fatRNA from ob/ob following anti-miR silencing of miR-103/107. (C)Real-time PCR of target genes using muscle RNA from ob/ob mice followinganti-miR silencing of miR-103/107.

FIG. 5. Modulation of miR-103 or miR-107 regulates target proteins. (A)Western blot of total extracts from fat of ob/ob mice injected witheither PBS or anti-miR-103 as in FIGS. 1A and B. Membranes were blottedwith antibodies against Caveolin 1 (Santa Cruz), Insulin receptorb(IRb), pAKT, AKT and y-tubulin. (B, C) Western (B), and northernblotting (C) of 35 μg protein extracts, or 25 μg total RNA from HEK293cells transfected with PBS, anti-miR-124, or anti-miR-103 inconcentrations as indicated. Cells were harvested 3 days after theanti-miR treatment. (D) Western blotting of total cell extracts fromHEK293 cells plated in 6-well format and incubated with anti-miR-103.Cells were harvested 3 days after anti-miR treatment. (E and F) Westernblot of total cell extracts from HEK293 cells plated in 6-well formatharvested 2 days after transfection with mock, scrambled or miR103 siRNAin concentration of 250 pmol/well of a 6 well plate. (G) Western blot oftotal cell extracts from 3T3 cells plated in 6 well format and harvested2 days after transfection with mock, scrambled 1, scrambled 2, ormiR-103 siRNA in concentration of 250 pmol/well of a 6-well plate.

FIG. 6. Liposomal delivery of anti-miR-103. Northern blotting formiR-103 or miR-16 on 30 μg of total RNA from liver, fat, or muscle fromob/ob mice injected with different amounts of Lip-anti-miR-103,Lip-anti-miR-107, or PBS as control.

FIG. 7. Effects of miR-103/107 inhibition in adipose tissue. (A)Computer tomography (CT) in anti-miR-107, or anti-miR-103 injected DIO(top), or ob/ob mice (bottom). (B, C) Hematoxylin (HE) staining ofparaffin sections from SC, or V fat of anti-miR-107, or anti-miR-103ob/ob (B), and DIO (C) injected mice. (D) BODIPY lipid dropletsstaining, Hoechst nuclear detection and Syto60 cytosolic staining in SVFcells after 8 days of differentiation in presence of anti-miR-103, oranti-miR-107.

FIG. 8. Regulation of gene expression and insulin signaling by miR-103.(A) Western blotting of 50 μg total protein extracts from livers ofC57Bl/6 mice injected with Ad-GFP, or ad-107/GFP. (B) Western blottingon 20 μg protein extracts from V fat of C57Bl/6 mice surgically V fatinjected with ad-GFP, or ad-107/GFP. Each lane represents pool ofprotein extracts from two mice. (C) Western blotting on 20 μg proteinextracts from fat of anti-miR-107, or anti-miR-103 injected ob/ob mice.(D) Western blotting on 20 μg protein extracts from fat of C57Bl/6, orCav1 knockout (Cav1 KO) mice kept on high fat diet for 5 weeks, 8 daysafter injection with anti-miR-107, or anti-miR-103. Mice were fasted for12 h and stimulated for 8 minutes with insulin at a dose of 1.2 U/kg.

FIG. 9. miR-103 binding sites. Graphical representation of Cav1 codingsequence (CDS) and its 3′UTR with the seeds motifs in human and mouse.The seed sequences are marked in brown, and the matching residuesbetween Cav1 3′UTR and the miR-103 proximal to the seed sequence in red.Multiple alignment of Cav1 seed 2 3′UTR region.

DETAILED DESCRIPTION

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of skill in thearts to which the invention belongs. Unless specific definitions areprovided, the nomenclature utilized in connection with, and theprocedures and techniques of analytical chemistry, synthetic organicchemistry, and medicinal and pharmaceutical chemistry described hereinare those well known and commonly used in the art. In the event thatthere is a plurality of definitions for terms herein, those in thissection prevail. Standard techniques may be used for chemical synthesis,chemical analysis, pharmaceutical preparation, formulation and delivery,and treatment of subjects. Certain such techniques and procedures may befound for example in “Carbohydrate Modifications in Antisense Research”Edited by Sangvi and Cook, American Chemical Society, Washington D.C.,1994; and “Remington's Pharmaceutical Sciences,” Mack Publishing Co.,Easton, Pa., 18th edition, 1990; and which is hereby incorporated byreference for any purpose. Where permitted, all patents, patentapplications, published applications and publications, GENBANKsequences, websites and other published materials referred to throughoutthe entire disclosure herein, unless noted otherwise, are incorporatedby reference in their entirety. Where reference is made to a URL orother such identifier or address, it is understood that such identifierscan change and particular information on the internet can command go,but equivalent information can be found by searching the internet.Reference thereto evidences the availability and public dissemination ofsuch information.

Before the present compositions and methods are disclosed and described,it is to be understood that the terminology used herein is for thepurpose of describing particular embodiments only and is not intended tobe limiting. It must be noted that, as used in the specification and theappended claims, the singular forms “a,” “an” and “the” include pluralreferents unless the context clearly dictates otherwise.

DEFINITIONS

“Blood glucose level” means the concentration of glucose in the blood ofa subject. In certain embodiments, blood glucose levels are expressed asmilligrams of glucose per deciliter of blood. In certain embodiments,blood glucose levels are expressed as mmol of glucose per liter ofblood.

“Elevated blood glucose level” means a blood glucose level that ishigher than normal.

“Fasted blood glucose level” means a blood glucose level after a subjecthas fasted for a certain length of time. For example, a subject may fastfor at least 8 hours prior to measurement of a fasted blood glucoselevel.

“Post-prandial blood glucose level” means a blood glucose level after asubject has eaten a meal. In certain embodiments, a post-prandial bloodglucose level is measured two hours after a subject has eaten a meal.

“Whole blood glucose level” means the concentration of glucose in wholeblood which has not been subjected to separation.

“Plasma blood glucose level” means the concentration of glucose inplasma following separation of whole blood into plasma and red bloodcell fractions.

“Insulin sensitivity” means the ability of cells to take up glucose inresponse to insulin action.

“Insulin resistance” means a condition in which normal amounts ofinsulin are inadequate to produce a normal insulin response from fat,muscle and liver cells. Insulin resistance in fat cells results inhydrolysis of stored triglycerides, which elevates free fatty acids inthe blood. Insulin resistance in muscle reduces the uptake of glucosefrom the blood by muscle cells. Insulin resistance in liver reducesglucose storage and a failure to suppress glucose production. Elevatedfree fatty acids, reduced glucose uptake, and elevated glucoseproduction all contribute to elevated blood glucose levels. High plasmalevels of insulin and glucose due to insulin resistance often leads tometabolic syndrome and type 2 diabetes.

“Improving insulin resistance” means increasing the ability of cells toproduce a normal insulin response. In certain embodiments, insulinresistance is improved in muscle cells, leading to an increased uptakeof glucose in muscle cells. In certain embodiments, insulin resistanceis improved in liver cells, leading to increased glucose storage inliver cells. In certain embodiments, insulin resistance is improved infat cells, leading to reduced hydrolysis of triglycerides, andconsequently reduced free fatty acid in the blood.

“Metabolic disorder” means a condition characterized by an alteration ordisturbance in one or more metabolic processes in the body. Metabolicdisorders include, but are not limited to, hyperglycemia, prediabetes,diabetes, type 1 diabetes, type 2 diabetes, obesity, diabeticdyslipidemia, metabolic syndrome, and hyperinsulinemia. “Diabetes” or“diabetes mellitus” means a disease in which the body does not produceor properly use insulin, resulting in abnormally high blood glucoselevels. In certain embodiments, diabetes is type 1 diabetes. In certainembodiments, diabetes is type 2 diabetes.

“Prediabetes” means a condition in which a subject's blood glucoselevels are higher than in a subject with normal blood glucose levels butlower but not high enough for a diagnosis of diabetes.

“Type 1 diabetes” means diabetes characterized by loss of theinsulin-producing beta cells of the islets of Langerhans in the pancreasleading to a deficiency of insulin (also known as insulin-dependentdiabetes mellitus or IDDM). Type I diabetes can affect children oradults, but typically appears between the ages of 10 and 16.

“Type 2 diabetes” means diabetes characterized by insulin resistance andrelative insulin deficiency (also known as diabetes mellitus type 2, andformerly called diabetes mellitus type 2, non-insulin-dependent diabetes(NIDDM), obesity related diabetes, or adult-onset diabetes).

“Obesity” means an excessively high amount of body fat or adipose tissuein relation to lean body mass. The amount of body fat (or adiposity)includes both the distribution of fat throughout the body and the sizeof the adipose tissue deposits. Body fat distribution can be estimatedby skin-fold measures, waist-to-hip circumference ratios, or techniquessuch as ultrasound, computed tomography, or magnetic resonance imaging.According to the Center for Disease Control and Prevention, individualswith a body mass index (BMI) of 30 or more are considered obese.

“Diabetic dyslipidemia” or “Type 2 diabetes with dyslipidemia” means acondition characterized by Type 2 diabetes, reduced HDL-C, elevatedserum triglycerides, and elevated small, dense LDL particles.

“Metabolic syndrome” means a condition characterized by a clustering oflipid and nonlipid risk factors of metabolic origin. In certainembodiments, metabolic syndrome is identified by the presence of any 3of the following factors: waist circumference of greater than 102 cm inmen or greater than 88 cm in women; serum triglyceride of at least 150mg/dL; HDL-C less than 40 mg/dL in men or less than 50 mg/dL in women;blood pressure of at least 130/85 mmHg; and fasting glucose of at least110 mg/dL. These determinants can be readily measured in clinicalpractice (JAMA, 2001, 285: 2486-2497).

“Steatosis” means a condition characterized by the excessiveaccumulation of triglycerides in hepatocytes.

“Steatohepatitis” means steatosis with inflammation.

“Non-alcoholic fatty liver disease (NAFLD)” means a conditioncharacterized accumulation of fat in the liver in subjects who consumelittle to no alcohol. In certain embodiments, NAFLD is related toinsulin resistance and the metabolic syndrome.

“Nonalcoholic steatohepatitis (NASH)” means a condition characterized byaccumulation of fat in the liver, combined with inflammation andscarring in the liver. In certain embodiments NASH results from aworsening progression of NAFLD.

“Alcoholic steatohepatitis (ASH)” means an alcohol-induced conditioncharacterized by accumulation of fat in the liver, combined withinflammation and scarring in the liver.

“Glucose Tolerance Test” or “GTT” means a test performed to determinehow quickly glucose is cleared from the blood. Typically, the testinvolves administration of glucose, followed by measurement of glucoselevels in blood at intervals over a period of time. “IPGTT” means a GTTperformed following intraperitoneal injection of glucose. “OGTT” means aGTT performed following oral administration of glucose. In certainembodiments, a GTT is used to test for pre-diabetes. In certainembodiments, a GTT is used to identify a subject with diabetes. Incertain embodiments, a GTT is used to identify a subject at risk fordeveloping diabetes. In certain embodiments a GTT is used to identify asubject having insulin resistance.

“Insulin Tolerance Test (ITT)” means a test performed to measure insulinsensitivity through hormone response to the stress of a low blood sugarlevel. In certain embodiments, a ITT is used to test or pre-diabetes. Incertain embodiments, a ITT is used to identify a subject with diabetes.In certain embodiments, a ITT is used to identify a subject at risk fordeveloping diabetes. In certain embodiments a ITT is used to identify asubject having insulin resistance.

“Metabolic rate” means the rate of metabolism or the amount of energyexpended in a given period. “Basal metabolic rate” means the amount ofenergy expended while at rest in a neutrally temperate environment, inthe post-absorptive state (meaning that the digestive system isinactive, which requires about twelve hours of fasting in humans); therelease of energy in this state is sufficient only for the functioningof the vital organs, such as the heart, lungs, brain and the rest of thenervous system, liver, kidneys, sex organs, muscles and skin.

“Anti-miR” means an oligonucleotide having a nucleobase sequencecomplementary to a microRNA. In certain embodiments, an anti-miR is amodified oligonucleotide.

“Subject” means a human or non-human animal selected for treatment ortherapy.

“Subject in need thereof” means a subject identified as in need of atherapy or treatment. In certain embodiments, a subject has livercancer. In such embodiments, a subject has one or more clinicalindications of liver cancer or is at risk for developing liver cancer.

“Administering” means providing a pharmaceutical agent or composition toa subject, and includes, but is not limited to, administering by amedical professional and self-administering.

“Parenteral administration,” means administration through injection orinfusion. Parenteral administration includes, but is not limited to,subcutaneous administration, intravenous administration, orintramuscular administration.

“Subcutaneous administration” means administration just below the skin.

“Intravenous administration” means administration into a vein.

“Administered concomitantly” refers to the administration of at leasttwo agents to a subject in any manner in which the pharmacologicaleffects of both are manifest in the subject at the same time.Concomitant administration does not require that both agents beadministered in a single pharmaceutical composition, in the same dosageform, or by the same route of administration. The time during which theeffects of the agents need not be identical. The effects need only beoverlapping for a period of time and need not be coextensive. “Duration”means the period of time during which an activity or event continues. Incertain embodiments, the duration of treatment is the period of timeduring which doses of a pharmaceutical agent or pharmaceuticalcomposition are administered.

“Therapy” means a disease treatment method. In certain embodiments,therapy includes, but is not limited to, chemotherapy, surgicalresection, liver transplant, and/or chemoembolization.

“Treatment” means the application of one or more specific proceduresused for the cure or amelioration of a disease. In certain embodiments,the specific procedure is the administration of one or morepharmaceutical agents.

“Amelioration” means a lessening of severity of at least one indicatorof a condition or disease. In certain embodiments, amelioration includesa delay or slowing in the progression of one or more indicators of acondition or disease. The severity of indicators may be determined bysubjective or objective measures which are known to those skilled in theart.

“At risk for developing” means a subject is predisposed to developing acondition or disease. In certain embodiments, a subject at risk fordeveloping a condition or disease exhibits one or more symptoms of thecondition or disease, but does not exhibit a sufficient number ofsymptoms to be diagnosed with the condition or disease. In certainembodiments, a subject at risk for developing a condition or diseaseexhibits one or more symptoms of the condition or disease, but to alesser extent required to be diagnosed with the condition or disease.

“Prevent the onset of” means to prevent the development a condition ordisease in a subject who is at risk for developing the disease orcondition. In certain embodiments, a subject at risk for developing thedisease or condition receives treatment similar to the treatmentreceived by a subject who already has the disease or condition.

“Delay the onset of” means to delay the development of a condition ordisease in a subject who is at risk for developing the disease orcondition. In certain embodiments, a subject at risk for developing thedisease or condition receives treatment similar to the treatmentreceived by a subject who already has the disease or condition.

“Therapeutic agent” means a pharmaceutical agent used for the cure,amelioration or prevention of a disease.

“Dose” means a specified quantity of a pharmaceutical agent provided ina single administration. In certain embodiments, a dose may beadministered in two or more boluses, tablets, or injections. Forexample, in certain embodiments, where subcutaneous administration isdesired, the desired dose requires a volume not easily accommodated by asingle injection. In such embodiments, two or more injections may beused to achieve the desired dose. In certain embodiments, a dose may beadministered in two or more injections to minimize injection sitereaction in an individual.

“Dosage unit” means a form in which a pharmaceutical agent is provided.In certain embodiments, a dosage unit is a vial containing lyophilizedoligonucleotide. In certain embodiments, a dosage unit is a vialcontaining reconstituted oligonucleotide.

“Therapeutically effective amount” refers to an amount of apharmaceutical agent that provides a therapeutic benefit to an animal.

“Pharmaceutical composition” means a mixture of substances suitable foradministering to an individual that includes a pharmaceutical agent. Forexample, a pharmaceutical composition may comprise a sterile aqueoussolution.

“Pharmaceutical agent” means a substance that provides a therapeuticeffect when administered to a subject.

“Active pharmaceutical ingredient” means the substance in apharmaceutical composition that provides a desired effect.

“Improved liver function” means the change in liver function towardnormal limits. In certain embodiments, liver function is assessed bymeasuring molecules found in a subject's blood. For example, in certainembodiments, improved liver function is measured by a reduction in bloodliver transaminase levels.

“Acceptable safety profile” means a pattern of side effects that iswithin clinically acceptable limits.

“Side effect” means a physiological response attributable to a treatmentother than desired effects. In certain embodiments, side effectsinclude, without limitation, injection site reactions, liver functiontest abnormalities, renal function abnormalities, liver toxicity, renaltoxicity, central nervous system abnormalities, and myopathies. Suchside effects may be detected directly or indirectly. For example,increased aminotransferase levels in serum may indicate liver toxicityor liver function abnormality. For example, increased bilirubin mayindicate liver toxicity or liver function abnormality.

“Injection site reaction” means inflammation or abnormal redness of skinat a site of injection in an individual.

“Subject compliance” means adherence to a recommended or prescribedtherapy by a subject.

“Comply” means the adherence with a recommended therapy by a subject.

“Recommended therapy” means a treatment recommended by a medicalprofessional for the treatment, amelioration, or prevention of adisease.

“Target nucleic acid” means a nucleic acid to which an oligomericcompound is designed to hybridize.

“Targeting” means the process of design and selection of nucleobasesequence that will hybridize to a target nucleic acid.

“Targeted to” means having a nucleobase sequence that will allowhybridization to a target nucleic acid.

“Modulation” means to a perturbation of function or activity. In certainembodiments, modulation means an increase in gene expression. In certainembodiments, modulation means a decrease in gene expression.

“Expression” means any functions and steps by which a gene's codedinformation is converted into structures present and operating in acell.

“5′ target site” refers to the nucleobase of a target nucleic acid whichis complementary to the 5′-most nucleobase of a particularoligonucleotide.

“3′ target site” means the nucleobase of a target nucleic acid which iscomplementary to the 3′-most nucleobase of a particular oligonucleotide.

“Region” means a portion of linked nucleosides within a nucleic acid. Incertain embodiments, an has a nucleobase sequence that is complementaryto a region of a target nucleic acid. For example, in certain suchembodiments an is complementary to a region of a miRNA stem-loopsequence. In certain such embodiments, an is fully complementary to aregion of a miRNA stem-loop sequence.

“Segment” means a smaller or sub-portion of a region.

“Nucleobase sequence” means the order of contiguous nucleobases, in a 5′to 3′ orientation, independent of any sugar, linkage, and/or nucleobasemodification.

“Contiguous nucleobases” means nucleobases immediately adjacent to eachother in a nucleic acid.

“Nucleobase complementarity” means the ability of two nucleobases topair non-covalently via hydrogen bonding.

“Complementary” means that an oligomeric compound is capable ofhybridizing to a target nucleic acid under stringent hybridizationconditions.

“Fully complementary” means each nucleobase of an oligomeric compound iscapable of pairing a nucleobase at each corresponding position in atarget nucleic acid. For example, in certain embodiments, an oligomericcompound wherein each nucleobase has complementarity to a nucleobasewithin a region of a miRNA stem-loop sequence is fully complementary tothe miRNA stem-loop sequence.

“Percent complementarity” means the percentage of nucleobases of anoligomeric compound that are complementary to an equal-length portion ofa target nucleic acid. Percent complementarity is calculated by dividingthe number of nucleobases of the oligomeric compound that arecomplementary to nucleobases at corresponding positions in the targetnucleic acid by the total length of the oligomeric compound. In certainembodiments, percent complementarity of an means the number ofnucleobases that are complementary to the target nucleic acid, dividedby the length of the modified oligonucleotide.

“Percent identity” means the number of nucleobases in first nucleic acidthat are identical to nucleobases at corresponding positions in a secondnucleic acid, divided by the total number of nucleobases in the firstnucleic acid.

“Hybridize” means the annealing of complementary nucleic acids thatoccurs through nucleobase complementarity.

“Mismatch” means a nucleobase of a first nucleic acid that is notcapable of pairing with a nucleobase at a corresponding position of asecond nucleic acid.

“Identical” means having the same nucleobase sequence.

“miR-103” means the mature miRNA having the nucleobase sequence setforth in SEQ ID NO: 1 (AGCAGCAUUGUACAGGGCUAUGA).

“miR-107” means the mature miRNA having the nucleobase sequence setforth in SEQ ID NO: 2 (AGCAGCAUUGUACAGGGCUAUCA). “miR-103-1 stem-loopsequence” means the miR-103 precursor having the nucleobase sequence setforth in SEQ ID NO: 3(UACUGCCCUCGGCUUCUUUACAGUGCUGCCUUGUUGCAUAUGGAUCAAGCAGCAUUGUACAGGGCUAUGAAGGCAUUG).

“miR-103-2” means the miR-103 precursor having the nucleobase sequenceset forth in SEQ ID NO: 4(UUGUGCUUUCAGCUUCUUUACAGUGCUGCCUUGUAGCAUUCAGGUCAAGCAGCAUUGUACAGGGCUAUGAAAGAACCA.

“miR-107 stem loop sequence” means the miR-107 precursor having thenucleobase sequence set forth in SEQ ID NO: 5(CUCUCUGCUUUCAGCUUCUUUACAGUGUUGCCUUGUGGCAUGGAGUUCAAGCAGCAUUGUACAGGGCUAUCAAAGCACAGA).

“miR-103/miR-107” means a microRNA having the nucleobase sequence of SEQID NO: 1 or SEQ ID NO: 2.

“MicroRNA” means a non-coding RNA between 18 and 25 nucleobases inlength, which is the product of cleavage of a pre-miRNA by the enzymeDicer. Examples of mature miRNAs are found in the miRNA database knownas miRBase (http://microma.sanger.ac.uk/). In certain embodiments,microRNA is abbreviated as “miRNA” or “miR.”

“Pre-miRNA” or “pre-miR” means a non-coding RNA having a hairpinstructure, which is the product of cleavage of a pri-miR by thedouble-stranded RNA-specific ribonuclease known as Drosha.

“Stem-loop sequence” means an RNA having a hairpin structure andcontaining a mature miRNA sequence. Pre-miRNA sequences and stem-loopsequences may overlap. Examples of stem-loop sequences are found in themiRNA database known as miRBase (http://microma.sanger.ac.uk/).

“Pri-miRNA” or “pri-miR” means a non-coding RNA having a hairpinstructure that is a substrate for the double-stranded RNA-specificribonuclease Drosha.

“miRNA precursor” means a transcript that originates from a genomic DNAand that comprises a non-coding, structured RNA comprising one or moremiRNA sequences. For example, in certain embodiments a miRNA precursoris a pre-miRNA. In certain embodiments, a miRNA precursor is apri-miRNA.

“Monocistronic transcript” means a miRNA precursor containing a singlemiRNA sequence.

“Polycistronic transcript” means a miRNA precursor containing two ormore miRNA sequences.

“Seed sequence” means nucleotides 2 to 6 or 2 to 7 from the 5′-end of amature miRNA sequence.

“Compound comprising an oligonucleotide consisting of” a number oflinked nucleosides means a compound that includes an oligonucleotidehaving the specified number of linked nucleosides. Thus, the compoundmay include additional substituents or conjugates. Unless otherwiseindicated, the compound does not include any additional nucleosidesbeyond those of the oligonucleotide. “Oligomeric compound” means acompound comprising a polymer of linked monomeric subunits.

“Oligonucleotide” means a polymer of linked nucleosides, each of whichcan be modified or unmodified, independent from one another.

“Naturally occurring internucleoside linkage” means a 3′ to 5′phosphodiester linkage between nucleosides.

“Natural sugar” means a sugar found in DNA (2′-H) or RNA (2′-OH).

“Natural nucleobase” means a nucleobase that is unmodified relative toits naturally occurring form.

“Internucleoside linkage” means a covalent linkage between adjacentnucleosides.

“Linked nucleosides” means nucleosides joined by a covalent linkage.

“Nucleobase” means a heterocyclic moiety capable of non-covalentlypairing with another nucleobase.

“Nucleoside” means a nucleobase linked to a sugar.

“Nucleotide” means a nucleoside having a phosphate group covalentlylinked to the sugar portion of a nucleoside.

“Modified oligonucleotide” means an oligonucleotide having one or moremodifications relative to a naturally occurring terminus, sugar,nucleobase, and/or internucleoside linkage.

“Single-stranded modified oligonucleotide” means an which is nothybridized to a complementary strand.

“Modified internucleoside linkage” means any change from a naturallyoccurring internucleoside linkage.

“Phosphorothioate internucleoside linkage” means a linkage betweennucleosides where one of the non-bridging atoms is a sulfur atom.

“Modified sugar” means substitution and/or any change from a naturalsugar.

“Modified nucleobase” means any substitution and/or change from anatural nucleobase.

“5-methylcytosine” means a cytosine modified with a methyl groupattached to the 5′ position.

“2′-O-methyl sugar” or “2′-OMe sugar” means a sugar having a O-methylmodification at the 2′ position.

“2′-O-methoxyethyl sugar” or “2′-MOE sugar” means a sugar having aO-methoxyethyl modification at the 2′ position.

“2′-O-fluoro” or “2′-F” means a sugar having a fluoro modification ofthe 2′ position.

“Bicyclic sugar moiety” means a sugar modified by the bridging of twonon-geminal ring atoms.

“2′-O-methoxyethyl nucleoside” means a 2′-modified nucleoside having a2′-O-methoxyethyl sugar modification.

“2′-fluoro nucleoside” means a 2′-modified nucleoside having a 2′-fluorosugar modification.

“2′-O-methyl” nucleoside means a 2′-modified nucleoside having a2′-O-methyl sugar modification.

“Bicyclic nucleoside” means a 2′-modified nucleoside having a bicyclicsugar moiety.

“Motif” means a pattern of modified and/or unmodified nucleobases,sugars, and/or internucleoside linkages in an oligonucleotide.

A “fully modified oligonucleotide” means each nucleobase, each sugar,and/or each internucleoside linkage is modified.

A “uniformly modified oligonucleotide” means each nucleobase, eachsugar, and/or each internucleoside linkage has the same modificationthroughout the modified oligonucleotide.

A “gapmer” means a modified oligonucleotide having an internal region oflinked nucleosides positioned between two external regions of linkednucleosides, where the nucleosides of the internal region comprise asugar moiety different than that of the nucleosides of each externalregion.

A “gap segment” is an internal region of a gapmer that is positionedbetween the external regions.

A “wing segment” is an external region of a gapmer that is located atthe 5′ or 3′ terminus of the internal region.

A “symmetric gapmer” means each nucleoside of each external regioncomprises the same sugar modification.

An “asymmetric gapmer” means each nucleoside of one external regioncomprises a first sugar modification, and each nucleoside of the otherexternal region comprises a second sugar modification.

A “stabilizing modification” means a modification to a nucleoside thatprovides enhanced stability to a modified oligonucleotide, in thepresence of nucleases, relative to that provided by 2′-deoxynucleosideslinked by phosphodiester internucleoside linkages. For example, incertain embodiments, a stabilizing modification is a stabilizingnucleoside modification. In certain embodiments, a stabilizingmodification is a internucleoside linkage modification.

A “stabilizing nucleoside” means a nucleoside modified to provideenhanced nuclease stability to an oligonucleotide, relative to thatprovided by a 2′-deoxynucleoside. In one embodiment, a stabilizingnucleoside is a 2′-modified nucleoside.

A “stabilizing internucleoside linkage” means an internucleoside linkagethat provides improved nuclease stability to an oligonucleotide relativeto that provided by a phosphodiester internucleoside linkage. In oneembodiment, a stabilizing internucleoside linkage is a phosphorothioateinternucleoside linkage.

Overview

Metabolic disorders are characterized by one or more abnormalities inmetabolic function in the body. Certain metabolic disorders are relatedto defects in how the body uses blood glucose, resulting in abnormallyhigh levels of blood glucose. Metabolic disorders may also becharacterized by a deficiency in insulin production, or a deficiency insensitivity to insulin. Metabolic disorders affect millions of peopleworldwide, and can be life-threatening disorders. As such, there is aneed for method and compositions to treat, prevent, or delay the onsetof metabolic disorders.

As illustrated herein, the administration of oligonucleotidescomplementary to miR-103 and/or miR-107 resulted in improved bloodglucose levels, decreased gluconeogenesis, enhanced insulin sensitivity,and decreased plasma cholesterol. These effects were observed in animalmodels of diabetes/insulin resistance. Also observed was a decrease inbody weight, which was due to a decrease in body fat. As miR-103 andmiR-107 differ by one nucleobase, an oligonucleotide having a sequencecomplementary to the nucleobase sequence of miR-103 may hybridize to andinhibit the activity of both miR-103 and miR-107. Likewise, anoligonucleotide having a sequence complementary to the nucleobasesequence of miR-107 may hybridize to and inhibit the activity of bothmiR-103 and miR-107. As such, oligonucleotides complementary to eitherone or both of miR-103 and miR-107 may be used to achieve the phenotypicoutcomes described herein.

Administration of a compound comprising an oligonucleotide complementaryto miR-103, miR-107 or a precursor thereof may result in one or moreclinically desirable outcomes. Such clinically desirable outcomesinclude but are not limited to reduced blood glucose levels, reducedHbA1c levels, improved glucose tolerance, improved insulin resistance,and reduced gluconeogenesis.

Accordingly, provided herein are methods and compositions to reduceblood glucose levels, decrease gluconeogenesis, improve insulinsensitivity, and decrease plasma cholesterol. Also provided herein aremethods to treat, prevent, or delay the onset of metabolic disordersthat are related to elevated blood glucose levels, increasedgluconeogenesis, impaired insulin sensitivity, and increased plasmacholesterol. In certain embodiments, metabolic disorders include, butare not limited to, prediabetes, diabetes, including Type 1 or Type 2diabetes, metabolic syndrome, obesity, diabetic dyslipidemia,hyperglycemia, hypoglycemia, and hyperinsulinemia. In certainembodiments, a subject having a metabolic disorder also has a fattyliver disease. In certain embodiments, fatty liver diseases include, butare not limited to, non-alcoholic fatty liver disease, alchoholic fattyliver disease, and non-alchoholic steatohepatitis.

In certain embodiments, provided herein are methods for reducing bloodglucose levels in a subject comprising administering to the subject acompound comprising an oligonucleotide consisting of 12 to 30 linkednucleosides and having a nucleobase sequence complementary to miR-103and/or miR-107.

In certain embodiments, provided herein are methods for reducing bloodglucose levels in a subject comprising administering to the subject acompound comprising an oligonucleotide consisting of 7 to 12 linkednucleosides and having a nucleobase sequence complementary to miR-103and miR-107.

In certain embodiments, the methods provided herein comprise measuringblood glucose levels. Blood glucose levels may be measured before and/orafter administration of a compound comprising an oligonucleotideconsisting of 12 to 30 linked nucleosides and having a nucleobasesequence complementary to miR-103 and/or miR-107. Blood glucose levelsmay be measured in whole blood, or may be measured in plasma. Bloodglucose levels may be measured in a clinical laboratory, or may bemeasured using a blood glucose meter.

In certain embodiments, blood glucose levels are measured in a subjectwhen the subject has fasted for at least 8 hours. In certainembodiments, blood glucose levels are measured at random times, and themeasurement is not timed according to the intake of food or drink. Incertain embodiments, blood glucose levels are measured in thepost-prandial state, i.e. after the subject has eaten a meal. In certainembodiments, blood glucose levels are measured in a subject two hoursafter the subject has eaten a meal. In certain embodiments, bloodglucose levels are measured at timed intervals following administrationof glucose to the subject, in order to determine how quickly thesubject's body clears glucose from the blood. Any measurements of bloodglucose levels may be made in whole blood or in plasma.

In certain embodiments, the subject has elevated blood glucose levels.In certain embodiments, a subject is identified as having elevated bloodglucose levels. Such identification is typically made by a medicalprofessional. In certain embodiments, an elevated blood glucose levelsis a fasting blood glucose level between 100 and 125 mg/dL. In certainembodiments, an elevated blood glucose level is a fasting blood glucoselevel above 126 mg/dL. In certain embodiments, an elevated blood glucoselevel is a two-hour post-prandial glucose level between 140 and 199mg/dL. In certain embodiments, an elevated blood glucose level is atwo-hour post-prandial glucose level at 200 mg/dL or higher.

In certain embodiments, a subject having elevated blood glucose levelshas pre-diabetes. In certain embodiments, a subject is identified ashaving pre-diabetes. In certain such embodiments, the subject has afasting blood glucose level between 100 and 125 mg/dL. In certain suchembodiments, the subject has a two-hour post-prandial blood glucoselevel between 140 and 199 mg/dL. A diagnosis of pre-diabetes istypically made by a medical professional, who may consider factors inaddition to blood glucose levels when determining whether a subject haspre-diabetes.

In certain embodiments, a subject having elevated blood glucose levelshas diabetes. In certain embodiments, a subject is identified as havingdiabetes according to the subject's blood glucose levels. In certainsuch embodiments, the subject has a fasting blood glucose level above126 mg/dL. In certain such embodiments, the subject has a two-hourpost-prandial blood glucose level at or above 200 mg/dL. A diagnosis ofdiabetes is typically made by a medical professional, who may considerfactors in addition to blood glucose levels when determining whether asubject has diabetes.

In certain embodiments, the method provided herein comprise monitoringblood glucose levels before administration of a compound comprising anoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence complementary to miR-103 and/or miR-107. In certainembodiments, the methods provided herein comprise measuring bloodglucose levels after administration of a compound comprising anoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence complementary to miR-103 and/or miR-107. In certainembodiments, a subject measures blood glucose levels one or more timesdaily.

In certain embodiments, methods for reducing blood glucose levelscomprise reducing a subject's blood glucose levels to blood glucoselevels determined as desirable by medical organizations, such as theAmerican Diabetes Association or the World Health Organization. Incertain embodiments, blood glucose levels are reduced below 130 mg/dLwhen measured before a subject has had a meal. In certain embodiments,blood glucose levels are reduced to below 180 mg/dL when measured aftera subject has had a meal.

In certain embodiments, the administration occurs at least once perweek. In certain embodiments, the administration occurs once every twoweeks. In certain embodiments, the administration occurs once everythree weeks. In certain embodiments, the administration occurs onceevery four weeks. The frequency of administration may be set by amedical professional to achieve a desirable blood glucose level in asubject. The frequency of administration may be dependent upon asubject's blood glucose levels. For example, in certain embodiments,administration may be more frequent when a subject has elevated bloodglucose levels.

Measurements of HbA1c levels may be used to determine how well asubject's blood glucose levels are controlled over time. HbA1c levelsare an indication of the amount of glycated hemoglobin in the blood, andcan provide an estimate of how well a subject's blood glucose levelshave been managed over 2-3 month period prior to the measurement ofHbA1c levels. High HbA1c levels may put a subject at risk for developingcomplications related to diabetes, such as eye disease, heart disease,kidney disease, nerve damage, or stroke. As such, in certain embodimentsit is desirable that a subject's HbA1c levels be within ranges that areconsidered normal by a medical professional. In certain embodiments, anHbA1c level of 6% or less is normal. In certain embodiments, a medicalprofessional may recommend that a subject's HbA1c level be 7% or less.In certain embodiments, the administering results in reduced HbA1clevels.

In certain embodiments, a subject having elevated blood glucose levelsis insulin resistant. One of the main functions of insulin is to lowerblood glucose levels. A subject whose cells are sensitive to the effectsof insulin needs only a relatively small amount of insulin to keep bloodglucose levels in the normal range. A subject who is insulin resistantrequires more insulin to get the same blood glucose-lowering effects.Insulin resistance may cause hyperinsulinemia. Hyperinsulinemia may beassociated with high blood pressure, heart disease and heart failure,obesity (particularly abdominal obesity), osteoporosis, and certaintypes of cancer, such as colon, breast, and prostate cancer.

Insulin resistance may be detected using a procedure known as thehyperinsulinemic euglycemic clamp, which measures the amount of glucosenecessary to compensate for an increased insulin level without causinghypoglycemia. During the procedure, insulin is infused at 10-120 mU perm² per minute. In order to compensate for the insulin infusion, a 20%solution of glucose is infused to maintain blood sugar levels between 5and 5.5 mmol/L. The rate of glucose infusion is determined by checkingthe blood sugar levels every 5 to 10 minutes. Low-dose insulin infusionsare more useful for assessing the response of the liver, whereashigh-dose insulin infusions are useful for assessing peripheral (i.e.,muscle and fat) insulin action. The rate of glucose infusion during thelast 30 minutes of the test determines insulin sensitivity. If highlevels (7.5 mg/min or higher) are required, the subject isinsulin-sensitive. Very low levels (4.0 mg/min or lower) indicate thatthe subject is resistant to insulin action. Levels between 4.0 and 7.5mg/min are not definitive and suggest impaired glucose tolerance.Impaired glucose tolerance may be an early sign of insulin resistance.Glucose tracers, such as 3-³H glucose, 6,6 ²H-glucose, or 1-¹³C glucose,may be used in the procedure. Other radioactive forms of glucose may beemployed in a research setting. Prior to beginning the hyperinsulinemicperiod, a 3 hour tracer infusion enables the determination of the basalrate of glucose production. During the clamp procedure, the plasmatracer concentrations enable the calculation of whole-bodyinsulin-stimulated glucose metabolism, as well as the production ofglucose by the body (i.e., endogenous glucose production).

In certain embodiments, provided herein are methods for improvinginsulin resistance in a subject comprising administering a subject tothe subject a compound comprising an oligonucleotide consisting of 12 to30 linked nucleosides and having a nucleobase sequence complementary tomiR-103, miR-107, or precursor thereof. In certain embodiments, thesubject has insulin resistance. In certain embodiments, the methodscomprise selecting a subject having insulin resistance.

In certain embodiments, provided herein are methods for improvinginsulin resistance in a subject comprising administering a subject tothe subject a compound comprising an oligonucleotide consisting of 7 to12 linked nucleosides and having a nucleobase sequence complementary tomiR-103 and miR-107. In certain embodiments, a subject having elevatedblood glucose levels has insulin resistance.

In certain embodiments, a subject having diabetes has insulinresistance. In certain embodiments, a subject having type 2 diabetes hasinsulin resistance. In certain embodiments, a subject having type 1diabetes has insulin resistance.

In certain embodiments, provided herein are methods for reducinggluconeogenesis in a subject comprising administering to the subject acompound comprising an oligonucleotide consisting of 12 to 30 linkednucleosides and having a nucleobase sequence complementary to miR-103,miR-107, or precursor thereof. In certain embodiments, the subject haselevated gluconeogenesis. In certain embodiments, the subject isidentified as having elevated gluconeogenesis. In certain embodiments,the administering results in a reduction in gluconeogenesis. In certainembodiments, a pyruvate tolerance test is used to measuregluconeogenesis in a subject. In certain embodiments, blood glucoselevels are used to measure gluconeogenesis in a subject. In certainembodiments, the rate of gluconeogenesis is measured in a subject. Incertain embodiments, a reduction in gluconeogenesis is a reduction inthe rate of gluconeogenesis. In certain embodiments, the rate ofgluconeogenesis is measured in the subject prior to administration. Incertain embodiments, the rate of gluconeogenesis is measured in thesubject after administration.

In certain embodiments, provided herein are methods for reducing plasmacholesterol in a subject comprising administering to the subject acompound comprising an oligonucleotide consisting of 12 to 30 linkednucleosides and having a nucleobase sequence complementary to miR-103,miR-107, or precursor thereof. In certain embodiments, the subject haselevated plasma cholesterol. In certain embodiments, the subject isidentified as having elevated plasma cholesterol. In certainembodiments, the administering reduces plasma cholesterol. In certainembodiments, the plasma cholesterol is plasma LDL-cholesterol. Incertain embodiments, the plasma cholesterol is plasma VLDL-cholesterol.

In certain embodiments, provided herein are methods for reducing plasmacholesterol in a subject comprising administering to the subject acompound comprising an oligonucleotide consisting of 7 to 12 linkednucleosides and having a nucleobase sequence complementary to miR-103and miR-107.

In certain embodiments, provided herein are methods for treating ametabolic disorder in a subject comprising administering to the subjecta compound comprising an oligonucleotide consisting of 12 to 30 linkednucleosides and having a nucleobase sequence complementary to miR-103,miR-107, or a precursor thereof. In certain embodiments, the subject hasa metabolic disorder. In certain embodiments, the subject is identifiedas having a metabolic disorder. In certain embodiments, a metabolicdisorder includes, without limitation, prediabetes, diabetes (includingType 1 or Type 2 diabetes), metabolic syndrome, obesity, or diabeticdyslipidemia, hyperglycemia, hypoglycemia, and hyperinsulinemia. Incertain embodiments, the subject is diagnosed with one or more metabolicdisorders. A subject may be diagnosed with a metabolic disorderfollowing the administration of medical tests well-known to those in themedical profession.

In certain embodiments, provided herein are methods for treating ametabolic disorder in a subject comprising administering to the subjecta compound comprising an oligonucleotide consisting of 7 to 12 linkednucleosides and having a nucleobase sequence complementary to miR-103and miR-107.

Fatty liver diseases are often associated with metabolic disorders. Incertain embodiments, a subject having a metabolic disorder also has afatty liver disease. In certain embodiments, a fatty liver disease isnon-alcoholic fatty liver disease. In certain embodiments, a fatty liverdisease is alcoholic fatty liver disease. In certain embodiments, afatty liver disease is alcoholic steatohepatitis.

In certain embodiments, provided herein are methods for preventing theonset of a metabolic disorder in a subject comprising administering tothe subject a compound comprising an oligonucleotide consisting of 12 to30 linked nucleosides and having a nucleobase sequence complementary tomiR-103, miR-107, or a precursor thereof. In certain embodiments, thesubject is at risk for developing a metabolic disorder. In certainembodiments, the subject is identified being at risk for developing ametabolic disorder. In certain embodiments, a metabolic disorder isprediabetes, diabetes (including Type 1 or Type 2 diabetes), metabolicsyndrome, obesity, or diabetic dyslipidemia, hyperglycemia,hypoglycemia, hyperinsulinemia, ketoacidosis and celiac disease.

In certain embodiments, provided herein are methods for preventing theonset of a metabolic disorder in a subject comprising administering tothe subject a compound comprising an oligonucleotide consisting of 7 to12 linked nucleosides and having a nucleobase sequence complementary tomiR-103 and miR-107.

In certain embodiments, provided herein are methods for delaying theonset of a metabolic disorder in a subject comprising administering tothe subject a compound comprising an oligonucleotide consisting of 12 to30 linked nucleosides and having a nucleobase sequence complementary tomiR-103, miR-107, or a precursor thereof. In certain embodiments, thesubject is at risk for developing a metabolic disorder. In certainembodiments, the subject is identified being at risk for developing ametabolic disorder. In certain embodiments, a metabolic disorderincludes, without limitation, prediabetes, diabetes (including Type 1 orType 2 diabetes), metabolic syndrome, obesity, or diabetic dyslipidemia,hyperglycemia, hypoglycemia, and hyperinsulinemia.

In certain embodiments, provided herein are methods for delaying theonset of a metabolic disorder in a subject comprising administering tothe subject a compound comprising an oligonucleotide consisting of 7 to12 linked nucleosides and having a nucleobase sequence complementary tomiR-103 and miR-107.

In certain embodiments, a subject has one or more metabolic disorders.In certain embodiments, a subject has been diagnosed with one or moremetabolic disorders. A subject may be diagnosed with a metabolicdisorder following the administration of medical tests well-known tothose in the medical profession.

A subject's response to treatment may be evaluated by tests similar tothose used to diagnosis the metabolic disorder, including blood glucoselevel tests, glucose tolerance tests, and HbA1c tests. Response totreatment may also be assessed by comparing post-treatment test resultsto pre-treatment test results.

Fatty liver diseases may be associated with metabolic disorders. Incertain embodiments, a fatty liver disease is non-alcoholic fatty liverdisease. In certain embodiments, a fatty liver disease is alcoholicfatty liver disease. In certain embodiments, a fatty liver disease isalcoholic steatohepatitis.

In certain embodiments, provided herein are methods for treating fattyliver disease in a subject comprising administering to the subject acompound comprising an oligonucleotide consisting of 12 to 30 linkednucleosides and having a nucleobase sequence complementary to miR-103,miR-107, or a precursor thereof.

In certain embodiments, provided herein are methods for treating fattyliver disease in a subject comprising administering to the subject acompound comprising an oligonucleotide consisting of 7 to 12 linkednucleosides and having a nucleobase sequence complementary to miR-103and miR-107.

In certain embodiments, provided herein are methods for preventing afatty liver disease in a subject comprising administering to the subjecta compound comprising an oligonucleotide consisting of 12 to 30 linkednucleosides and having a nucleobase sequence complementary to miR-103,miR-107, or a precursor thereof. In certain such embodiments, thesubject is at risk for developing a fatty liver disease.

In certain embodiments, provided herein are methods for preventing fattyliver disease in a subject comprising administering to the subject acompound comprising an oligonucleotide consisting of 7 to 12 linkednucleosides and having a nucleobase sequence complementary to miR-103and miR-107.

In certain embodiments, provided herein are methods for delaying theonset of a fatty liver disease in a subject comprising administering tothe subject a compound comprising an oligonucleotide consisting of 12 to30 linked nucleosides and having a nucleobase sequence complementary tomiR-103, miR-107, or a precursor thereof. In certain such embodiments,the subject is at risk for developing a fatty liver disease.

In certain embodiments, provided herein are methods for delaying theonset of fatty liver disease in a subject comprising administering tothe subject a compound comprising an oligonucleotide consisting of 7 to12 linked nucleosides and having a nucleobase sequence complementary tomiR-103 and miR-107.

In certain embodiments, the activity of miR-103 and/or miR-107 isinhibited by use of a microRNA sponge, which comprises one or moresequences having nucleobase complementarity to miR-103 and/or miR-107.“MicroRNA sponge” means a competitive inhibitor of a microRNA in theform of a transcript expressed from a strong promoter, containingmultiple, tandem binding sites to a microRNA of interest. When vectorsencoding these sponges are introduced into cells, sponges derepressmicroRNA targets at least as strongly as chemically modified antisenseoligonucleotides. They specifically inhibit microRNAs with acomplementary heptameric seed, such that a single sponge can be used toblock an entire microRNA seed family. In certain embodiments, themicroRNA seed family comprises miR-103 and miR-107.

Certain Compounds

The compounds provided herein are useful for the treatment of metabolicdisorders. In certain embodiments, the compound comprises anoligonucleotide. In certain such embodiments, the compound consists ofan oligonucleotide. In certain embodiments, the oligonucleotide is amodified oligonucleotide.

In certain such embodiments, embodiments, the compound comprises anoligonucleotide hybridized to a complementary strand, i.e. the compoundcomprises a double-stranded oligomeric compound. In certain embodiments,the hybridization of an oligonucleotide to a complementary strand formsat least one blunt end. In certain such embodiments, the hybridizationof an oligonucleotide to a complementary strand forms a blunt end ateach terminus of the double-stranded oligomeric compound. In certainembodiments, a terminus of an oligonucleotide comprises one or moreadditional linked nucleosides relative to the number of linkednucleosides of the complementary strand. In certain embodiments, the oneor more additional nucleosides are at the 5′ terminus of anoligonucleotide. In certain embodiments, the one or more additionalnucleosides are at the 3′ terminus of an oligonucleotide. In certainembodiments, at least one nucleobase of a nucleoside of the one or moreadditional nucleosides is complementary to the target RNA. In certainembodiments, each nucleobase of each one or more additional nucleosidesis complementary to the target RNA. In certain embodiments, a terminusof the complementary strand comprises one or more additional linkednucleosides relative to the number of linked nucleosides of anoligonucleotide. In certain embodiments, the one or more additionallinked nucleosides are at the 3′ terminus of the complementary strand.In certain embodiments, the one or more additional linked nucleosidesare at the 5′ terminus of the complementary strand. In certainembodiments, two additional linked nucleosides are linked to a terminus.In certain embodiments, one additional nucleoside is linked to aterminus.

In certain embodiments, the compound comprises an oligonucleotideconjugated to one or more moieties which enhance the activity, cellulardistribution or cellular uptake of the resulting antisenseoligonucleotides. In certain such embodiments, the moiety is acholesterol moiety or a lipid moiety. Additional moieties forconjugation include carbohydrates, phospholipids, biotin, phenazine,folate, phenanthridine, anthraquinone, acridine, fluoresceins,rhodamines, coumarins, and dyes. In certain embodiments, a conjugategroup is attached directly to an oligonucleotide. In certainembodiments, a conjugate group is attached to an oligonucleotide by alinking moiety selected from amino, hydroxyl, carboxylic acid, thiol,unsaturations (e.g., double or triple bonds), 8-amino-3,6-dioxaoctanoicacid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate(SMCC), 6-aminohexanoic acid (AHEX or AHA), substituted C1-C10 alkyl,substituted or unsubstituted C2-C10 alkenyl, and substituted orunsubstituted C2-C10 alkynyl. In certain such embodiments, a substituentgroup is selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl,nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

In certain such embodiments, the compound comprises an oligonucleotidehaving one or more stabilizing groups that are attached to one or bothtermini of an oligonucleotide to enhance properties such as, forexample, nuclease stability. Included in stabilizing groups are capstructures. These terminal modifications protect an oligonucleotide fromexonuclease degradation, and can help in delivery and/or localizationwithin a cell. The cap can be present at the 5′-terminus (5′-cap), or atthe 3′-terminus (3′-cap), or can be present on both termini. Capstructures include, for example, inverted deoxy abasic caps.

Suitable cap structures include a 4′,5′-methylene nucleotide, a1-(beta-D-erythrofuranosyl) nucleotide, a 4′-thio nucleotide, acarbocyclic nucleotide, a 1,5-anhydrohexitol nucleotide, anL-nucleotide, an alpha-nucleotide, a modified base nucleotide, aphosphorodithioate linkage, a threo-pentofuranosyl nucleotide, anacyclic 3′,4′-seco nucleotide, an acyclic 3,4-dihydroxybutyl nucleotide,an acyclic 3,5-dihydroxypentyl nucleotide, a 3′-3′-inverted nucleotidemoiety, a 3′-3′-inverted abasic moiety, a 3′-2′-inverted nucleotidemoiety, a 3′-2′-inverted abasic moiety, a 1,4-butanediol phosphate, a3′-phosphoramidate, a hexylphosphate, an aminohexyl phosphate, a3′-phosphate, a 3′-phosphorothioate, a phosphorodithioate, a bridgingmethylphosphonate moiety, and a non-bridging methylphosphonate moiety5′-amino-alkyl phosphate, a 1,3-diamino-2-propyl phosphate,3-aminopropyl phosphate, a 6-aminohexyl phosphate, a 1,2-aminododecylphosphate, a hydroxypropyl phosphate, a 5′-5′-inverted nucleotidemoiety, a 5′-5′-inverted abasic moiety, a 5′-phosphoramidate, a5′-phosphorothioate, a 5′-amino, a bridging and/or non-bridging5′-phosphoramidate, a phosphorothioate, and a 5′-mercapto moiety.

Certain Nucleobase Sequences

In certain embodiments, an oligonucleotide has a sequence that iscomplementary to a miRNA or a precursor thereof. Nucleobase sequences ofmature miRNAs and their corresponding stem-loop sequences describedherein are the sequences found in miRBase, an online searchable databaseof miRNA sequences and annotation, found athttp://microma.sanger.ac.uk/. Entries in the miRBase Sequence databaserepresent a predicted hairpin portion of a miRNA transcript (thestem-loop), with information on the location and sequence of the maturemiRNA sequence. The miRNA stem-loop sequences in the database are notstrictly precursor miRNAs (pre-miRNAs), and may in some instancesinclude the pre-miRNA and some flanking sequence from the presumedprimary transcript. The miRNA nucleobase sequences described hereinencompass any version of the miRNA, including the sequences described inRelease 10.0 of the miRBase sequence database and sequences described inany earlier Release of the miRBase sequence database. A sequencedatabase release may result in the re-naming of certain miRNAs. Thecompositions of the present invention encompass modifiedoligonucleotides that are complementary to any nucleobase sequenceversion of the miRNAs described herein.

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to a miRNA or a precursor thereof. Accordingly, incertain embodiments the nucleobase sequence of an oligonucleotide mayhave one or more mismatched basepairs with respect to its target miRNAor precursor sequence, and remains capable of hybridizing to its targetsequence. In certain embodiments, an oligonucleotide has a nucleobasesequence that is fully complementary to a miRNA or precursor thereof.

In certain embodiments, an oligonucleotide has a sequence that iscomplementary to a nucleobase sequence of a miRNA stem-loop sequenceselected from the miR-103-1 stem-loop sequence, the miR-103-2 stem loopsequence, and the miR-107 stem loop sequence.

In certain embodiments, an oligonucleotide has a sequence that iscomplementary to a nucleobase sequence of a miRNA, where the nucleobasesequence of the miRNA is selected from SEQ ID NO: 1 or 2.

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to a region of the miR-103-1 stem-loop sequence(SEQ ID NO: 3). In certain embodiments, an oligonucleotide has anucleobase sequence that is complementary to the region of nucleobases48-70 of SEQ ID NO: 3.

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to a region of the miR-103-2 stem-loop sequence(SEQ ID NO: 4). In certain embodiments, an oligonucleotide has anucleobase sequence that is complementary to the region of nucleobases48-70 of SEQ ID NO: 4.

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to a region of the miR-107 stem-loop sequence (SEQID NO: 5). In certain embodiments, an oligonucleotide has a nucleobasesequence that is complementary to the region of nucleobases 50-72 of SEQID NO: 5.

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to the nucleobase sequence of miR-103 (SEQ ID NO:1). In certain embodiments, an oligonucleotide has a nucleobase sequencecomprising the nucleobase sequence UCAUAGCCCUGUACAAUGCUGCU (SEQ ID NO:6). In certain embodiments, an oligonucleotide has a nucleobase sequenceconsisting of the nucleobase sequence UCAUAGCCCUGUACAAUGCUGCU (SEQ IDNO: 6).

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to the nucleobase sequence of miR-107 (SEQ ID NO:2). In certain embodiments, an oligonucleotide has a nucleobase sequencecomprising the nucleobase sequence UGAUAGCCCUGUACAAUGCUGCU (SEQ ID NO:7). In certain embodiments, an oligonucleotide has a nucleobase sequenceconsisting of the nucleobase sequence UGAUAGCCCUGUACAAUGCUGCU (SEQ IDNO: 7).

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to the nucleobase sequence of miR-103 or miR-107,and is capable of inhibiting the activity of both miR-103 and miR-107,as a result of the sequence similarity between miR-103 and miR-107. Anoligonucleotide having a nucleobase sequence fully complementary tomiR-103 will have only one mismatch relative to miR-107, thus such anoligonucleotide fully complementary to miR-103 may inhibit the activityof both miR-103 and miR-107. Likewise, an oligonucleotide having anucleobase sequence fully complementary to miR-107 will have only onemismatch relative to miR-103, thus such an oligonucleotide fullycomplementary to miR-107 may inhibit the activity of both miR-103 andmiR-107. As such, oligonucleotides complementary to one or both ofmiR-103 and miR-107 may be used in the methods provided herein. Incertain embodiments, an oligonucleotide has a nucleobase sequence thatis complementary to nucleobases 1-21 of SEQ ID NO: 1 (miR-103) or tonucleobases 1-21 of SEQ ID NO: 2 (miR-107). Such oligonucleotides are100% complementary to both miR-103 and miR-107. In certain suchembodiments, an oligonucleotide comprises the nucleobase sequenceAUAGCCCUGUACAAUGCUGCU (SEQ ID NO: 8). In certain such embodiments, anoligonucleotide consists of the nucleobase sequenceAUAGCCCUGUACAAUGCUGCU (SEQ ID NO: 8).

In certain embodiments, an oligonucleotide comprises a nucleobasesequence that is complementary to a seed sequence shared between miR-103and miR-107. Oligonucleotides having any length described herein maycomprise a seed-match sequence. In certain such embodiments, themodified oligonucleotide consists of 7 linked nucleosides. In certainembodiments, the modified oligonucleotide consists of 8 linkednucleosides. In certain embodiments, the modified oligonucleotideconsists of 9 linked nucleosides. In certain embodiments, the modifiedoligonucleotide consists of 10 linked nucleosides. In certainembodiments, the modified oligonucleotide consists of 11 linkednucleosides. In certain embodiments, the modified oligonucleotideconsists of 12 linked nucleosides.

In certain embodiments, the nucleobase sequence of the modifiedoligonucleotide is comprises the nucleobase sequence AUGCUGCU (SEQ IDNO: 10), which is complementary to nucleotides 1-8 of miR-103 (SEQ IDNO: 1) and miR-107 (SEQ ID NO: 2). In certain embodiments, thenucleobase sequence of the modified oligonucleotide comprises thenucleobase sequence AUGCUGC (SEQ ID NO: 11) which is complementary tonucleotides 2-8 of miR-103 and miR-107. In certain embodiments, thenucleobase sequence of the modified oligonucleotide comprises thenucleobase sequence UGCUGCU (SEQ ID NO: 12) which is complementary tonucleotides 1-7 of miR-103 and miR-107. In certain embodiments, thenucleobase sequence of the modified oligonucleotide comprises thenucleobase sequence AUGCUGC (SEQ ID NO: 13) which is complementary tonucleotides 2-8 of miR-103 and miR-107. In certain embodiments, thenucleobase sequence of the modified oligonucleotide comprises thenucleobase sequence GCUGCU (SEQ ID NO: 14) which is complementary tonucleotides 1-6 of miR-103 or miR-107. In certain embodiments, thenucleobase sequence of the modified oligonucleotide comprises thenucleobase sequence UGCUGC (SEQ ID NO: 15) which is complementary tonucleotides 2-7 of miR-103 and miR-107. In certain embodiments, thenucleobase sequence of the modified oligonucleotide comprises thenucleobase sequence AUGCUG (SEQ ID NO: 16) which is complementary tonucleotides 3-8 of miR-103 and miR-107.

Modified oligonucleotides consisting of 7, 8, 9, 10, or 11 linkednucleosides and complementary to nucleotides 2 through 8 or 2 through 7of a miRNA have been shown to inhibit activity of the miRNA. Modifiedoligonucleotides consisting of 8 linked nucleosides and complementary tonucleotides 2 through 9 of a miRNA have also been shown to inhibitactivity of the miRNA. Certain of these modified oligonucleotides havean LNA sugar modification at each nucleoside. Such inhibitory activityis described in PCT Publication No. WO/2009/043353, which is hereinincorporated by reference in its entirety for its description ofmodified oligonucleotides targeting miRNA seed sequences.

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to a nucleobase sequence having at least 80%identity to a nucleobase sequence of a miR stem-loop sequence selectedfrom SEQ ID NO: 3, 4, and 5. In certain embodiments, an oligonucleotidehas a nucleobase sequence that is complementary to a nucleobase sequencehaving at least 85%, at least 90%, at least 92%, at least 94%, at least96%, at least 98% identity, or 100% identity to a nucleobase sequence ofa miR stem-loop sequence selected from SEQ ID NOs 3, 4, and 5.

In certain embodiments, an oligonucleotide has a nucleobase sequencethat is complementary to a nucleobase sequence having at least 80%identity to a nucleobase sequence of a miRNA having a nucleobasesequence selected from SEQ ID NOs 1 and 2. In certain embodiments, anoligonucleotide has a nucleobase sequence that is complementary to anucleobase sequence having at least 85%, at least 90%, at least 92%, atleast 94%, at least 96%, at least 98% identity, or 100% identity to anucleobase sequence of a miRNA nucleobase sequence selected from SEQ IDNOs 1 and 2.

In certain embodiments, a nucleobase sequence of an oligonucleotide isfully complementary to a miRNA nucleobase sequence listed herein, or aprecursor thereof. In certain embodiments, an oligonucleotide has anucleobase sequence having one mismatch with respect to the nucleobasesequence of the mature miRNA, or a precursor thereof. In certainembodiments, an oligonucleotide has a nucleobase sequence having twomismatches with respect to the nucleobase sequence of the miRNA, or aprecursor thereof. In certain such embodiments, an oligonucleotide has anucleobase sequence having no more than two mismatches with respect tothe nucleobase sequence of the mature miRNA, or a precursor thereof. Incertain such embodiments, the mismatched nucleobases are contiguous. Incertain such embodiments, the mismatched nucleobases are not contiguous.

In certain embodiments, an oligonucleotide consists of a number oflinked nucleosides that is equal to the length of the mature miR towhich it is complementary.

In certain embodiments, the number of linked nucleosides of anoligonucleotide is less than the length of the mature miRNA to which itis complementary. In certain such embodiments, the number of linkednucleosides of an oligonucleotide is one less than the length of themature miR to which it is complementary. In certain such embodiments, anoligonucleotide has one less nucleoside at the 5′ terminus. In certainsuch embodiments, an oligonucleotide has one less nucleoside at the 3′terminus. In certain such embodiments, an oligonucleotide has two fewernucleosides at the 5′ terminus. In certain such embodiments, anoligonucleotide has two fewer nucleosides at the 3′ terminus. Anoligonucleotide having a number of linked nucleosides that is less thanthe length of the miRNA, wherein each nucleobase of an oligonucleotideis complementary to each nucleobase at a corresponding position in amiRNA, is considered to be an oligonucleotide having a nucleobasesequence that is fully complementary to a portion of a miRNA sequence.

In certain embodiments, the number of linked nucleosides of anoligonucleotide is greater than the length of the miRNA to which it iscomplementary. In certain such embodiments, the nucleobase of anadditional nucleoside is complementary to a nucleobase of a miRNAstem-loop sequence. In certain embodiments, the number of linkednucleosides of an oligonucleotide is one greater than the length of themiRNA to which it is complementary. In certain such embodiments, theadditional nucleoside is at the 5′ terminus of an oligonucleotide. Incertain such embodiments, the additional nucleoside is at the 3′terminus of an oligonucleotide. In certain embodiments, the number oflinked nucleosides of an oligonucleotide is two greater than the lengthof the miRNA to which it is complementary. In certain such embodiments,the two additional nucleosides are at the 5′ terminus of anoligonucleotide. In certain such embodiments, the two additionalnucleosides are at the 3′ terminus of an oligonucleotide. In certainsuch embodiments, one additional nucleoside is located at the 5′terminus and one additional nucleoside is located at the 3′ terminus ofan oligonucleotide.

In certain embodiments, a portion of the nucleobase sequence of anoligonucleotide is fully complementary to the nucleobase sequence of themiRNA, but the entire modified oligonucleotide is not fullycomplementary to the miRNA. In certain such embodiments, the number ofnucleosides of an oligonucleotide having a fully complementary portionis greater than the length of the miRNA. For example, an oligonucleotideconsisting of 24 linked nucleosides, where the nucleobases ofnucleosides 1 through 23 are each complementary to a correspondingposition of a miRNA that is 23 nucleobases in length, has a 23nucleoside portion that is fully complementary to the nucleobasesequence of the miRNA and approximately 96% overall complementarity tothe nucleobase sequence of the miRNA.

In certain embodiments, the nucleobase sequence of an oligonucleotide isfully complementary to a portion of the nucleobase sequence of a miRNA.For example, an oligonucleotide consisting of 22 linked nucleosides,where the nucleobases of nucleosides 1 through 22 are each complementaryto a corresponding position of a miRNA that is 23 nucleobases in length,is fully complementary to a 22 nucleobase portion of the nucleobasesequence of a miRNA. Such an oligonucleotide has approximately 96%overall complementarity to the nucleobase sequence of the entire miRNA,and has 100% complementarity to a 22 nucleobase portion of the miRNA.

In certain embodiments, a portion of the nucleobase sequence of anoligonucleotide is fully complementary to a portion of the nucleobasesequence of a miRNA, or a precursor thereof. In certain suchembodiments, 15 contiguous nucleobases of an oligonucleotide are eachcomplementary to 15 contiguous nucleobases of a miRNA, or a precursorthereof. In certain such embodiments, 16 contiguous nucleobases of anoligonucleotide are each complementary to 16 contiguous nucleobases of amiRNA, or a precursor thereof. In certain such embodiments, 17contiguous nucleobases of an oligonucleotide are each complementary to17 contiguous nucleobases of a miRNA, or a precursor thereof. In certainsuch embodiments, 18 contiguous nucleobases of an oligonucleotide areeach complementary to 18 contiguous nucleobases of a miRNA, or aprecursor thereof. In certain such embodiments, 19 contiguousnucleobases of an oligonucleotide are each complementary to 19contiguous nucleobases of a miRNA, or a precursor thereof. In certainsuch embodiments, 20 contiguous nucleobases of an oligonucleotide areeach complementary to 20 contiguous nucleobases of a miRNA, or aprecursor thereof. In certain such embodiments, 22 contiguousnucleobases of an oligonucleotide are each complementary to 22contiguous nucleobases of a miRNA, or a precursor thereof. In certainsuch embodiments, 23 contiguous nucleobases of an oligonucleotide areeach complementary to 23 contiguous nucleobases of a miRNA, or aprecursor thereof. In certain such embodiments, 24 contiguousnucleobases of an oligonucleotide are each complementary to 24contiguous nucleobases of a miRNA, or a precursor thereof.

The nucleobase sequences set forth herein, including but not limited tothose found in the Examples and in the sequence listing, are independentof any modification to the nucleic acid. As such, nucleic acids definedby a SEQ ID NO may comprise, independently, one or more modifications toone or more sugar moieties, to one or more internucleoside linkages,and/or to one or more nucleobases.

Although the sequence listing accompanying this filing identifies eachnucleobase sequence as either “RNA” or “DNA” as required, in practice,those sequences may be modified with any combination of chemicalmodifications. One of skill in the art will readily appreciate that suchdesignation as “RNA” or “DNA” to describe modified oligonucleotides issomewhat arbitrary. For example, an oligonucleotide comprising anucleoside comprising a 2′-OH sugar moiety and a thymine base could bedescribed as a DNA having a modified sugar (2′-OH for the natural 2′-Hof DNA) or as an RNA having a modified base (thymine (methylated uracil)for natural uracil of RNA).

Accordingly, nucleic acid sequences provided herein, including, but notlimited to those in the sequence listing, are intended to encompassnucleic acids containing any combination of natural or modified RNAand/or DNA, including, but not limited to such nucleic acids havingmodified nucleobases. By way of further example and without limitation,an oligomeric compound having the nucleobase sequence “ATCGATCG”encompasses any oligomeric compounds having such nucleobase sequence,whether modified or unmodified, including, but not limited to, suchcompounds comprising RNA bases, such as those having sequence “AUCGAUCG”and those having some DNA bases and some RNA bases such as “AUCGATCG”and oligomeric compounds having other modified bases, such as“AT^(me)CGAUCG,” wherein ^(me)C indicates a cytosine base comprising amethyl group at the 5-position.

Certain Modified Oligonucleotides

In certain embodiments, an oligonucleotide consists of 7 to 25 linkednucleosides. In certain embodiments, an oligonucleotide consists of 7 to11 linked nucleosides. In certain embodiments, an oligonucleotideconsists of 12 to 30 linked nucleosides. In certain embodiments, anoligonucleotide consists of 15 to 30 linked nucleosides. In certainembodiments, an oligonucleotide consists of 19 to 24 linked nucleosides.In certain embodiments, an oligonucleotide consists of 21 to 24 linkednucleosides.

In certain embodiments, an oligonucleotide consists of 7 linkednucleosides. In certain embodiments, an oligonucleotide consists of 8linked nucleosides. In certain embodiments, an oligonucleotide consistsof 9 linked nucleosides. In certain embodiments, an oligonucleotideconsists of 10 linked nucleosides. In certain embodiments, anoligonucleotide consists of 11 linked nucleosides. In certainembodiments, an oligonucleotide consists of 12 linked nucleosides. Incertain embodiments, an oligonucleotide consists of 13 linkednucleosides. In certain embodiments, an oligonucleotide consists of 14linked nucleosides. In certain embodiments, an oligonucleotide consistsof 15 linked nucleosides. In certain embodiments, an oligonucleotideconsists of 16 linked nucleosides. In certain embodiments, anoligonucleotide consists of 17 linked nucleosides. In certainembodiments, an oligonucleotide consists of 18 linked nucleosides. Incertain embodiments, an oligonucleotide consists of 19 linkednucleosides. In certain embodiments, an oligonucleotide consists of 20linked nucleosides. In certain embodiments, an oligonucleotide consistsof 21 linked nucleosides. In certain embodiments, an oligonucleotideconsists of 22 linked nucleosides. In certain embodiments, anoligonucleotide consists of 23 linked nucleosides. In certainembodiments, an oligonucleotide consists of 24 linked nucleosides. Incertain embodiments, an oligonucleotide consists of 25 linkednucleosides. In certain embodiments, an oligonucleotide consists of 26linked nucleosides. In certain embodiments, an oligonucleotide consistsof 27 linked nucleosides. In certain embodiments, an oligonucleotideconsists of 28 linked nucleosides. In certain embodiments, anoligonucleotide consists of 29 linked nucleosides. In certainembodiments, an oligonucleotide consists of 30 linked nucleosides.

Certain Modifications

In certain embodiments, oligonucleotides provided herein may compriseone or more modifications to a nucleobase, sugar, and/or internucleosidelinkage, and as such is a modified oligonucleotide. A modifiednucleobase, sugar, and/or internucleoside linkage may be selected overan unmodified form because of desirable properties such as, for example,enhanced cellular uptake, enhanced affinity for other oligonucleotidesor nucleic acid targets and increased stability in the presence ofnucleases.

In certain embodiments, a modified oligonucleotide comprises one or moremodified nucleosides. In certain such embodiments, a modified nucleosideis a stabilizing nucleoside. An example of a stabilizing nucleoside is asugar-modified nucleoside.

In certain embodiments, a modified nucleoside is a sugar-modifiednucleoside. In certain such embodiments, the sugar-modified nucleosidescan further comprise a natural or modified heterocyclic base moietyand/or a natural or modified internucleoside linkage and may includefurther modifications independent from the sugar modification. Incertain embodiments, a sugar modified nucleoside is a 2′-modifiednucleoside, wherein the sugar ring is modified at the 2′ carbon fromnatural ribose or 2′-deoxy-ribose.

In certain embodiments, a 2′-modified nucleoside has a bicyclic sugarmoiety. In certain embodiments, the bicyclic sugar moiety is a D sugarin the alpha configuration. In certain embodiments, the bicyclic sugarmoiety is a D sugar in the beta configuration. In certain embodiments,the bicyclic sugar moiety is an L sugar in the alpha configuration. Incertain embodiments, the bicyclic sugar moiety is an L sugar in the betaconfiguration.

In certain embodiments, the bicyclic sugar moiety comprises a bridgegroup between the 2′ and the 4′-carbon atoms. In certain suchembodiments, the bridge group comprises from 1 to 8 linked biradicalgroups. In certain embodiments, the bicyclic sugar moiety comprises from1 to 4 linked biradical groups. In certain embodiments, the bicyclicsugar moiety comprises 2 or 3 linked biradical groups. In certainembodiments, the bicyclic sugar moiety comprises 2 linked biradicalgroups. In certain embodiments, a linked biradical group is selectedfrom —O—, —S—, —N(R₁)—, —C(R₁)(R₂)—, —C(R₁)═C(R₁)—, —C(R₁)═N—,—C(═NR₁)—, —Si(R₁)(R₂)—, —S(═O)—, —C(═O)— and —C(═S)—; where each R₁ andR₂ is, independently, H, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl,substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, aheterocycle radical, a substituted heterocycle radical, heteroaryl,substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇alicyclic radical, halogen, substituted oxy (—O—), amino, substitutedamino, azido, carboxyl, substituted carboxyl, acyl, substituted acyl,CN, thiol, substituted thiol, sulfonyl (S(═O)₂—H), substituted sulfonyl,sulfoxyl (S(═O)—H) or substituted sulfoxyl; and each substituent groupis independently, halogen, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl,C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substitutedC₂-C₁₂ alkynyl, amino, substituted amino, acyl, substituted acyl, C₁-C₁₂aminoalkyl, C₁-C₁₂ aminoalkoxy, substituted C₁-C₁₂ aminoalkyl,substituted C₁-C₁₂ aminoalkoxy or a protecting group.

In some embodiments, the bicyclic sugar moiety is bridged between the 2′and 4′ carbon atoms with a biradical group selected from —O—(CH₂)_(p)—,—O—CH₂—, —O—CH₂CH₂—, —O—CH(alkyl)-, —NH—(CH₂)_(p)—,—N(alkyl)-(CH₂)_(p)—, —O—CH(alkyl)-, —(CH(alkyl))—(CH₂)_(p)—,—NH—O—(CH₂)_(p)—, —N(alkyl)-O—(CH₂)_(p)—, or —O—N(alkyl)-(CH₂)_(p)—,wherein p is 1, 2, 3, 4 or 5 and each alkyl group can be furthersubstituted. In certain embodiments, p is 1, 2 or 3. In certainembodiments, a bicyclic sugar moiety is —O—(CH₂)), also known as ‘lockednucleic acid’ or ‘LNA.’

In certain embodiments, a 2′-modified nucleoside comprises a2′-substituent group selected from halo, allyl, amino, azido, SH, CN,OCN, CF₃, OCF₃, O—, S—, or N(R_(m))-alkyl; O—, S—, or N(R_(m))-alkenyl;O—, S— or N(R_(m))-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl,aralkyl, O-alkaryl, O-aralkyl, O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n))or O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m), and R_(n) is,independently, H, an amino protecting group or substituted orunsubstituted C₁-C₁₀ alkyl. These 2′-substituent groups can be furthersubstituted with one or more substituent groups independently selectedfrom hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO₂),thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.

In certain embodiments, a 2′-modified nucleoside comprises a2′-substituent group selected from F, NH₂, N₃, OCF₃, O—CH₃, O(CH₂)₃NH₂,CH₂—CH═CH₂, O—CH₂—CH═CH₂, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃,O—(CH₂)₂—O—N(R_(m))(R_(n)), —O(CH₂)₂—O—(CH₂)₂N(CH₃)₂, and N-substitutedacetamide (O—CH, —C(═O)—N(R_(m))(R_(n)) where each R_(m) and R_(n) is,independently, H, an amino protecting group or substituted orunsubstituted C₁-C₁₀ alkyl.

In certain embodiments, a 2′-modified nucleoside comprises a2′-substituent group selected from F, OCF₃, O—CH₃, OCH₂CH₂OCH₃,2′-O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(CH₃)₂, —O(CH₂)₂O(CH₂)₂N(CH₃)₂, andO—CH₂—C(═O)—N(H)CH₃.

In certain embodiments, a 2′-modified nucleoside comprises a2′-substituent group selected from F, O—CH₃, and OCH₂CH₂OCH₃.

In certain embodiments, a sugar-modified nucleoside is a 4′-thiomodified nucleoside. In certain embodiments, a sugar-modified nucleosideis a 4′-thio-2′-modified nucleoside. A 4′-thio modified nucleoside has aβ-D-ribonucleoside where the 4′-O replaced with 4′-S. A4′-thio-2′-modified nucleoside is a 4′-thio modified nucleoside havingthe 2′-OH replaced with a 2′-substituent group. Suitable 2′-substituentgroups include 2′-OCH₃, 2′-O—(CH₂)₂—OCH₃, and 2′-F.

In certain embodiments, a modified oligonucleotide comprises one or moreinternucleoside modifications. In certain such embodiments, eachinternucleoside linkage of an oligonucleotide is a modifiedinternucleoside linkage. In certain embodiments, a modifiedinternucleoside linkage comprises a phosphorus atom.

In certain embodiments, a modified oligonucleotide comprises at leastone phosphorothioate internucleoside linkage. In certain embodiments,each internucleoside linkage of a modified oligonucleotide is aphosphorothioate internucleoside linkage.

In certain embodiments, a modified internucleoside linkage does notcomprise a phosphorus atom. In certain such embodiments, aninternucleoside linkage is formed by a short chain alkyl internucleosidelinkage. In certain such embodiments, an internucleoside linkage isformed by a cycloalkyl internucleoside linkages. In certain suchembodiments, an internucleoside linkage is formed by a mixed heteroatomand alkyl internucleoside linkage. In certain such embodiments, aninternucleoside linkage is formed by a mixed heteroatom and cycloalkylinternucleoside linkages. In certain such embodiments, aninternucleoside linkage is formed by one or more short chainheteroatomic internucleoside linkages. In certain such embodiments, aninternucleoside linkage is formed by one or more heterocyclicinternucleoside linkages. In certain such embodiments, aninternucleoside linkage has an amide backbone. In certain suchembodiments, an internucleoside linkage has mixed N, O, S and CH,component parts.

In certain embodiments, a modified oligonucleotide comprises one or moremodified nucleobases. In certain embodiments, a modified oligonucleotidecomprises one or more 5-methylcytosines. In certain embodiments, eachcytosine of a modified oligonucleotide comprises a 5-methylcytosine.

In certain embodiments, a modified nucleobase is selected from5-hydroxymethyl cytosine, 7-deazaguanine and 7-deazaadenine. In certainembodiments, a modified nucleobase is selected from 7-deaza-adenine,7-deazaguanosine, 2-aminopyridine and 2-pyridone. In certainembodiments, a modified nucleobase is selected from 5-substitutedpyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines,including 2 aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

In certain embodiments, a modified nucleobase comprises a polycyclicheterocycle. In certain embodiments, a modified nucleobase comprises atricyclic heterocycle. In certain embodiments, a modified nucleobasecomprises a phenoxazine derivative. In certain embodiments, thephenoxazine can be further modified to form a nucleobase known in theart as a G-clamp.

Certain Oligonucleotide Motifs

Suitable motifs for modified oligonucleotides of the present inventioninclude, but are not limited to, fully modified, uniformly modified,positionally modified, and gapmer. Modified oligonucleotides having afully modified motif, including a uniformly modified motif, may bedesigned to target mature miRNAs. Alternatively, modifiedoligonucleotides having a fully modified motif, including a uniformlymodified motif, may be designed to target certain sites of pri-miRNAs orpre-miRNAs, to block the processing of miRNA precursors into maturemiRNAs. Modified oligonucleotides having a fully modified motif oruniformly modified motif are effective inhibitors of miRNA activity.

In certain embodiments, a fully modified oligonucleotide comprises asugar modification at each nucleoside. In certain such embodiments,pluralities of nucleosides are 2′-O-methoxyethyl nucleosides and theremaining nucleosides are 2′-fluoro nucleosides. In certain suchembodiments, each of a plurality of nucleosides is a 2′-O-methoxyethylnucleoside and each of a plurality of nucleosides is a bicyclicnucleoside. In certain such embodiments, a fully modifiedoligonucleotide further comprises at least one modified internucleosidelinkage. In certain such embodiments, each internucleoside linkage of afully sugar-modified oligonucleotide is a modified internucleosidelinkage. In certain embodiments, a fully sugar-modified oligonucleotidefurther comprises at least one phosphorothioate internucleoside linkage.In certain such embodiments, each internucleoside linkage of a fullysugar-modified oligonucleotide is a phosphorothioate internucleosidelinkage.

In certain embodiments, a fully modified oligonucleotide is modified ateach internucleoside linkage. In certain such embodiments, eachinternucleoside linkage of a fully modified oligonucleotide is aphosphorothioate internucleoside linkage.

In certain embodiments, a uniformly modified oligonucleotide comprisesthe same sugar modification at each nucleoside. In certain suchembodiments, each nucleoside of a modified oligonucleotide comprises a2′-O-methoxyethyl sugar modification. In certain embodiments, eachnucleoside of a modified oligonucleotide comprises a 2′-O-methyl sugarmodification. In certain embodiments, each nucleoside of a modifiedoligonucleotide comprises a 2′-fluoro sugar modification. In certainsuch embodiments, a uniformly modified oligonucleotide further comprisesat least one modified internucleoside linkage. In certain suchembodiments, each internucleoside linkage of a uniformly sugar-modifiedoligonucleotide is a modified internucleoside linkage. In certainembodiments, a uniformly sugar-modified oligonucleotide furthercomprises at least one phosphorothioate internucleoside linkage. Incertain such embodiments, each internucleoside linkage of a uniformlysugar-modified oligonucleotide is a phosphorothioate internucleosidelinkage.

In certain embodiments, a uniformly modified oligonucleoside comprisesthe same internucleoside linkage modifications throughout. In certainsuch embodiments, each internucleoside linkage of a uniformly modifiedoligonucleotide is a phosphorothioate internucleoside linkage.

In certain embodiments, a positionally modified oligonucleotidecomprises regions of linked nucleosides, where each nucleoside of eachregion comprises the same sugar moiety, and where each nucleoside ofeach region comprises a sugar moiety different from that of an adjacentregion.

In certain embodiments, a positionally modified oligonucleotidecomprises at least 10 2′-fluoro modified nucleosides. Such apositionally modified oligonucleotide may be represented by thefollowing formula I:

5′-T₁-(Nu₂-L₂)_(n1)-(Nu₂-L₂)_(n2)-(L₃-Nu₃)_(n3)-T₂-3′,wherein:

each Nu₁ and Nu₃ is, independently, a stabilizing nucleoside; at least10 Nu₂ are 2′-fluoro nucleosides;

each L₁, L₂ and L₃ is, independently, an internucleoside linkage;

each T₁ and T₂ is, independently, H, a hydroxyl protecting group, anoptionally linked conjugate group or a capping group;

n₁ is from 0 to about 3;

n₂ is from about 14 to about 22;

n₃ is from 0 to about 3; and

provided that if n₁ is 0 then T₁ is not H or a hydroxyl protectinggroup, and if n₃ is 0, then T₂ is not H or a hydroxyl protecting group.

In certain such embodiments, n₁ and n₃ are each, independently, from 1to about 3. In certain embodiments, n₁ and n₃ are each, independently,from 2 to about 3. In certain embodiments, n₁ is 1 or 2 and n₃ is 2 or3. In certain embodiments, n₁ and n₃ are each 2. In certain embodiments,at least one of n₁ and n₃ is greater than zero. In certain embodiments,n₁ and n₃ is each greater than zero. In certain embodiments, one of n₁and n₃ is greater than zero. In certain embodiments, one of n₂ and n₃ isgreater than one.

In certain embodiments, n₂ is from 16 to 20. In certain embodiments, n₂is from 17 to 19. In certain embodiments, n₂ is 18. In certainembodiments, n₂ is 19. In certain embodiments, n₂ is 20.

In certain embodiments, about 2 to about 8 of the Nu₂ nucleosides arestabilizing nucleosides. In certain embodiments, from about 2 to about 6of the Nu₂ nucleosides are stabilizing nucleosides. In certainembodiments, from about 3 to about 4 of the Nu₂ nucleosides arestabilizing nucleosides. In certain embodiments, 3 of the Nu₂nucleosides are stabilizing nucleosides.

In certain embodiments, each of the Nu₂ stabilizing nucleosides isseparated from the Nu₃ stabilizing nucleosides by from 2 to about 82′-fluoro nucleosides. In certain embodiments each of the Nu₂stabilizing nucleosides is separated from the Nu₃ stabilizingnucleosides by from 3 to about 8 2′-fluoro nucleosides. In certainembodiments each of the Nu₂ stabilizing nucleosides is separated fromthe Nu₃ stabilizing nucleosides by from 5 to about 8 2′-fluoronucleosides.

In certain embodiments, a modified oligonucleotide comprises from 2 toabout 6 Nu₂ stabilizing nucleosides. In certain embodiments, a modifiedoligonucleotide comprises 3 Nu₂ stabilizing nucleosides.

In certain embodiments, each of the Nu₂ stabilizing nucleosides islinked together in one contiguous sequence. In certain embodiments, atleast two of the Nu₂ stabilizing nucleosides are separated by at leastone of the 2′-fluoro nucleosides. In certain embodiments, each of theNu₂ stabilizing nucleosides is separated by at least one of the2′-fluoro nucleosides.

In certain embodiments, at least two contiguous sequences of the Nu₂2′-fluoro nucleosides are separated by at least one of the stabilizingnucleosides wherein each of the contiguous sequences have the samenumber of 2′-fluoro nucleosides.

In certain embodiments, T₁ and T₂ are each, independently, H or ahydroxyl protecting group. In certain embodiments, at least one of T₁and T₂ is 4,4′-dimethoxytrityl. In certain embodiments, at least one ofT₁ and T₂ is an optionally linked conjugate group. In certainembodiments, at least one of T₁ and T₂ is a capping group. In certainembodiments, the capping group is an inverted deoxy abasic group.

In certain embodiments, a positionally modified oligonucleotidecomprises at least one modified internucleoside linkage. In certain suchembodiments, each internucleoside linkage of a positionally modifiedoligonucleoside is a modified internucleoside linkage. In certainembodiments, at least one internucleoside linkage of a positionallymodified oligonucleotide is a phosphorothioate internucleoside linkage.In certain such embodiments, each internucleoside linkage of apositionally modified oligonucleotide is a phosphorothioateinternucleoside linkage.

In certain embodiments, a positionally modified motif is represented bythe following formula II, which represents a modified oligonucleotideconsisting of linked nucleosides:

T₁-(Nu₁)_(n1)-(Nu₂)_(n2)-(Nu₃)_(n3)-(Nu₄)_(n4)-(Nu₅)_(n5)-T₂,wherein:

Nu₁ and Nu₅ are, independently, 2′ stabilizing nucleosides;

Nu₂ and Nu₄ are 2′-fluoro nucleosides;

Nu₃ is a 2′-modified nucleoside;

each of n₁ and n₅ is, independently, from 0 to 3;

the sum of n₂ plus n₄ is between 10 and 25;

n₃ is from 0 and 5; and

each T₁ and T₂ is, independently, H, a hydroxyl protecting group, anoptionally linked conjugate group or a capping group.

In certain embodiments, the sum of n₂ and n₄ is 16. In certainembodiments, the sum of n₂ and n₄ is 17. In certain embodiments, the sumof n₂ and n₄ is 18. In certain embodiments, n₁ is 2; n₃ is 2 or 3; andn₅ is 2.

In certain embodiments, Nu₁ and Nu₅ are, independently, 2′-modifiednucleosides. In certain embodiments, each internucleoside linkage is amodified internucleoside linkage. In certain such embodiments, eachinternucleoside is a phosphorothioate linkage.

In certain embodiments, a nucleoside comprises a modified nucleobase. Incertain embodiments, where a 2′-O-methoxyethyl nucleoside comprisescytosine, the cytosine is a 5-methylcytosine.

In certain embodiments, Nu₁ is O—(CH₂)₂—OCH₃, Nu₃ is O—(CH₂)₂—OCH₃, andNu₅ O—(CH₂)₂—OCH₃.

In certain embodiments, Nu₁ is O—(CH₂)₂—OCH₃, N₃ is O—(CH₂)₂—OCH₃, Nu₅O—(CH₂)₂—OCH₃, T₁ is H and T₂ is H.

In certain embodiments, the sum of n₂ and n₄ is 13. In certainembodiments, the sum of n₂ and n₄ is 14. In certain embodiments, the sumof n₂ and n₄ is 15. In certain embodiments, the sum of n₂ and n₄ is 16.In certain embodiments, the sum of n₂ and n₄ is 17. In certainembodiments, the sum of n₂ and n₄ is 18.

In certain embodiments, n₁, n₂, and n₃ are each, independently, from 1to 3. In certain embodiments, n₁, n₂, and n₃ are each, independently,from 2 to 3. In certain embodiments, n₁ is 1 or 2; n₂ is 2 or 3; and n₃is 1 or 2. In certain embodiments, n₁ is 2; n₃ is 2 or 3; and n₅ is 2.In certain embodiments, n₁ is 2; n₃ is 3; and n₅ is 2. In certainembodiments, n₁ is 2; n₃ is 2; and n₅ is 2.

In certain embodiments, a modified oligonucleotide consists of 20 linkednucleosides. In certain such embodiments, the sum of n₂ and n₄ is 13; n₁is 2; n₃ is 3; and n₅ is 2. In certain such embodiments, the sum of n₂and n₄ is 14; n₁ is 2; n₃ is 2; and n₅ is 2.

In certain embodiments, a modified oligonucleotide consists of 21 linkednucleosides. In certain such embodiments, the sum of n₂ and n₄ is 14; n₁is 2; n₃ is 3; and n₅ is 2. In certain such embodiments, the sum of n₂and n₄ is 15; n₁ is 2; n₃ is 2; and n₅ is 2.

In certain embodiments, a modified oligonucleotide consists of 22 linkednucleosides. In certain such embodiments, the sum of n₂ and n₄ is 15; n₁is 2; n₃ is 3; and n₅ is 2. In certain such embodiments, the sum of n₂and n₄ is 16; n₁ is 2; n₃ is 2; and n₅ is 2.

In certain embodiments, a modified oligonucleotide consists of 23 linkednucleosides. In certain such embodiments, the sum of n₂ and n₄ is 16; n₁is 2; n₃ is 3; and n₅ is 2. In certain such embodiments, the sum of n₂and n₄ is 17; n₁ is 2; n₃ is 2; and n₅ is 2.

In certain embodiments, a modified oligonucleotide consists of 24 linkednucleosides. In certain such embodiments, the sum of n₂ and n₄ is 17; n₁is 2; n₃ is 3; and n₅ is 2. In certain such embodiments, the sum of n₂and n₄ is 18; n₁ is 2; n₃ is 2; and n₅ is 2.

In certain embodiments, a modified oligonucleotide consists of 23 linkednucleosides; n₁ is 2; n₂ is 10; n₃ is 3; n₄ is 6; n₅ is 2; Nu₁ isO—(CH₂)₂—OCH₃; Nu₃ is O—(CH₂)₂—OCH₃; and Nu₅ O—(CH₂)₂—OCH₃.

In certain embodiments, a modified oligonucleotide consists of 23 linkednucleosides; n₁ is 2; n₁ is 10; n₃ is 3; n₄ is 6; n₅ is 2; Nu₁ isO—(CH₂)₂—OCH₃; Nu₃ is O—(CH₂)₂—OCH₃; and Nu₅ O—(CH₂)₂—OCH₃; and eachinternucleoside linkage is a phosphorothioate linkage.

In certain embodiments, a modified oligonucleotide consists of 23 linkednucleosides; has the nucleobase sequence of SEQ ID NO: 6; n₁ is 2; n₂ is10; n₃ is 3; n₄ is 6; n₅ is 2; Nu₁ is O—(CH₂)₂—OCH₃; Nu₃ isO—(CH₂)₂—OCH₃; Nu₅ O—(CH₂); each internucleoside linkage is aphosphorothioate linkage; the cytosine at nucleobase 2 is a5-methylcytosine; the cytosine at position 14 is a 5-methylcytosine; andthe cytosine at nucleobase 22 is a 5-methylcytosine.

In certain embodiments, a modified oligonucleotide consists of 23 linkednucleosides; has the nucleobase sequence of SEQ ID NO: 7; n₁ is 2; n₂ is10; n₃ is 3; n₄ is 6; n₅ is 2; Nu₁ is O—(CH₂)₂—OCH₃; Nu₃ isO—(CH₂)₂—OCH₃; Nu₅ O—(CH₂); each internucleoside linkage is aphosphorothioate linkage; the cytosine at nucleobase 2 is a5-methylcytosine; the cytosine at position 14 is a 5-methylcytosine; andthe cytosine at nucleobase 22 is a 5-methylcytosine.

In certain embodiments, a modified oligonucleotide consists of 21 linkednucleosides; has the nucleobase sequence of SEQ ID NO: 8; n₁ is 2; n₂ is8; n₃ is 3; n₄ is 6; n₅ is 2; Nu₁ is O—(CH₂)₂—OCH₃; Nu₃ isO—(CH₂)₂—OCH₃; Nu₅ O—(CH₂); each internucleoside linkage is aphosphorothioate linkage; the cytosine at nucleobase 2 is a5-methylcytosine; and the cytosine at position 14 is a 5-methylcytosine.

In certain embodiments, a modified oligonucleotide complementary to amiRNA and consisting of 21 linked nucleosides has a Formula II selectedfrom Table 2, where each internucleoside linkage is a phosphorothioateinternucleoside linkage. In certain embodiments, a modifiedoligonucleotide having a Formula II selected from Table 2 has thenucleobase sequence of SEQ ID NO: 8.

TABLE 2 SEQ ID NO n₁ n₂ n₃ n₄ n₅ Nu₁ Nu₃ Nu₅ T₁ T₂ 8 2 17 0 0 2 2′-MOE2′-MOE 2′-MOE H H 8 2 2 2 13 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 3 2 12 22′-MOE 2′-MOE 2′-MOE H H 8 2 4 2 11 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 5 210 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 6 2 9 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 72 8 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 8 2 7 2 2′-MOE 2′-MOE 2′-MOE H H 8 29 2 6 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 10 2 5 2 2′-MOE 2′-MOE 2′-MOE H H 82 11 2 4 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 12 2 3 2 2′-MOE 2′-MOE 2′-MOE HH 8 2 13 2 2 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 2 3 12 2 2′-MOE 2′-MOE2′-MOE H H 8 2 3 3 11 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 4 3 10 2 2′-MOE2′-MOE 2′-MOE H H 8 2 5 3 9 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 6 3 8 22′-MOE 2′-MOE 2′-MOE H H 8 2 7 3 7 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 8 3 62 2′-MOE 2′-MOE 2′-MOE H H 8 2 9 3 5 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 10 34 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 11 3 3 2 2′-MOE 2′-MOE 2′-MOE H H 8 212 3 2 2 2′-MOE 2′-MOE 2′-MOE H H 8 2 8 6 3 2 2′-MOE 2′-MOE 2′-MOE H H

In certain embodiments, a modified oligonucleotide complementary to amiRNA and consisting of 22 linked nucleosides has a Formula II selectedfrom Table 3, where each internucleoside linkage is a phosphorothioateinternucleoside linkage. In certain embodiments, a modifiedoligonucleotide having a Formula II selected from Table 3 comprises 22linked nucleosides of SEQ ID NO: 6, 7, or 8.

TABLE 3 n₁ n₂ n₃ n₄ n₅ Nu₁ Nu₃ Nu₅ T₁ T₂ 2 18 0 0 2 2′-MOE 2′-MOE 2′-MOEH H 2 2 2 14 2 2′-MOE 2′-MOE 2′-MOE H H 2 3 2 13 2 2′-MOE 2′-MOE 2′-MOEH H 2 4 2 12 2 2′-MOE 2′-MOE 2′-MOE H H 2 5 2 11 2 2′-MOE 2′-MOE 2′-MOEH H 2 6 2 10 2 2′-MOE 2′-MOE 2′-MOE H H 2 7 2 9 2 2′-MOE 2′-MOE 2′-MOE HH 2 8 2 8 2 2′-MOE 2′-MOE 2′-MOE H H 2 9 2 7 2 2′-MOE 2′-MOE 2′-MOE H H2 10 2 6 2 2′-MOE 2′-MOE 2′-MOE H H 2 11 2 5 2 2′-MOE 2′-MOE 2′-MOE H H2 12 2 4 2 2′-MOE 2′-MOE 2′-MOE H H 2 13 2 3 2 2′-MOE 2′-MOE 2′-MOE H H2 14 2 2 2 2′-MOE 2′-MOE 2′-MOE H H 2 2 3 13 2 2′-MOE 2′-MOE 2′-MOE H H2 3 3 12 2 2′-MOE 2′-MOE 2′-MOE H H 2 4 3 11 2 2′-MOE 2′-MOE 2′-MOE H H2 5 3 10 2 2′-MOE 2′-MOE 2′-MOE H H 2 6 3 9 2 2′-MOE 2′-MOE 2′-MOE H H 27 3 8 2 2′-MOE 2′-MOE 2′-MOE H H 2 8 3 7 2 2′-MOE 2′-MOE 2′-MOE H H 2 93 6 2 2′-MOE 2′-MOE 2′-MOE H H 2 10 3 5 2 2′-MOE 2′-MOE 2′-MOE H H 2 113 4 2 2′-MOE 2′-MOE 2′-MOE H H 2 12 3 3 2 2′-MOE 2′-MOE 2′-MOE H H 2 133 2 2 2′-MOE 2′-MOE 2′-MOE H H 2 8 6 4 2 2′-MOE 2′-MOE 2′-MOE H H

In certain embodiments, a modified oligonucleotide complementary to amiRNA and consisting of 23 linked nucleosides has a Formula II selectedfrom Table 4, where each internucleoside linkage is a phosphorothioateinternucleoside linkage. In certain embodiments, a modifiedoligonucleotide having a Formula II selected from Table 4 comprises anucleobase sequence selected SEQ ID NO: 6, 7, or 8.

TABLE 4 n₁ n₂ n₃ n₄ n₅ Nu₁ Nu₃ Nu₅ T₁ T₂ 2 19 0 0 2 2′-MOE 2′-MOE 2′-MOEH H 2 2 2 15 2 2′-MOE 2′-MOE 2′-MOE H H 2 3 2 14 2 2′-MOE 2′-MOE 2′-MOEH H 2 4 2 13 2 2′-MOE 2′-MOE 2′-MOE H H 2 5 2 12 2 2′-MOE 2′-MOE 2′-MOEH H 2 6 2 11 2 2′-MOE 2′-MOE 2′-MOE H H 2 7 2 10 2 2′-MOE 2′-MOE 2′-MOEH H 2 8 2 9 2 2′-MOE 2′-MOE 2′-MOE H H 2 9 2 8 2 2′-MOE 2′-MOE 2′-MOE HH 2 10 2 7 2 2′-MOE 2′-MOE 2′-MOE H H 2 11 2 6 2 2′-MOE 2′-MOE 2′-MOE HH 2 12 2 5 2 2′-MOE 2′-MOE 2′-MOE H H 2 13 2 4 2 2′-MOE 2′-MOE 2′-MOE HH 2 14 2 3 2 2′-MOE 2′-MOE 2′-MOE H H 2 15 2 2 2 2′-MOE 2′-MOE 2′-MOE HH 2 2 3 14 2 2′-MOE 2′-MOE 2′-MOE H H 2 3 3 13 2 2′-MOE 2′-MOE 2′-MOE HH 2 4 3 12 2 2′-MOE 2′-MOE 2′-MOE H H 2 5 3 11 2 2′-MOE 2′-MOE 2′-MOE HH 2 6 3 10 2 2′-MOE 2′-MOE 2′-MOE H H 2 7 3 9 2 2′-MOE 2′-MOE 2′-MOE H H2 8 3 8 2 2′-MOE 2′-MOE 2′-MOE H H 2 9 3 7 2 2′-MOE 2′-MOE 2′-MOE H H 210 3 6 2 2′-MOE 2′-MOE 2′-MOE H H 2 11 3 5 2 2′-MOE 2′-MOE 2′-MOE H H 212 3 4 2 2′-MOE 2′-MOE 2′-MOE H H 2 13 3 3 2 2′-MOE 2′-MOE 2′-MOE H H 214 3 2 2 2′-MOE 2′-MOE 2′-MOE H H 2 8 6 5 2 2′-MOE 2′-MOE 2′-MOE H H

In certain embodiments, a modified oligonucleotide complementary to amiRNA and consisting of 24 linked nucleosides has a Formula II selectedfrom Table 5, where each internucleoside linkage is a phosphorothioateinternucleoside linkage. In certain embodiments, a modifiedoligonucleotide having a Formula II selected from Table 5 comprises anucleobase sequence of SEQ ID NO: 6, 7, or 8.

TABLE 5 n₁ n₂ n₃ n₄ n₅ Nu₁ Nu₃ Nu₅ T₁ T₂ 2 20 0 0 2 2′-MOE 2′-MOE 2′-MOEH H 2 2 2 16 2 2′-MOE 2′-MOE 2′-MOE H H 2 3 2 15 2 2′-MOE 2′-MOE 2′-MOEH H 2 4 2 14 2 2′-MOE 2′-MOE 2′-MOE H H 2 5 2 13 2 2′-MOE 2′-MOE 2′-MOEH H 2 6 2 12 2 2′-MOE 2′-MOE 2′-MOE H H 2 7 2 11 2 2′-MOE 2′-MOE 2′-MOEH H 2 8 2 10 2 2′-MOE 2′-MOE 2′-MOE H H 2 9 2 9 2 2′-MOE 2′-MOE 2′-MOE HH 2 10 2 8 2 2′-MOE 2′-MOE 2′-MOE H H 2 11 2 7 2 2′-MOE 2′-MOE 2′-MOE HH 2 12 2 6 2 2′-MOE 2′-MOE 2′-MOE H H 2 13 2 5 2 2′-MOE 2′-MOE 2′-MOE HH 2 14 2 4 2 2′-MOE 2′-MOE 2′-MOE H H 2 15 2 3 2 2′-MOE 2′-MOE 2′-MOE HH 2 16 2 2 2 2′-MOE 2′-MOE 2′-MOE H H 2 2 3 15 2 2′-MOE 2′-MOE 2′-MOE HH 2 3 3 14 2 2′-MOE 2′-MOE 2′-MOE H H 2 4 3 13 2 2′-MOE 2′-MOE 2′-MOE HH 2 5 3 12 2 2′-MOE 2′-MOE 2′-MOE H H 2 6 3 11 2 2′-MOE 2′-MOE 2′-MOE HH 2 7 3 10 2 2′-MOE 2′-MOE 2′-MOE H H 2 8 3 9 2 2′-MOE 2′-MOE 2′-MOE H H2 9 3 8 2 2′-MOE 2′-MOE 2′-MOE H H 2 10 3 7 2 2′-MOE 2′-MOE 2′-MOE H H 211 3 6 2 2′-MOE 2′-MOE 2′-MOE H H 2 12 3 5 2 2′-MOE 2′-MOE 2′-MOE H H 213 3 4 2 2′-MOE 2′-MOE 2′-MOE H H 2 14 3 3 2 2′-MOE 2′-MOE 2′-MOE H H 215 3 2 2 2′-MOE 2′-MOE 2′-MOE H H 2 8 6 6 2 2′-MOE 2′-MOE 2′-MOE H H

In certain embodiments, a modified oligonucleotide complementary to amiRNA and consisting of 25 linked nucleosides has a Formula II selectedfrom Table 6, where each internucleoside linkage is a phosphorothioateinternucleoside linkage. In certain embodiments, a modifiedoligonucleotide having a Formula II selected from Table 6 comprises anucleobase sequence of SEQ ID NO: 6, 7, or 8.

TABLE 6 n₁ n₂ n₃ n₄ n₅ Nu₁ Nu₃ Nu₅ T₁ T₂ 2 21 0 0 2 2′-MOE 2′-MOE 2′-MOEH H 2 2 2 17 2 2′-MOE 2′-MOE 2′-MOE H H 2 3 2 16 2 2′-MOE 2′-MOE 2′-MOEH H 2 4 2 15 2 2′-MOE 2′-MOE 2′-MOE H H 2 5 2 14 2 2′-MOE 2′-MOE 2′-MOEH H 2 6 2 13 2 2′-MOE 2′-MOE 2′-MOE H H 2 7 2 12 2 2′-MOE 2′-MOE 2′-MOEH H 2 8 2 11 2 2′-MOE 2′-MOE 2′-MOE H H 2 9 2 10 2 2′-MOE 2′-MOE 2′-MOEH H 2 10 2 9 2 2′-MOE 2′-MOE 2′-MOE H H 2 11 2 8 2 2′-MOE 2′-MOE 2′-MOEH H 2 12 2 7 2 2′-MOE 2′-MOE 2′-MOE H H 2 13 2 6 2 2′-MOE 2′-MOE 2′-MOEH H 2 14 2 5 2 2′-MOE 2′-MOE 2′-MOE H H 2 15 2 4 2 2′-MOE 2′-MOE 2′-MOEH H 2 16 2 3 2 2′-MOE 2′-MOE 2′-MOE H H 2 17 2 2 2 2′-MOE 2′-MOE 2′-MOEH H 2 2 3 16 2 2′-MOE 2′-MOE 2′-MOE H H 2 3 3 15 2 2′-MOE 2′-MOE 2′-MOEH H 2 4 3 14 2 2′-MOE 2′-MOE 2′-MOE H H 2 5 3 13 2 2′-MOE 2′-MOE 2′-MOEH H 2 6 3 12 2 2′-MOE 2′-MOE 2′-MOE H H 2 7 3 11 2 2′-MOE 2′-MOE 2′-MOEH H 2 8 3 10 2 2′-MOE 2′-MOE 2′-MOE H H 2 9 3 9 2 2′-MOE 2′-MOE 2′-MOE HH 2 10 3 8 2 2′-MOE 2′-MOE 2′-MOE H H 2 11 3 7 2 2′-MOE 2′-MOE 2′-MOE HH 2 12 3 6 2 2′-MOE 2′-MOE 2′-MOE H H 2 13 3 5 2 2′-MOE 2′-MOE 2′-MOE HH 2 14 3 4 2 2′-MOE 2′-MOE 2′-MOE H H 2 15 3 3 2 2′-MOE 2′-MOE 2′-MOE HH 2 16 3 2 2 2′-MOE 2′-MOE 2′-MOE H H 2 8 6 7 2 2′-MOE 2′-MOE 2′-MOE H H

In certain embodiments, a compound is represented by the followingformula III:

(5′)QxQz¹(Qy)_(n)Qz²Qz³Qz⁴-L(3′)

In certain embodiments, Q is a 2′-O-methyl modified nucleoside. Incertain embodiments, x is phosphorothioate. In certain embodiments, y isphosphodiester. In certain embodiments, each of z1, z2, z3, and z4 is,independently phosphorothioate or phosphodiester. In certainembodiments, n is 6 to 17. In certain embodiments, L is cholesterol. Incertain embodiments, n is 12 to 17.

In certain embodiments, x is

-   -   One of A and B is S while the other is O;    -   y is

-   -   Each of z1, z2, z3, and z4 is independently x or y;    -   n=6-17    -   L is

-   -   Wherein:    -   X is N(CO)R⁷, or NR⁷;    -   Each of R¹, R³ and R⁹, is independently, H, OH, or —CH₂OR^(b)        provided that at least one of R¹,    -   R³ and R⁹ is OH and at least one of R¹, R³ and R⁹ is —CH₂OR^(b);    -   R⁷ is R^(d) or C₁-C₂₀ alkyl substituted with NR^(c)R^(d) or        NHC(O)R^(d);    -   R^(c) is H or C₁-C₆ alkyl;

R^(d) is a carbohydrate radical; or a steroid radical, which isoptionally tethered to at least one carbohydrate radical; and

R^(b) is

with one of A and B is S while the other is O.

In certain embodiments, R^(d) is cholesterol. In certain embodimentseach of z¹, z², z³, and z⁴ is

with one of A and B is S while the other is O.

In certain embodiments, R¹ is —CH₂OR^(b). In certain embodiments, R⁹ isOH. In certain embodiments, R¹ and R⁹ are trans. In certain embodiments,R⁹ is OH. In certain embodiments, R¹ and R³ are trans. In certainembodiments, R³ is —CH₂OR^(b). In certain embodiments, R¹ is OH. Incertain embodiments, R¹ and R³ are trans. In certain embodiments, R⁹ isOH. In certain embodiments, R³ and R⁹ are trans. In certain embodiments,R⁹ is CH₂OR^(b). In certain embodiments, R¹ is OH. In certainembodiments, R¹ and R⁹ are trans. In certain embodiments, X is NC(O)R⁷.In certain embodiments, R⁷ is —CH₂(CH₂)₁CH₂NHC(O)R^(d).

In certain embodiments, a modified oligonucleotide having a positionallymodified motif comprises LNA. In certain embodiments, a modifiedoligonucleotide has a motif selected from among one of the motifs listedbelow, wherein L=an LNA nucleoside, d=a DNA nucleoside, M=a 2′-MOEnucleoside, and F=a 2′-Fluoro nucleoside. In certain embodiments,nucleosides in parentheses are optionally included in the modifiedoligonucleotide, in other words, the motif encompasses modifiedoligonucleotides of varying lengths depending upon how many nucleosidesin parentheses are included.

LdLddLLddLdLdLL Ld Ld LLLd d LLLd LL LMLMMLLMMLMLMLL LMLMLLLMMLLLMLLLFLFFLLFFLFLFLL LFLFLLLFFLLLFLL LddLddLddL(d)(d)(L)(d)(d)(L)(d)dLddLddLdd(L)(d)(d)(L)(d)(d)(L) ddLddLddLd(d)(L)(d)(d)(L)(d)(d)LMMLMMLMML(M)(M)(L)(M)(M)(L)(M) MLMMLMMLMM(L)(M)(M)(L)(M)(M)(L)MMLMMLMMLM(M)(L)(M)(M)(L)(M)(M) LFFLFFLFFL(F)(F)(L)(F)(F)(L)(F)FLFFLFFLFF(L)(F)(F)(L)(F)(F)(L) FFLFFLFFLF(F)(L)(F)(F)(L)(F)(F)dLdLdLdLdL(d)(L)(d)(L)(d)(L)(d) LdLdLdLdL(d)(L)(d)(L)(d)(L)(d)(L)MLMLMLMLML(M)(L)(M)(L)(M)(L)(M) LMLMLMLML(M)(L)(M)(L)(M)(L)(M)(L)FLFLFLFLFL(F)(L)(F)(L)(F)(L)(F) LFLFLFLFL(F)(L)(F)(L)(F)(L)(F)(L)

Additional motifs are disclosed in PCT Publication No. WO/2007/112754,which is herein incorporated by reference in its entirety for thedescription of oligonucleotide modifications and patterns ofoligonucleotide modifications.

A modified oligonucleotide having a gapmer motif may have an internalregion consisting of linked 2′-deoxynucleotides, and external regionsconsisting of linked 2′-modified nucleosides. Such a gapmer may bedesigned to elicit RNase H cleavage of a miRNA precursor. The internal2′-deoxynucleoside region serves as a substrate for RNase H, allowingthe cleavage of the miRNA precursor to which a modified oligonucleotideis targeted. In certain embodiments, each nucleoside of each externalregion comprises the same 2′-modified nucleoside. In certainembodiments, one external region is uniformly comprised of a first2′-modified nucleoside and the other external region is uniformlycomprised of a second 2′-modified nucleoside.

A modified oligonucleotide having a gapmer motif may have a sugarmodification at each nucleoside. In certain embodiments, the internalregion is uniformly comprised of a first 2′-modified nucleoside and eachof the external regions is uniformly comprised of a second 2′-modifiednucleoside. In certain such embodiments, the internal region isuniformly comprised of 2′-fluoro nucleosides and each external region isuniformly comprised of 2′-O-methoxyethyl nucleosides.

In certain embodiments, each external region of a gapmer consists oflinked 2′-O-methoxyethyl nucleosides. In certain embodiments, eachexternal region of a gapmer consists of linked 2′-O-methyl nucleosides.In certain embodiments, each external region of a gapmer consists of2′-fluoro nucleosides. In certain embodiments, each external region of agapmer consists of linked bicyclic nucleosides.

In certain embodiments, each nucleoside of one external region of agapmer comprises 2′-O-methoxyethyl nucleosides and each nucleoside ofthe other external region comprises a different 2′-modification. Incertain such embodiments, each nucleoside of one external region of agapmer comprises 2% O-methoxyethyl nucleosides and each nucleoside ofthe other external region comprises 2′-O-methyl nucleosides. In certainsuch embodiments, each nucleoside of one external region of a gapmercomprises 2′-O-methoxyethyl nucleosides and each nucleoside of the otherexternal region comprises 2′-fluoro nucleosides. In certain suchembodiments, each nucleoside of one external region of a gapmercomprises 2′-O-methyl nucleosides and each nucleoside of the otherexternal region comprises 2′-fluoro nucleosides. In certain suchembodiments, each nucleoside of one external region of a gapmercomprises 2′-O-methoxyethyl nucleosides and each nucleoside of the otherexternal region comprises bicyclic nucleosides. In certain suchembodiments, each nucleoside of one external region of a gapmercomprises 2′-O-methyl nucleosides and each nucleoside of the otherexternal region comprises bicyclic nucleosides.

In certain embodiments, nucleosides of one external region comprise twoor more sugar modifications. In certain embodiments, nucleosides of eachexternal region comprise two or more sugar modifications. In certainembodiments, at least one nucleoside of an external region comprises a2′-O-methoxyethyl sugar and at least one nucleoside of the same externalregion comprises a 2′-fluoro sugar. In certain embodiments, at least onenucleoside of an external region comprises a 2′-O-methoxyethyl sugar andat least one nucleoside of the same external region comprises a bicyclicsugar moiety. In certain embodiments, at least one nucleoside of anexternal region comprises a 2′-O-methyl sugar and at least onenucleoside of the same external region comprises a bicyclic sugarmoiety. In certain embodiments at least one nucleoside of an externalregion comprises a 2′-O-methyl sugar and at least one nucleoside of thesame external region comprises a 2′-fluoro sugar. In certainembodiments, at least one nucleoside of an external region comprises a2′-fluoro sugar and at least one nucleoside of the same external regioncomprises a bicyclic sugar moiety.

In certain embodiments, each external region of a gapmer consists of thesame number of linked nucleosides. In certain embodiments, one externalregion of a gapmer consists a number of linked nucleosides differentthat that of the other external region.

In certain embodiments, the external regions comprise, independently,from 1 to 6 nucleosides. In certain embodiments, an external regioncomprises 1 nucleoside. In certain embodiments, an external regioncomprises 2 nucleosides. In certain embodiments, an external regioncomprises 3 nucleosides. In certain embodiments, an external regioncomprises 4 nucleosides. In certain embodiments, an external regioncomprises 5 nucleosides. In certain embodiments, an external regioncomprises 6 nucleosides in certain embodiments, the internal regionconsists of 17 to 28 linked nucleosides. In certain embodiments, aninternal region consists of 17 to 21 linked nucleosides. In certainembodiments, an internal region consists of 17 linked nucleosides. Incertain embodiments, an internal region consists of 18 linkednucleosides. In certain embodiments, an internal region consists of 19linked nucleosides. In certain embodiments, an internal region consistsof 20 linked nucleosides. In certain embodiments, an internal regionconsists of 21 linked nucleosides. In certain embodiments, an internalregion consists of 22 linked nucleosides. In certain embodiments, aninternal region consists of 23 linked nucleosides. In certainembodiments, an internal region consists of 24 linked nucleosides. Incertain embodiments, an internal region consists of 25 linkednucleosides. In certain embodiments, an internal region consists of 26linked nucleosides. In certain embodiments, an internal region consistsof 27 linked nucleosides. In certain embodiments, an internal regionconsists of 28 linked nucleosides.

Certain Additional Therapies

Treatments for metabolic disorders may comprise more than one therapy.As such, in certain embodiments the present invention provides methodsfor treating metabolic disorders comprising administering to a subjectin need thereof a compound comprising an oligonucleotide complementaryto miR-103 and/or miR-107, or a precursor thereof, and furthercomprising administering at least one additional pharmaceutical agent.

In certain embodiments, the additional pharmaceutical agent is aglucose-lowering agent.

In certain embodiments, the glucose-lowering agent is a PPAR agonist(gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a GLP-Ianalog, insulin or an insulin analog, an insulin secretagogue, a SGLT2inhibitor, a human amylin analog, a biguanide, an alpha-glucosidaseinhibitor, a meglitinide, a thiazolidinedione, or a sulfonylurea.

In certain embodiments, the glucose-lowering agent is a GLP-I analog. Incertain embodiments, the GLP-I analog is exendin-4 or liraglutide.

In certain embodiments, the glucose-lowering agent is a sulfonylurea. Incertain embodiments, the sulfonylurea is acetohexamide, chlorpropamide,tolbutamide, tolazamide, glimepiride, a glipizide, a glyburide, or agliclazide.

In certain embodiments, the glucose-lowering agent is a biguanide. Incertain embodiments, the biguanide is metformin. In certain embodiments,blood glucose levels are decreased without increased lactic acidosis ascompared to the lactic acidosis observed after treatment with metforminalone.

In certain embodiments, the glucose-lowering agent is a meglitinide. Incertain embodiments, the meglitinide is nateglinide or repaglinide.

In certain embodiments, the glucose-lowering agent is athiazolidinedione. In certain embodiments, the thiazolidinedione ispioglitazone, rosiglitazone, or troglitazone. In certain embodiments,blood glucose levels are decreased without greater weight gain thanobserved with rosiglitazone treatment alone.

In certain embodiments, the glucose-lowering agent is analpha-glucosidase inhibitor. In certain embodiments, thealpha-glucosidase inhibitor is acarbose or miglitol.

In certain embodiments, the glucose-lowering agent is an antisenseoligonucleotide targeted to PTP1B.

In certain embodiments, an additional therapy is an anti-obesity agent.In certain embodiments, an anti-obesity agent is Orlistat, Sibutramine,or Rimonabant.

In a certain embodiment, the additional therapy is therapeutic lifestylechange. In certain embodiments, the therapeutic lifestyle changeincludes an exercise regimen and/or diet.

In certain embodiments the dose of an additional pharmaceutical agent isthe same as the dose that would be administered if the additionalpharmaceutical agent was administered alone.

In certain embodiments the dose of an additional pharmaceutical agent islower than the dose that would be administered if the additionalpharmaceutical agent was administered alone. In certain embodiments thedose of an additional pharmaceutical agent is greater than the dose thatwould be administered if the additional pharmaceutical agent wasadministered alone.

Further examples of additional pharmaceutical agents include, but arenot limited to, corticosteroids, including but not limited toprednisone; immunoglobulins, including, but not limited to intravenousimmunoglobulin (IVIg); analgesics (e.g., acetaminophen);anti-inflammatory agents, including, but not limited to non-steroidalanti-inflammatory drugs (e.g., ibuprofen, COX-I inhibitors, and COX-2,inhibitors); salicylates; antibiotics; antivirals; antifungal agents;antidiabetic agents (e.g., biguanides, glucosidase inhibitors, insulins,sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics;hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin,progestin, somatostan, and thyroid hormones); immunomodulators; musclerelaxants; antihistamines; osteoporosis agents (e.g., biphosphonates,calcitonin, and estrogens); prostaglandins, antineoplastic agents;psychotherapeutic agents; sedatives; poison oak or poison sumacproducts; antibodies; and vaccines.

In certain embodiments, an additional therapy is a lipid-loweringtherapy. In certain such embodiments, a lipid-lowering therapy istherapeutic lifestyle change. In certain such embodiments, alipid-lowering therapy is LDL apheresis.

Certain Pharmaceutical Compositions

Provided herein are pharmaceutical compositions comprisingoligonucleotides. In certain embodiments, such pharmaceuticalcompositions are used for the treatment of metabolic disorders, andassociated conditions. In certain embodiments, a pharmaceuticalcomposition provided herein comprises a compound comprising anoligonucleotide consisting of 12 to 30 linked nucleosides and having anucleobase sequence complementary to miR-103, miR-107, or a precursorthereof. In certain embodiments, a pharmaceutical composition providedherein comprises a compound consisting of an oligonucleotide consistingof 12 to 30 linked nucleosides and having a nucleobase sequencecomplementary to miR-103, miR-107, or a precursor thereof.

Suitable administration routes include, but are not limited to, oral,rectal, transmucosal, intestinal, enteral, topical, suppository, throughinhalation, intrathecal, intraventricular, intraperitoneal, intranasal,intraocular, intratumoral, and parenteral (e.g., intravenous,intramuscular, intramedullary, and subcutaneous). In certainembodiments, pharmaceutical intrathecals are administered to achievelocal rather than systemic exposures. For example, pharmaceuticalcompositions may be injected directly in the area of desired effect(e.g., into the liver).

In certain embodiments, a pharmaceutical composition is administered inthe form of a dosage unit (e.g., tablet, capsule, bolus, etc.). Incertain embodiments, such pharmaceutical compositions comprise anoligonucleotide in a dose selected from 25 mg, 30 mg, 35 mg, 40 mg, 45mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 270mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315 mg, 320mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450 mg, 455mg, 460 mg, 465 mg, 470 mg, 475 mg, 480 mg, 485 mg, 490 ma, 495 mg, 500mg, 505 mg, 510 mg, 515 mg, 520 ma, 525 mg, 530 mg, 535 mg, 540 mg, 545mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585 mg, 590mg, 595 mg, 600 mg, 605 mg, 610 mg, 615 mg, 620 mg, 625 mg, 630 mg, 635mg, 640 mg, 645 mg, 650 mg, 655 mg, 660 mg, 665 mg, 670 mg, 675 mg, 680mg, 685 mg, 690 mg, 695 mg, 700 mg, 705 mg, 710 mg, 715 mg, 720 mg, 725mg, 730 mg, 735 mg, 740 mg, 745 mg, 750 mg, 755 mg, 760 mg, 765 mg, 770mg, 775 mg, 780 mg, 785 mg, 790 mg, 795 mg, and 800 mg. In certain suchembodiments, a pharmaceutical composition of the comprises a dose ofmodified oligonucleotide selected from 25 mg, 50 mg, 75 mg, 100 mg, 150mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, 600 mg, 700 mg, and800 mg.

In certain embodiments, a pharmaceutical agent is sterile lyophilizedmodified oligonucleotide that is reconstituted with a suitable diluent,e.g., sterile water for injection or sterile saline for injection. Thereconstituted product is administered as a subcutaneous injection or asan intravenous infusion after dilution into saline. The lyophilized drugproduct consists of an oligonucleotide which has been prepared in waterfor injection, or in saline for injection, adjusted to pH 7.0-9.0 withacid or base during preparation, and then lyophilized. The lyophilizedmodified oligonucleotide may be 25-800 mg of an oligonucleotide. It isunderstood that this encompasses 25, 50, 75, 100, 125, 150, 175, 200,225, 250, 275, 300, 325, 350, 375, 425, 450, 475, 500, 525, 550, 575,600, 625, 650, 675, 700, 725, 750, 775, and 800 mg of modifiedlyophilized oligonucleotide. The lyophilized drug product may bepackaged in a 2 mL Type I, clear glass vial (ammonium sulfate-treated),stoppered with a bromobutyl rubber closure and sealed with an aluminumFLIP-OFF® overseal.

In certain embodiments, the pharmaceutical compositions provided hereinmay additionally contain other adjunct components conventionally foundin pharmaceutical compositions, at their art-established usage levels.Thus, for example, the compositions may contain additional, compatible,pharmaceutically-active materials such as, for example, antipruritics,astringents, local anesthetics or anti-inflammatory agents, or maycontain additional materials useful in physically formulating variousdosage forms of the compositions of the present invention, such as dyes,flavoring agents, preservatives, antioxidants, opacifiers, thickeningagents and stabilizers. However, such materials, when added, should notunduly interfere with the biological activities of the components of thecompositions of the present invention. The formulations can besterilized and, if desired, mixed with auxiliary agents, e.g.,lubricants, preservatives, stabilizers, wetting agents, emulsifiers,salts for influencing osmotic pressure, buffers, colorings, flavoringsand/or aromatic substances and the like which do not deleteriouslyinteract with the oligonucleotide(s) of the formulation.

Lipid moieties have been used in nucleic acid therapies in a variety ofmethods. In one method, the nucleic acid is introduced into preformedliposomes or lipoplexes made of mixtures of cationic lipids and neutrallipids. In another method, DNA complexes with mono- or poly-cationiclipids are formed without the presence of a neutral lipid. In certainembodiments, a lipid moiety is selected to increase distribution of apharmaceutical agent to a particular cell or tissue. In certainembodiments, a lipid moiety is selected to increase distribution of apharmaceutical agent to fat tissue. In certain embodiments, a lipidmoiety is selected to increase distribution of a pharmaceutical agent tomuscle tissue.

In certain embodiments, INTRALIPID is used to prepare a pharmaceuticalcomposition comprising an oligonucleotide. Intralipid is fat emulsionprepared for intravenous administration. It is made up of 10% soybeanoil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water forinjection. In addition, sodium hydroxide has been added to adjust the pHso that the final product pH range is 6 to 8.9.

In certain embodiments, a pharmaceutical composition provided hereincomprise a polyamine compound or a lipid moiety complexed with a nucleicacid. In certain embodiments, such preparations comprise one or morecompounds each individually having a structure defined by formula (I) ora pharmaceutically acceptable salt thereof,

wherein each X^(a) and X^(b), for each occurrence, is independently C₁₋₆alkylene; n is 0, 1, 2, 3, 4, or 5; each R is independently H, whereinat least n+2 of the R moieties in at least about 80% of the molecules ofthe compound of formula (I) in the preparation are not H; m is 1, 2, 3or 4; Y is O, NR², or S; R¹ is alkyl, alkenyl, or alkynyl; each of whichis optionally substituted with one or more substituents; and R² is H,alkyl, alkenyl, or alkynyl; each of which is optionally substituted eachof which is optionally substituted with one or more substituents;provided that, if n=0, then at least n+3 of the R moieties are not H.Such preparations are described in PCT publication WO/2008/042973, whichis herein incorporated by reference in its entirety for the disclosureof lipid preparations. Certain additional preparations are described inAkinc et al., Nature Biotechnology 26, 561-569 (1 May 2008), which isherein incorporated by reference in its entirety for the disclosure oflipid preparations.

In certain embodiments, pharmaceutical compositions provided hereincomprise one or more modified oligonucleotides and one or moreexcipients. In certain such embodiments, excipients are selected fromwater, salt solutions, alcohol, polyethylene glycols, gelatin, lactose,amylase, magnesium stearate, talc, silicic acid, viscous paraffin,hydroxymethylcellulose and polyvinylpyrrolidone.

In certain embodiments, a pharmaceutical composition provided herein isprepared using known techniques, including, but not limited to mixing,dissolving, granulating, dragee-making, levigating, emulsifying,encapsulating, entrapping or tabletting processes.

In certain embodiments, a pharmaceutical composition provided herein isa liquid (e.g., a suspension, elixir and/or solution). In certain ofsuch embodiments, a liquid pharmaceutical composition is prepared usingingredients known in the art, including, but not limited to, water,glycols, oils, alcohols, flavoring agents, preservatives, and coloringagents.

In certain embodiments, a pharmaceutical composition provided herein isa solid (e.g., a powder, tablet, and/or capsule). In certain of suchembodiments, a solid pharmaceutical composition comprising one or moreoligonucleotides is prepared using ingredients known in the art,including, but not limited to, starches, sugars, diluents, granulatingagents, lubricants, binders, and disintegrating agents.

In certain embodiments, a pharmaceutical composition provided herein isformulated as a depot preparation. Certain such depot preparations aretypically longer acting than non-depot preparations. In certainembodiments, such preparations are administered by implantation (forexample subcutaneously or intramuscularly) or by intramuscularinjection. In certain embodiments, depot preparations are prepared usingsuitable polymeric or hydrophobic materials (for example an emulsion inan acceptable oil) or ion exchange resins, or as sparingly solublederivatives, for example, as a sparingly soluble salt.

In certain embodiments, a pharmaceutical composition provided hereincomprises a delivery system. Examples of delivery systems include, butare not limited to, liposomes and emulsions. Certain delivery systemsare useful for preparing certain pharmaceutical compositions includingthose comprising hydrophobic compounds. In certain embodiments, certainorganic solvents such as dimethylsulfoxide are used.

In certain embodiments, a pharmaceutical composition provided hereincomprises one or more tissue-specific delivery molecules designed todeliver the one or more pharmaceutical agents of the present inventionto specific tissues or cell types. For example, in certain embodiments,pharmaceutical compositions include liposomes coated with atissue-specific antibody.

In certain embodiments, a pharmaceutical composition provided hereincomprises a co-solvent system. Certain of such co-solvent systemscomprise, for example, benzyl alcohol, a nonpolar surfactant, awater-miscible organic polymer, and an aqueous phase. In certainembodiments, such co-solvent systems are used for hydrophobic compounds.A non-limiting example of such a co-solvent system is the VPD co-solventsystem, which is a solution of absolute ethanol comprising 3% w/v benzylalcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™ and 65% w/vpolyethylene glycol 300. The proportions of such co-solvent systems maybe varied considerably without significantly altering their solubilityand toxicity characteristics. Furthermore, the identity of co-solventcomponents may be varied: for example, other surfactants may be usedinstead of Polysorbate 80™; the fraction size of polyethylene glycol maybe varied; other biocompatible polymers may replace polyethylene glycol,e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides maysubstitute for dextrose.

In certain embodiments, a pharmaceutical composition provided hereincomprises a sustained-release system. A non-limiting example of such asustained-release system is a semi-permeable matrix of solid hydrophobicpolymers. In certain embodiments, sustained-release systems may,depending on their chemical nature, release pharmaceutical agents over aperiod of hours, days, weeks or months.

In certain embodiments, a pharmaceutical composition provided herein isprepared for oral administration. In certain of such embodiments, apharmaceutical composition is formulated by combining one or morecompounds comprising an oligonucleotide with one or morepharmaceutically acceptable carriers. Certain of such carriers enablepharmaceutical compositions to be formulated as tablets, pills, dragees,capsules, liquids, gels, syrups, slurries, suspensions and the like, fororal ingestion by a subject. In certain embodiments, pharmaceuticalcompositions for oral use are obtained by mixing oligonucleotide and oneor more solid excipient. Suitable excipients include, but are notlimited to, fillers, such as sugars, including lactose, sucrose,mannitol, or sorbitol; cellulose preparations such as, for example,maize starch, wheat starch, rice starch, potato starch, gelatin, gumtragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodiumcarboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In certainembodiments, such a mixture is optionally ground and auxiliaries areoptionally added. In certain embodiments, pharmaceutical compositionsare formed to obtain tablets or dragee cores. In certain embodiments,disintegrating agents (e.g., cross-linked polyvinyl pyrrolidone, agar,or alginic acid or a salt thereof, such as sodium alginate) are added.

In certain embodiments, dragee cores are provided with coatings. Incertain such embodiments, concentrated sugar solutions may be used,which may optionally contain gum arabic, talc, polyvinyl pyrrolidone,carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquersolutions, and suitable organic solvents or solvent mixtures. Dyestuffsor pigments may be added to tablets or dragee coatings.

In certain embodiments, pharmaceutical compositions for oraladministration are push-fit capsules made of gelatin. Certain of suchpush-fit capsules comprise one or more pharmaceutical agents of thepresent invention in admixture with one or more filler such as lactose,binders such as starches, and/or lubricants such as talc or magnesiumstearate and, optionally, stabilizers. In certain embodiments,pharmaceutical compositions for oral administration are soft, sealedcapsules made of gelatin and a plasticizer, such as glycerol orsorbitol. In certain soft capsules, one or more pharmaceutical agents ofthe present invention are be dissolved or suspended in suitable liquids,such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Inaddition, stabilizers may be added.

In certain embodiments, pharmaceutical compositions are prepared forbuccal administration. Certain of such pharmaceutical compositions aretablets or lozenges formulated in conventional manner.

In certain embodiments, a pharmaceutical composition is prepared foradministration by injection (e.g., intravenous, subcutaneous,intramuscular, etc.). In certain of such embodiments, a pharmaceuticalcomposition comprises a carrier and is formulated in aqueous solution,such as water or physiologically compatible buffers such as Hanks'ssolution, Ringer's solution, or physiological saline buffer. In certainembodiments, other ingredients are included (e.g., ingredients that aidin solubility or serve as preservatives). In certain embodiments,injectable suspensions are prepared using appropriate liquid carriers,suspending agents and the like. Certain pharmaceutical compositions forinjection are presented in unit dosage form, e.g., in ampoules or inmulti-dose containers. Certain pharmaceutical compositions for injectionare suspensions, solutions or emulsions in oily or aqueous vehicles, andmay contain formulatory agents such as suspending, stabilizing and/ordispersing agents. Certain solvents suitable for use in pharmaceuticalcompositions for injection include, but are not limited to, lipophilicsolvents and fatty oils, such as sesame oil, synthetic fatty acidesters, such as ethyl oleate or triglycerides, and liposomes. Aqueousinjection suspensions may contain substances that increase the viscosityof the suspension, such as sodium carboxymethyl cellulose, sorbitol, ordextran. Optionally, such suspensions may also contain suitablestabilizers or agents that increase the solubility of the pharmaceuticalagents to allow for the preparation of highly concentrated solutions.

In certain embodiments, a pharmaceutical composition is prepared fortransmucosal administration. In certain of such embodiments penetrantsappropriate to the barrier to be permeated are used in the formulation.Such penetrants are generally known in the art.

In certain embodiments, a pharmaceutical composition is prepared foradministration by inhalation. Certain of such pharmaceuticalcompositions for inhalation are prepared in the form of an aerosol sprayin a pressurized pack or a nebulizer. Certain of such pharmaceuticalcompositions comprise a propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gas. In certain embodiments using a pressurized aerosol,the dosage unit may be determined with a valve that delivers a meteredamount. In certain embodiments, capsules and cartridges for use in aninhaler or insufflator may be formulated. Certain of such formulationscomprise a powder mixture of a pharmaceutical agent of the invention anda suitable powder base such as lactose or starch.

In certain embodiments, a pharmaceutical composition is prepared forrectal administration, such as a suppositories or retention enema.Certain of such pharmaceutical compositions comprise known ingredients,such as cocoa butter and/or other glycerides.

In certain embodiments, a pharmaceutical composition is prepared fortopical administration. Certain of such pharmaceutical compositionscomprise bland moisturizing bases, such as ointments or creams.Exemplary suitable ointment bases include, but are not limited to,petrolatum, petrolatum plus volatile silicones, and lanolin and water inoil emulsions. Exemplary suitable cream bases include, but are notlimited to, cold cream and hydrophilic ointment.

In certain embodiments, a pharmaceutical composition provided hereincomprises an oligonucleotide in a therapeutically effective amount. Incertain embodiments, the therapeutically effective amount is sufficientto prevent, alleviate or ameliorate symptoms of a disease or to prolongthe survival of the subject being treated. Determination of atherapeutically effective amount is well within the capability of thoseskilled in the art.

In certain embodiments, one or more modified oligonucleotides providedherein is formulated as a prodrug. In certain embodiments, upon in vivoadministration, a prodrug is chemically converted to the biologically,pharmaceutically or therapeutically more active form of anoligonucleotide. In certain embodiments, prodrugs are useful becausethey are easier to administer than the corresponding active form. Forexample, in certain instances, a prodrug may be more bioavailable (e.g.,through oral administration) than is the corresponding active form. Incertain instances, a prodrug may have improved solubility compared tothe corresponding active form. In certain embodiments, prodrugs are lesswater soluble than the corresponding active form. In certain instances,such prodrugs possess superior transmittal across cell membranes, wherewater solubility is detrimental to mobility. In certain embodiments, aprodrug is an ester. In certain such embodiments, the ester ismetabolically hydrolyzed to carboxylic acid upon administration. Incertain instances the carboxylic acid containing compound is thecorresponding active form. In certain embodiments, a prodrug comprises ashort peptide (polyaminoacid) bound to an acid group. In certain of suchembodiments, the peptide is cleaved upon administration to form thecorresponding active form.

In certain embodiments, a prodrug is produced by modifying apharmaceutically active compound such that the active compound will beregenerated upon in vivo administration. The prodrug can be designed toalter the metabolic stability or the transport characteristics of adrug, to mask side effects or toxicity, to improve the flavor of a drugor to alter other characteristics or properties of a drug. By virtue ofknowledge of pharmacodynamic processes and drug metabolism in vivo,those of skill in this art, once a pharmaceutically active compound isknown, can design prodrugs of the compound (see, e.g., Nogrady (1985)Medicinal Chemistry A Biochemical Approach, Oxford University Press, NewYork, pages 388-392).

Certain Kits

The present invention also provides kits. In some embodiments, the kitscomprise one or more compounds of the invention comprising a modifiedoligonucleotide, wherein the nucleobase sequence of the oligonucleotideis complementary to miR-103 and/or 107. The compounds complementary tomiR-103 and/or miR-107 can be any of the compounds described herein, andcan have any of the modifications described herein. In some embodiments,the compounds complementary to miR-103 and/or miR-107 can be presentwithin a vial. A plurality of vials, such as 10, can be present in, forexample, dispensing packs. In some embodiments, the vial is manufacturedso as to be accessible with a syringe. The kit can also containinstructions for using the compounds complementary to miR-103 and/ormiR-107.

In some embodiments, the kits may be used for administration of thecompound complementary to miR-103 and/or miR-107 to a subject. In suchinstances, in addition to compounds complementary to miR-103 and/ormiR-107, the kit can further comprise one or more of the following:syringe, alcohol swab, cotton ball, and/or gauze pad. In someembodiments, the compounds complementary to miR-103 and/or miR-107 canbe present in a pre-filled syringe (such as a single-dose syringes with,for example, a 27 gauge, ¼ inch needle with a needle guard), rather thanin a vial. A plurality of pre-filled syringes, such as 10, can bepresent in, for example, dispensing packs. The kit can also containinstructions for administering the compounds complementary to miR-103and/or miR-107.

Certain Experimental Models

In certain embodiments, the present invention provides methods of usingand/or testing modified oligonucleotides of the present invention in anexperimental model. Those having skill in the art are able to select andmodify the protocols for such experimental models to evaluate apharmaceutical agent of the invention.

Generally, modified oligonucleotides are first tested in cultured cells.Suitable cell types include those that are related to the cell type towhich delivery of an oligonucleotide is desired in vivo. For example,suitable cell types for the study of the methods described hereininclude primary hepatocytes, primary adipocytes, preadipocytes,differentiated adipocytes, HepG2 cells, Huh7 cells, 3T3L1 cells, andC2C12 cells (murine myoblasts).

In certain embodiments, the extent to which an oligonucleotideinterferes with the activity of a miRNA is assessed in cultured cells.In certain embodiments, inhibition of miRNA activity may be assessed bymeasuring the levels of the miRNA. Alternatively, the level of apredicted or validated miRNA target may be measured. An inhibition ofmiRNA activity may result in the increase in the mRNA and/or protein ofa miRNA target. Further, in certain embodiments, certain phenotypicoutcomes may be measured. For example, suitable phenotypic outcomesinclude insuling signaling.

Suitable experimental animal models for the testing of the methodsdescribed herein include: ob/ob mice (a model for diabetes, obesity andinsulin resistance), db/db mice (a model for diabetes, obesity andinsulin resistance), high-fat fed C57Bl6/J mice, Zucker diabetic rats,and aP2-SREBP transgenic mice.

Certain Quantitation Assays

The effects of antisense inhibition of a miRNA following theadministration of modified oligonucleotides may be assessed by a varietyof methods known in the art. In certain embodiments, these methods arebe used to quantitate miRNA levels in cells or tissues in vitro or invivo. In certain embodiments, changes in miRNA levels are measured bymicroarray analysis. In certain embodiments, changes in miRNA levels aremeasured by one of several commercially available PCR assays, such asthe TaqMan® MicroRNA Assay (Applied Biosystems). In certain embodiments,antisense inhibition of a miRNA is assessed by measuring the mRNA and/orprotein level of a target of a miRNA. Antisense inhibition of a miRNAgenerally results in the increase in the level of mRNA and/or protein ofa target of the miRNA.

The following examples are presented in order to more fully illustratesome embodiments of the invention. They should, in no way be construed,however, as limiting the broad scope of the invention.

Throughout the examples, unless otherwise indicated, statisticalsignificance is indicated as follow: *=p<0.05; **=p<0.01; ***=p<0.001.

EXAMPLES Example 1 Expression of microRNAs in Insulin Sensitive Tissues

To identify microRNAs involved in insulin signaling and response,insulin sensitive tissues were screened for microRNA expression.Microarray analysis was performed to identify microRNAs that aredysregulated in livers of ob/ob and high-fat diet induced obese (DIO)C57Bl6/J mice, both of which are animal models of obesity,insulin-resistance, and diabetes. The microRNAs miR-103 and miR-107, twoconserved and ubiquitously expressed microRNAs (see FIG. 1E, F) werefound to be upregulated in the liver in several of these models,including ob/ob mice and high-fat fed mice (DIO mice).

Northern blotting confirmed this result and demonstrated a 2 to 3-foldup-regulation in livers of both ob/ob and high fat fed induced obesemice (see FIG. 1A). Real-time PCR was used to distinguish miR-103 frommiR-107, which differ by one base at position 21 (see Table 7 and FIG.1B). Both miR-103 and miR-107 were up-regulated in livers of ob/ob andhigh fat fed induced obese mice (See Table 8).

TABLE 7 Distinguishing miR-103 from miR-107 by real-time PCR 0.5 nMSynthetic miR-107 0.5 nM Synthetic miR-103 + − − + Real time 1 No CT NoCT 0.016 107 level Real time 0.0002 No CT No CT 1 103 level

TABLE 8 Upregulation of miR-103 and miR-107 in ob/ob and DIO livers wtob/ob Normal chow fed DIO Relative miR-103 1 1.9194 1 2.272 expressionvalue Relative miR-107 1 2.1753 1 2.3992 expression value

MicroRNA expression was also analyzed in liver biopsies of healthyindividuals, HBV- and HCV-infected individuals, and human patients withalcoholic steatohepatitis (ASH), non-alcoholic fatty liver disease(NAFLD), and non-alcoholic steatohepatitis (NASH). miR-103 and miR-107were similar in normal subjects and HBV- and HCV-infected subjects.However, miR-103 and miR-107 levels were increased in liver samples ofsubjects with ASH, NAFLD, and NASH, conditions often associated withdiabetes (See Table 9).

TABLE 9 miR-103and miR-107 expression in liver samples of human subjectsmiR-103 miR-107 Relative Relative # Subjects Expression Level ExpressionLevel Control 8 1.0222 1.1253 HBV 7 1.106 0.9555 HCV 7 0.9652 0.9565 ASH7 1.516 1.2226 NAFLD 15 1.3033 1.3277 NASH 13 1.7141* 1.628* Control +HBV + HCV 22 1.0307 1.0176 ASH 7 1.516** 1.2226 NAFLD 15 1.3033**1.3277** NASH 13 1.7141*** 1.628***

Example 2 Inhibition of miR-103 or miR-107 Alleviates Hyperglycemia inAnimals

The inhibition of miR-103 or miR-107 may result in therapeutic benefitsin subjects having diabetes or insulin resistance. Obese,insulin-resistant ob/ob mice are commonly used as a model for diabetesand obesity. Mice fed a high fat diet are used as a model of impairedglucose tolerance and Type 2 diabetes. Accordingly, the inhibition ofmiR-103 or miR-107 was assessed in ob/ob mice and DIO mice.

Unless otherwise specified, anti-miRs used are modified as follows:

-   -   anti-miR-103 having the sequence of SEQ ID NO: 6,2′-O-methyl        modifications at each sugar, phosphorothioate modifications at        each of the first 4 internucleoside linkages (at the 5′ end),        phosphorothioate modifications at each of the last 2        internucleosides linkages (at the 3′ end), and a cholesterol        linked to the 3′ end through a hydroxyprolinol linkage    -   anti-miR-107 having the sequence of SEQ ID NO: 7,2′-O-methyl        modifications at each sugar, phosphorothioate modifications at        each of the first 4 internucleoside linkages (at the 5′ end),        phosphorothioate modifications at each of the last 2        internucleosides linkages (at the 3′ end), and a cholesterol        linked to the 3′ end through a hydroxyprolinol    -   Control anti-miR anti-mm-107, having the nucleobase sequence        TCATTGGCATGTACCATGCAGCT (SEQ ID NO: 9), 2′-O-methyl        modifications at each sugar, phosphorothioate modifications at        each of the first 4 internucleoside linkages, phosphorothioate        modifications at each of the last 2 internucleoside linkages,        and a cholesterol linked to the 3′ end through a hydroxyprolinol        linkage. As miR-103 and miR-107 differ by a single nucleotide,        anti-mm-107 is mismatched with respect to both miR-103 (4 total        mismatches) and miR-107 (5 total mismatches); and    -   Control anti-miR anti-miR-124, having the nucleobase sequence of        SEQ ID NO: 19; 2′-O-methyl modifications at each sugar,        phosphorothioate modifications at each of the first 4        internucleoside linkages, phosphorothioate modifications at each        of the last 2 internucleoside linkages, and a cholesterol linked        to the 3′ end through a hydroxyprolinol linkage.

Unless otherwise specified, wildtype mice were 6- to 8-week old wildtypemale C57Bl/6 mice (≈20 g); ob/ob mice were 6- to 8-week old male mice;and DIO mice were 12-week old male mice having been on a high fat dietfor 8 weeks. Mice were injected with either PBS, anti-miR-107 (1×15mg/kg), anti-miR103 (2×15 mg/kg), anti-mm-107 (2×15 μg/kg), oranti-miR-124 (2×15 μg/kg).

Wild-Type Mice

Wild-type mice received two injections of 15 mg/kg anti-miR-103 oranti-mm-107, intraperitoneally. PBS was administered as a controltreatment. Northern analysis of miR-103 and miR-107 demonstrated thatanti-miR-103 silenced miR-107 in fat while having no effect o theexpression of the unrelated microRNA miR-16. See FIG. 1 d.

Following treatment, mice were tested for blood glucose levels, both inad libitum fed and in fasted conditions. Silencing of miR-103/107 didnot reveal any significant changes in blood glucose levels in wild-typemice. Wild-type mice also responded well to an intraperitoneal glucosechallenge. Further, treatment with anti-miR-103 or anti-miR-107 did notcause overt toxicity, as judged by ALT levels (˜25 IU/L and ˜19 IU/L inmice treated with PBS and anti-miR-107, respectively; ˜17 IU/L and ˜18IU/L in mice treated with PBS and anti-miR-103, respectively).

Ob/ob Mice

Ob/ob mice received two injections of 15 mg/kg anti-miR-103 oranti-miR-107, intraperitoneally. PBS was administered as a controltreatment. Following treatment, mice were tested for blood glucoselevels (with and without fasting), IPGTT, ITT, and pyruvate tolerance.Each treatment group contained 5 to 6 8-week old mice. Controltreatments were PBS, anti-miR-124, or anti-mm-107. Northern analysis ofmiR-103 and miR-107 demonstrated that anti-miR-103 and anti-miR-107effectively silenced both miR-103 and miR-107 in liver and fat whilehaving no effect on the expression of the unrelated microRNA miR-16. SeeFIG. 1C, D.

To test blood glucose levels in the ad libitum fed condition, bloodglucose was measured 2, 3, and 5 days after the second dose ofanti-miR-103 or anti-miR-107. Inhibition of miR-103 resulted in astatistically significant reduction in blood glucose, compared to PBStreatment. Inhibition of miR-107 also resulted in statisticallysignificant reductions in blood glucose, compared to PBS treatment. SeeTable 10 (N.D. means ‘not determined’).

TABLE 10 Statistically Significant Reductions in Blood Glucose followinganti-miR inhibition of miR-103/107 Random Blood Glucose (mM) Bloodglucose 8 h fast (mM) Treatment Day2 Day3 Day5 Day3 Day5 PBS 9.73 11.6110.10 11.85 11.10 anti-miR- 7.67 6.77* 7.25* 6.69** 6.61** 103 anti-miR-6.96** 7.03* 6.27** N.D N.D. 107 anti-miR- N.D. N.D. N.D. 11.82 11.22124

Significant reductions in blood glucose were also observed following 3or 6 days of treatment with anti-miR-103, compared to anti-mm-107treatment. See Table 11.

TABLE 11 Statistically significant reductions in blood glucose followinganti-miR inhibition of miR-103/107 Random Blood Glucose (nM) TreatmentDay 0 Day 3 Day 6 anti-miR-103 8.58 5.50* 6.33* anti-mm-107 8.29 7.308.44

An IPGTT was also performed. Following a 16 hour fast, mice (n=5)received intraperitoneal injections of 2 grams of glucose per kg of bodyweight at day 6 after injection of anti-miR-103 or anti-miR-107. Bloodwas collected at 0, 15, 30, 60, 120, and 180 minutes. Statisticallysignificant improvements in glucose tolerance were observed in micetreated with anti-miR-103 or anti-miR-107, compared to PBS controltreatment. See Table 12. Statistically significant improvements inglucose tolerance are also evident when IPGTT results from anti-miR-103treated mice are compared to IPGTT results from anti-miR-124 treatedmice. See Table 13.

TABLE 12 IPGTT: anti-miR inhibition of miR- 103/107 improves glucosetolerance Blood Glucose (nM) after indicated time 0 min 15 min 30 min 60min 120 min 180 min PBS 7.69 21.41 26.76 22.53 17.13 14.64 anti-miR-1036.13 16.66 22.83* 19.70 11.28** 9.73** anti-miR-107 5.46 17.87* 21.52*18.75 11.89** 9.34**

TABLE 13 IPGTT: anti-miR inhibition of miR-103 improves glucosetolerance Blood Glucose (nM) after indicated time 0 min 15 min 30 min 60min 120 min 180 min anti-miR-124 7.65 21.43 26.54 22.74 17.03 14.49anti-miR-103 6.13 16.66* 22.83* 19.70 11.28** 9.73**

On day 9 following anti-miR treatment, an insulin tolerance test (ITT)was also performed in anti-miR-103 treated mice (n=5). 2 U insulin perkg bodyweight was administered following a 6 hour fast. Blood wascollected at 0, 15, 30, 60, 90, and 120 minutes; values at 0 minuteswere normalized to 100. Statistically significant reductions in bloodglucose levels were observed relative to control treatment with PBS (seeTable 14) or relative to control treatment with anti-miR-124 (see Table15), indicating an improvement in insulin sensitivity.

TABLE 14 ITT: anti-miR-103 treatment improves insulin tolerance in ob/obmice Blood Glucose (nM) after indicated time 0 min 15 min 30 min 60 min90 min 120 min PBS 100.00 111.79 104.84 82.89 75.19 77.12 anti- 100.00102.17 53.10*** 43.00*** 44.19** 58.91 miR-103

TABLE 15 ITT: Treatment with anti-miR-103 improves insulin tolerance inob/ob mice Blood Glucose (nM) after indicated time 0 min 15 min 30 min60 min 90 min 120 min anti-miR-124 100.00 121.66 110.72 86.92 77.8080.24 anti-miR-103 100.00 101.25 52.66 40.44 43.57 57.05

As a measure of gluconeogenesis (also known as de novo hepatic glucoseproduction), a pyruvate tolerance test was performed (n=5). On day 12following treatment with control or anti-miR-103, following an overnight(16 hour) fast mice (n=5) received intraperitoneal injections of 2 gramsof pyruvate per kg body weight. Statistically significant reductions inblood glucose levels were observed. See Table 16. The decrease ingluconeogenesis was also supported by a reduction in hepatic levels ofG-6-Pase, PC and FBPase in anti-miR-103 treated mice (n=5), compared tocontrol mice (anti-mm-107; n=5). See Table 17.

TABLE 16 Treatment with anti-miR-103 decreases gluconeogenesis BloodGlucose (nM) after indicated time 0 min 15 min 30 min 60 min 120 min PBS6.78 16.48 16.35 12.40 10.20 anti-miR-124 7.24 18.46 18.12 14.26 10.23anti-miR-103 5.53* 13.65*** 11.37 9.22* 6.28**

TABLE 17 Treatmentwith anti-miR-103 decreases expression of genesinvolved in gluconeogenesis Relative Expression Levels G6Pc PC FBPaseanti-mm-107 1.03 1.02 1.01 anti-miR-103 0.68** 0.67** 0.23***

Liver glycogen content was also measured (n=5 mice) and found to beincreased in livers of anti-miR-103 (367 umol) treated mice relative toPBS-treated mice (246 umol) (BioVision Glycogen Assay Kit according tomanufacturer's instructions).

Plasma insulin was measured (n=10 mice), after an overnight fast, andfound to be reduced in mice treated with anti-miR-103 (26 ng/mL,p<0.05), compared to control-treated mice (anti-mm-107; 34 ng/mL).

Measurements of ALT indicated no overt toxicities. In ob/ob mice, ALTlevels were 125 IU/L, 107 IU/L, 98 IU/L and 92 IU/L in mice treated withPBS, anti-miR-124, anti-miR-107, and anti-miR-103, respectively.

High Fat Fed Obese Mice

Anti-miR-103 was also administered to high-fat fed obese mice (alsocalled diet-induced obese mice or DIO mice), a model of impaired glucosetolerance and type 2 diabetes. Mice were kept on a high-fat diet for 12weeks, starting at age 4 weeks. Mice received two injections of 15 mg/kganti-miR-103. PBS was administered as a control treatment. Additionalcontrol treatments were anti-miR-124 or anti-mm-107. Each treatmentgroup contained 4 to 5 mice.

After 3 days, blood glucose was measured and observed to besignificantly reduced, in both the fed and fasted states, inanti-miR-103 treated mice (n=5; ˜8 nM ad libitum, ˜7.5 nM following 8hour fast) relative to the PBS control (n=4; 10.5 nM ad libitum, 9.5 nMfollowing 8 hour fast). Blood glucose in anti-miR-103 treated mice wasalso compared to anti-mm-107 treated mice, and found to be significantlyreduced in both fed and fasted states. See Table 18.

TABLE 18 Anti-miR-103 treatment reduces fed and fasted blood glucose inDIO mice Blood Glucose (nM) on indicated day (ad libitum unlessotherwise indicated) 3 17 Treatment 3 4 5 9 16 6 h fast 12 h fastanti-miR-124 8.55 9.38 8.93 9.35 9.10 7.33 9.10 anti-miR-103 4.26***5.14** 6.70** 7.92** 7.92** 3.64** 7.62**

On day 8 after anti-miR or PBS treatment, following an overnight (16hour) fast, an IPGTT was also performed by administering 2 g/kg glucose;n=5 mice. Glucose tolerance was improved in a statistically significantmanner, compared to PBS control treatment (see Table 19).

TABLE 19 Anti-miR-103 treatment improves glucose tolerance in DIO miceBlood Glucose (nM) after indicated time 0 min 15 min 30 min 60 min 120min 180 min PBS 7.55 24.68 31.10 29.10 18.98 12.53 anti-miR-103 6.8024.80 30.25 23.98* 13.65** 10.00*

Measurement of plasma insulin levels (n=5 mice) revealed a reduction inplasma insulin in anti-miR-103 treated mice (5.4 ng/ml), relative tocontrol treated mice (7 ng/ml, anti-mm-107).

Together, these data in animal models of diabetes and obesitydemonstrate that inhibition of miR-103/107 enhances insulin sensitivity.Compounds that enhance insulin sensitivity are useful for the treatmentand/or prevention of metabolic disorder, such as diabetes, pre-diabetes,metabolic syndrome, hyperglycemia, and insulin resistance.

Example 3 Overexpression of miR-107 Induces Hyperglycemia in Animals

To further investigate the role of miR-107, 8-week old male wild typemice were treated with an adenoviral vector expressing miR-107(ad-107/GFP; n=5), which resulted in the overexpression of miR-107 in avariety of cell types and tissues, including liver. Mice treated with anadenoviral vector expression green fluorescent protein (GFP) (ad-GFP;n=5) were used as control animals. Each mouse received an injection of5×10⁹ viral particles.

Northern blotting revealed increased levels of miR-107, similar tolevels observed in ob/ob mice (See FIG. 2A).

Blood glucose was found to be elevated in the mice treated withad-107/GFP, relative to the mice treated with ad-GFP, in both fed andfasted animals (see Table 20). These data demonstrate that increasedmiR-107 expression leads to increases in blood glucose.

TABLE 20 Viral expression of miR-103 elevates blood glucose BloodGlucose (nM) after indicated time Day 8 Day 5 Day 7 Day 8 8 hour fastad-GFP 5.93 5.60 5.66 5.02 ad-107/GFP 7.30** 7.52*** 7.65** 6.97***

The intraperitoneal glucose tolerance test (IPGTT) measures theclearance of intraperitoneally injected glucose from the body. This testwas used to identify whether animals treated with ad-107/GFP exhibitimpaired glucose tolerance. Animals were fasted for approximately 15hours, a solution of glucose was administered at 2 g/kg byintraperitoneal (IP) injection and blood glucose is measured atdifferent time points during the 2 hours following the injection.Glucose (mg/dl) was measured in blood from tail bleeds at 0, 30, 60 and120 min during IPGTT. The glucose area under the curve (AUC, mg/di min)was calculated as an indication of impaired glucose tolerance accordingto the trapezoid rule from the glucose measurements at 0, 30, 60 and 120min. Animals treated with ad-107/GFP exhibited an impaired tolerance toglucose, relative to animals injected with ad-GFP. See Table 21.

TABLE 21 Viral overexpression of miR-107 impairs glucose tolerance BloodGlucose (mM) at indicated time 0 min 15 min 30 min 60 min 120 min ad-GFP3.78 11.68 8.38 6.40 4.23 ad-miR- 4.13 17.07*** 13.48*** 8.90*** 5.28107/GFP

The insulin tolerance test (ITT) measures sensitivity to insulin. Thistest was used to identify whether the overexpression of miR-107 causessensitivity to insulin. Five days following treatment with ad-107/GFP orad-GFP, mice were fasted for approximately 6 hours and then given anintraperitoneal injection of 0.75 U/kg of insulin. Blood glucose wasmeasured in blood from tail bleeds at 0, 15, 30, 60, 90 and 120 minutesduring the ITT. At the 60 minute time point, animals treated withad-107/GFP exhibited a decreased sensitivity to insulin, as measured bya higher amount of blood glucose at this time point, relative to animalstreated with ad-GFP. See Table 22.

TABLE 22 Viral overexpression of miR-107 decreases insulin sensitivityBlood Glucose (mM) at indicated time 0 min 15 min 30 min 60 min 90 min120 min ad-GFP 100.00 57.48 35.05 22.20 27.80 100.00 ad-107/GFP 100.0066.85 48.62 34.62* 26.52 100.00

The pyruvate tolerance test measures gluconeogenesis, also known as denovo hepatic glucose production. This test was used to assess whetherthe overexpression of miR-107 adversely affects gluconeogenesis. Tendays following treatment with ad-107/GFP or ad-GFP, mice were fasted forapproximately 15 hours and then given an intraperitoneal injection of 2g/kg of pyruvate. Blood glucose was measured in blood from tail bleedsat 0, 20, 30, 60 and 120 minutes during the test. At the 30 minute timepoint and the 60 minute time point, animals treated with ad-107/GFPexhibited increased blood glucose relative to animals treated withad-GFP, indicating an increase in gluconeogenesis as a result ofoverexpression of miR-107. See Table 23.

TABLE 23 Viral overexpression of miR-107 increases gluconeogenesis BloodGlucose (mM) at indicated time 0 min 15 min 30 min 60 min 120 min ad-GFP3.72 6.70 7.84 6.74 4.30 ad-107/GFP 3.33 7.00 9.07 8.76*** 5.08

Real-time PCR was used to measure levels of genes associated withgluconeogenesis; levels were normalized to 36B4; n=5 mice. Additionally,the increase in hepatic glucose production was accompanied by augmentedexpression of glucose 6-phosphatase (G6Pc), phosphoenol pyruvatecarboxykinase (Pepck), pyruvate carboxylase (PC) and fructose 1,6bisphosphatase (FBPase), suggesting that increased gluconeogenesis isthe primary cause of the elevated glucose levels. See Table 24. Thesedata demonstrated that overexpression of miR-107 enhances de novohepatic glucose production.

TABLE 24 Viral overexpression of miR-107 decreases expression of genesassociated with gluconeogenesis Blood Glucose (mM) at indicated timeG6Pc Pepck PC FBPase ad-GFP 0.98 1.07 1.01 1.10 ad-107/GFP 2.00*** 1.39*1.23* 1.73*

Non-esterified fatty acids (NEFAs) were also measured, and found to bedecreased when miR-107 was overexpressed (˜0.25 nmol/uL in ad-GFPtreated mice; ˜0.30 mmol/uL, p<0.05, in ad-107/GFP treated mice).

These results demonstrate that increased expression of miR-107 resultsin an impaired tolerance to glucose, a decreased sensitivity to insulin,and increased gluconeogenesis. MiR-107 and miR-103 share a seedsequence, and are expected to regulate similar targets, effects observedfollowing overexpression of miR-107 may also be observed uponoverexpression of miR-103. Thus, miR-107 and miR-103 are targets for thetreatment of metabolic disorders, including but not limited to diabetesand insulin resistance.

Example 4 Inhibition of miR-103 or miR-107 Decreases Plasma Cholesterol

The inhibition of miR-103 or miR-107 was additionally tested for itseffects on blood lipid levels in both wild-type (C57Bl/6, 8 week-old)and ob/ob mice (12 week-old, on high fat diet for 8 weeks). Eachtreatment group contained 5 mice. In this experiment, anti-miR-103comprised the sequence of SEQ ID NO: 6,2′-O-methyl modifications at eachsugar, phosphorothioate modifications at each of the first 4internucleoside linkages (at the 5′ end) phosphorothioate modificationsat each of the last 2 internucleosides linkages (at the 3′ end), and acholesterol conjugate. Anti-miR-107 comprised the sequence of SEQ ID NO:7,2′-O-methyl modifications at each sugar, phosphorothioatemodifications at each of the first 4 internucleoside linkages (at the 5′end), phosphorothioate modifications at each of the last 2internucleosides linkages (at the 3′ end), and a cholesterol conjugate.

Wild-type mice were injected with PBS, a single intra-peritonealinjection of anti-miR-107 at a dose of 15 mg/kg, or two intraperitonealinjections of anti-miR-103 at a dose of 15 mg/kg. Ob/ob mice wereinjected with PBS, a single intra-peritoneal injection of anti-miR-107at a dose of 15 mg/kg, or two intraperitoneal injections of anti-miR-103at a dose of 15 mg/kg.

Total plasma cholesterol was measured and was found to be significantlylowered in ob/ob mice treated with anti-miR-103 (1.75 ug/ul, p<0.001;n=5) or anti-miR-107 (1.86 ug/ul, p<0.001; n=5), relative to PBS-treatedmice (2.67 ug/ul; n=5). HDL and LDL fractions of total plasmacholesterol were measured by FPLC gel filtration from 200 ul of plasma,revealing a preferential reduction in LDL cholesterol (See Table 25). Tomeasure the number of LDL and HDL particles, immunoblotting wasperformed using apolipoprotein B detection to measure the number of LDLparticles and apolipoprotein A1 detection to measure the number of HDLparticles (See FIG. 3A).

TABLE 25 Anti-miR-103 treatment preferentially reduces LDL cholesterolin ob/ob mice Fraction PBS anti-miR-103 1 0.68 0.70 2 0.72 0.69 3 0.700.72 4 0.68 0.68 5 0.65 0.68 6 0.71 0.71 7 0.70 0.68 8 0.66 0.70 9 0.670.67 10 0.70 0.68 11 0.72 0.68 12 0.69 0.68 13 0.63 0.66 14 0.69 0.69 150.69 0.83 16 0.70 0.89 17 0.77 0.93 18 0.80 0.96 19 0.87 1.01 20 1.001.09 21 1.18 1.22 22 1.42 1.39 23 1.81 1.70 24 2.34 2.04 25 2.99 2.58 263.74 3.13 27 4.52 3.62 28 5.20 3.96 29 5.67 3.92 30 5.86 3.93 31 5.833.81 32 5.81 3.82 33 5.58 3.84 34 5.47 3.91 35 5.34 3.99 36 5.19 4.16 375.24 4.72 38 5.71 3.66 39 6.49 6.55 40 7.86 7.94 41 8.74 8.37 42 8.897.88 43 8.10 6.82 44 6.47 5.19 45 4.91 3.95 46 3.53 2.92 47 2.56 2.19 481.91 1.70 49 1.43 1.30 50 1.06 0.98 51 0.94 0.85 52 0.81 0.78 53 0.820.78 54 0.83 0.76 55 0.86 0.82 56 0.83 0.82 57 0.82 0.79 58 0.80 0.80 590.81 0.79 60 0.77 0.74

Non-esterified fatty acids were also measured, and observed to beincreased following inhibition of miR-103 (˜0.5 nm01/ul) or miR-107(˜0.45 nmol/ul), relative to PBS treatment (˜0.35 nmol/ul); n=5 for eachgroup.

8-week old LDL-receptor deficient mice (LDLR−/− mice) were also treatedwith anti-miR-103 or PBS (n=3), and the major lipoprotein fractions wereseparated by FPLC gel filtration from 150 ul of plasma and assayed forVLDL, HDL, and LDL fractions. Western blotting was also performed on thefractions assayed for cholesterol, using apolipoprotein B antibody todetect the number of LDL particles and apolipoprotein A1 antibody todetect the number of HDL particles (See FIG. 3B). A preferentialreduction in LDL cholesterol was observed (See Table 26). A decrease inVLDL indicates a decrease in triglyceride (See FIG. 3C).

TABLE 26 Preferential reduction in LDL cholesterol in LDLR −/− miceFraction PBS anti-miR-103 1 −0.02 −0.08 2 −0.03 0.16 3 −0.06 −0.06 4−0.09 −0.12 5 −0.08 −0.08 6 −0.05 0.00 7 −0.08 −0.02 8 −0.06 −0.03 9−0.07 −0.03 10 −0.06 −0.04 11 −0.05 −0.05 12 −0.06 −0.07 13 −0.10 −0.1114 −0.05 −0.08 15 0.28 −0.07 16 0.75 −0.07 17 0.84 0.03 18 0.83 0.19 191.14 0.39 20 0.97 0.55 21 1.18 0.83 22 1.65 1.21 23 2.46 1.89 24 3.692.84 25 5.29 3.95 26 6.88 5.28 27 8.67 6.51 28 10.06 7.24 29 10.23 7.7230 9.82 7.49 31 8.68 6.67 32 7.36 5.67 33 5.85 4.55 34 4.62 3.63 35 3.582.84 36 2.78 2.23 37 2.35 1.89 38 2.18 1.80 39 2.18 1.91 40 2.56 2.44 413.33 3.38 42 4.67 4.99 43 6.31 6.75 44 7.46 7.74 45 8.00 7.90 46 7.506.70 47 6.06 5.25 48 4.23 3.73 49 2.97 2.55 50 1.82 1.58 51 1.06 0.89 520.62 0.50 53 0.38 0.28 54 0.30 0.17 55 0.28 0.19 56 0.24 0.19 57 0.230.18 58 0.20 0.18 59 0.23 0.15 60 0.14 0.09

These data demonstrate further that inhibition of miR-103 or miR-107reduces cholesterol levels, preferentially cholesterol levels, inaddition to reducing blood glucose levels, improving insulinsensitivity, reducing gluconeogenesis, and improving glucose tolerance.

Example 5 Analysis of Gene Expression Regulation by miR-103 or miR-107

To address the possible mechanism by which miR-103 and miR-107 regulateinsulin sensitivity, RNA expression analysis was performed to measuregenes in tissues in which miR-103/107 was inhibited or over-expressed.Real-time PCR was conducted to measure the RNA levels of genes that arepredicted to be targets of miR-103 or miR-107. Microarray analysis wasperformed to measure genome-wide changes in gene expression. As thesequences of miR-103 and miR-107 differ only by one nucleobase, they areexpected to have overlapping sets of target genes.

To address the possible mechanism by which miR-103 and miR-107 regulateinsulin sensitivity, genome-wide expression analysis was performed usingAffymetrix microarrays, to compare livers from C57Bl/6J mice infectedwith Ad-107/GFP and Ad-GFP, 10 days after administration of the virus(n=5 per treatment). In the livers of Ad-107/GFP mice, mRNAs carrying aseed match to miR-107 in the 3′UTR were significantly down-regulatedcompared to mRNAs whose 3′UTR did not carry a miR-107 seed match, withthe down-regulation being more pronounced for the subset of mRNAsharboring seed matches inferred to be under evolutionary selectivepressure (FIG. 2B). The data were confirmed for a subset of miR-107target genes by real-time PCR (see Table 27) performed on RNA collectedfrom the livers of C57Bl/6 mice infected with recombinant adenovirusexpressing miR-107 (as in Example 2). A reduction in RNA levels inpresence of adenovirus expressing miR-107, relative to the control virusAd-GFP, indicates that the RNA is a target of miR-103/107. Analysis ofthe functional annotation of the down-regulated genes indicated thatmetabolism would be affected by miR-103/107.

TABLE 27 Changes in gene expression following viral overexpression ofmiR-107 LIVER C57bl/6 ad-GFP ad-107/GFP G6Pc 0.98 2.00*** PEPCK 1.071.39* Pyruvate carboxylase 1.01 1.23* Fructose 1,6 bisphosphatase 1.101.73* Cav1 1.0000 0.7066** Gpnmb 0.9548 0.1521*** Prom1 1.0934 0.4454**LPL 1.0564 0.4401*** Pla2 (g4) 1.0345 0.3492*** Pla2 (g7) 1.09820.4065*** LYPLA2 1.0000 0.8787* LYPLA3 1.0050 0.5679*** Pld1 1.00000.7548** Pld3 1.0274 0.5772*** ApoBEC1 1.0055 0.5709*** ApoB48r 1.16300.3833***

Real-time PCR was performed on RNA collected from the livers of ob/obmice treated with anti-miR-103 or anti-miR-107 (as in Example 1; n=5mice). An increase in RNA levels in the presence of anti-miR-103 oranti-miR-107, relative to the PBS control, indicates that the RNA is atarget of miR-103 or miR-107. See Table 28 and additional geneexpression data in FIG. 4A.

TABLE 28 Changes in liver gene expression following inhibition ofmiR-103 in ob/ob mice PBS anti-miR-103 Cav1 1.0021 1.2232 Gpnmb 1.00372.5821 Prom1 0.9992 1.5617 LPL 1.0040 1.2673 Pla2 (g7) 1.0002 1.3347ApoBEC1 1.0031 1.2115 BCKDHA 1.0003 0.3698 SAA1 1.0020 0.4313 SAA31.1023 0.4360 LCN2 1.0020 0.4044

Real-time PCR was performed on RNA collected from the livers of LDLR−/−mice treated with anti-miR-103 (as in Example 4). An increase in RNAlevels in the presence of anti-miR-103, relative to the PBS control,indicates that the RNA is a target of miR-103. See Table 29.

TABLE 29 Anti-miR-103 increases gene expression in liver of LDLR−/− micePBS anti-miR-103 LPL 1.0026 1.8160*** Pla2g4 1.0123 1.7222*** Pla2g71.0690 3.0274*** ApoBEC1 1.0223 1.8388*** LYPLA3 1.0300 1.4017** ApoB48r1.0891 1.3525* LIPIN1 0.9896 1.3751**

Real-time PCR was performed on RNA collected from the fat of ob/ob orC57Bl/6 mice treated with anti-miR-103 or anti-miR-107 (as in Example1). An increase in RNA levels in the presence of anti-miR-103 oranti-miR-107, relative to the PBS control, indicates that the RNA is atarget of miR-103 or miR-107. See Table 30 and additional geneexpression data in FIG. 4B.

TABLE 30 mRNA increases in fat of ob/ob mice following anti-miR-103treatment ob/ob C57Bl/6 PBS anti-miR-103 PBS anti-miR-103 LPL 1.02411.7775** 1.0937 2.3323*** Lipin1 1.0238 1.5320** 1.2662 2.1105** Cav10.9860 3.4585*** 1.5891 2.3680* Pla2(g7) 0.9851 1.4429* N.D. N.D.

Real-time PCR was performed on RNA collected from the muscle of ob/ob orC57Bl/6 mice treated with anti-miR-103 (as in Example 1). An increase inRNA levels in the presence of anti-miR-103, relative to the PBS control,indicates that the RNA is a target of miR-103 or miR-107. See Table 31and additional gene expression data in FIG. 4C.

TABLE 31 mRNA changes in muscle of ob/ob mice following anti-miR-103treatment ob/ob PBS anti-miR-103 LPL 1.0215 1.4497** Cav1 1.02381.4333** G6Pc 0.9538 0.5288* PC 0.9840 0.1578*** BCAT2 1.0199 1.5041***

Caveolin 1 (Cav1), a key component of caveolae in adipocytes and amediator of insulin signaling, was among the miR-103/107 seed containinggenes that were down- or up-regulated in insulin-sensitive tissuesfollowing miR-107 over-expression and silencing, respectively. Asillustrated in the above tables, Cav1 transcript levels were reducedapproximately 30% in livers of C57Bl/6 mice injected with ad-107/GFP(relative expression of 0.71 in ad-107/GFP mice vs. ad-GFP mice) andincreased approximately 22% in livers of anti-miR-103 injected ob/obmice (relative expression of 1.22 vs. PBS-treated mice). Anti-miR-103treatment of C57Bl/6 mice lead to a 1.5-fold increase in fat Cav1 mRNAlevels (relative expression of 2.37 vs. 1.59 in PBS-treated mice).Strikingly, miR-103 silencing in the fat of ob/ob mice increased Cav1mRNA levels approximately 3.5-fold (relative expression of 3.45 vs.PBS-treated mice), and miR-103 silencing in muscle resulted inapproximately 1.4-fold up-regulation of Cav1 mRNA levels (1.43 relativeexpression vs. PBS-treated mice).

To test if Cav1 expression is directly regulated by miR-103/107 thecoding sequence and 3′UTR were analyzed for functional binding sites.Murine Cav1 (mCav1) contains three miR-103 seed motifs in the 3′UTR,while human Cav1 (hCav1) has three 6-mer seed motifs, one in the 5′, andtwo in the 3′ UTR (FIG. 9).

A luciferase assay was used to test constructs containing either thefull-length or partial 3′UTR of miR-103/107 target genes, as anadditional confirmation that the genes are regulated by miR-103/107.Measurements of luciferase activity from HEK293 cells transfected withplasmid constructs containing the 3′UTR mouse and human Cav1 (mCav1 andhCav1, respectively) showed reduced expression of these reporterconstructs in the presence of miR-103 (see Table 32). Mutating the seed,also conserved in mouse (NM_(—)001753 in RefSeq, 2004-2009 (ATGCTG)),resulted in the full reversal of the miR-103-induced decrease of theluciferase activity in both hCav1 3′UTR constructs (NM_(—)001753,1505-2679 nt(L), and 1749-2679 nt(S)). Furthermore, the total luciferaseactivity in the mutant 3′UTR hCav1 was increased compared to thewildtype 3′UTR hCav1, likely due to the derepression through theendogenously expressed miR-103.

TABLE 32 Caveolin 1 is a target of miR-103 Relative Luciferase Activity(firefly/renilla) Mock miR-103 Scrambled 1 mCav1 long 1 0.76* 0.96 hCav1short 1 0.8 0.93 hCav1 long 1 0.86* 0.98 hCav1 mut short 1 1.1 0.98hCav1 mut long 1 1.05 0.99 Total hCav1 mut/wt short 1.16** Total hCav1mut/wt long 1.21**

Among other RNAs, Caveolin 1 and lipin were identified as targets ofmiR-103/107. These genes are candidates for the targets that mediate theeffects of anti-miR-103 and/or anti-miR-107.

Example 6 Analysis of miR-103 or miR-107 Target Protein Expression

To further understand the regulation of target genes by miR-103 ormiR-107, samples from anti-miR treated mice were analyzed for proteinexpression.

Western blotting was performed on protein extracts from fat tissue ofob/ob mice treated with PBS or anti-miR-103 (as described in Example 1).Membranes were probed for Caveolin 1, Insulin receptor beta, pAKT, AKT,and gamma-tubulin. Phosphorylated p-AKT was observed to be increased. AspAKT is a kinase that is activated by insulin signaling, increased p-AKTlevels at similar plasma insulin levels indicated increased insulinsensitivity. See FIG. 5A.

HEK293 cells were also treated with anti-miR-103, and cells wereharvested 3 days following anti-miR treatment. Western blotting wasperformed to detect Caveolin 1 and gamma-tubulin. Caveolin 1 proteinlevels increased with increasing concentrations of anti-miR-103,indicating that Caveolin 1 was de-repressed by inhibition of miR-103.See FIGS. 5B and 5D.

Northern blotting was used to detect miR-103 in HEK293 cells treated asin FIG. 5B. See FIG. 5C.

To evaluate the effects of adding miR-103 to cells, HEK293 cells weretransfected with miR-103 siRNA. Control siRNAs were also used. Theaddition of miR-103 caused reduced levels of Caveolin 1 protein. SeeFIGS. 5E and 5F.

To evaluate the effects of adding miR-103 to cells, 3T3 cells weretransfected with miR-103 siRNA. Control siRNAs were also used. Theaddition of miR-103 caused reduced levels of Caveolin 1 protein. SeeFIG. 5G.

Taken together with the results on mRNA expression, these datademonstrate that Cav1 is a direct target of miR-103 in both mouse and inhuman.

Example 7 Contribution of Liver to miR-103 Mediated Effects on InsulinSensitivity

To test the relative contribution of the liver for the effect on insulinsensitivity, liposomal formulations were used to deliver anti-miRprimarily to the liver. Liver-targeting lipid nanoparticle (LNP)formulations of anti-miR were prepared using the novel ionizable lipidDLin-KC2-DMA (Semple et al., Nature Biotechnology, 28, 172-176 (2010)).LNPs were comprised of DLin-KC2-DMA, distearoyl phosphatidylcholine(DSPC), cholesterol and mPEG2000-DMG, utilized at the molar ratio of50:10:38.5:1.5. Ant-miRs were formulated in the LNPs at a totallipid:anti-miR weight ratio of approximately 11:1.

Anti-miR-103 or anti-mm-107, formulated in liposomes, was administeredto mice at a dose of 15 mg/kg of anti-miR (n=8 mice for anti-miR-103,n=7 mice for anti-mm-107). Mice received one injection per day, for twodays. Northern blotting was performed using 30 ug of total RNA fromliver, fat or muscle. Liposome-formulated anti-miR-103, but notliposome-formulated anti-mm-107, induced specific and potent silencingof miR-103 in liver, but not in fat and muscle. See FIG. 6. Silencing ofmiR-103/107 in livers of ob/ob mice neither had a significant effect onblood glucose levels in random and fasting conditions (see Table 33),nor did this treatment result in improved insulin sensitivity. Thisobservation indicates that the insulin-sensitizing actions ofmiR-103/107 are mainly mediated by extrahepatic tissues such as fat andmuscle.

TABLE 33 Liposomally formulated anti-miR-103 does not significantlyaffect blood glucose Blood Glucose (mM) ob/ob D 0 6 hfast D 3 random D 36 h fast D 5 random D 5 6 h fast D 8 12 h fast D 9 12 h fastLip-anti-mm-107 7.4429 13.7857 7.7000 7.5833 9.7667 6.4000 10.4286Lip-anti-miR-103 7.4125 9.6250 7.1000 7.1625 7.9000 5.0750 8.3000

Example 8 Effects of miR-103 Inhibition in Adipose Tissue

Since the expression of miR-103 is approximately 8-fold higher inadipose tissue compared to liver and muscle, the effects of silencingmiR-103/107 in adipose tissue were examined in more detail.

Obese (ob/ob) mice exhibited a slight reduction in body weight whenmiR-103/107 was systemically silenced using anti-miR-103 compared tocontrol-treated mice. See Table 34. In contrast, manipulation ofmiR-103/107 expression in the liver using liposomally-formulatedanti-miR-103 or Ad-107/GFP did not affect body weight compared tocontrol treated mice. In light of this observation, the fat distributionof both high-fat fed obese and ob/ob animals was investigated bycomputer tomography (CT) 13 days following treatment with anti-miR orcontrol. See FIG. 7A. Both high-fat fed and ob/ob mice treated withanti-miR-103 had reduced total fat due to a decrease in bothsubcutaneous (SC) and visceral (V) fat (See Tables 34 and 35).

TABLE 34 Anti-miR-103 decreases subcutaneous and visceral fat ComputerTomography at Day 13 Subcutaneous Visceral Total ob/ob DIO ob/ob DIOob/ob DIO anti-MM-103 8.16 5.44 16.58 12.06 30.18 34.07 anti-miR-1037.46 3.87 15.38 10.18 26.71* 29.43*

TABLE 35 Anti-miR-107 reduces body weight of obese ob/ob mice BodyWeight (g) ob/ob Day 0 Day 3 Day 6 Day 12 Day 15 Day 16 anti-MM-10344.21 46.10 47.84 50.17 49.76 48.80 anti-miR-103 43.94 45.55 46.16 47.8947.10 46.14*

To investigate whether this reduction is due to lower cell numbers orsmaller adipocytes, mean adipocyte cell size from fat tissue sectionswas quantified using an automated image analysis software. Anti-miR-103treated high-fat fed obese and ob/ob animals had smaller adipocytescompared to anti-mm-107 injected controls (FIG. 7B, 7C; quantificationin Table 36).

TABLE 36 Anti-miR-103 treatment results in smaller adipocyte size DIOob/ob SC V SC V anti-miR-124 N.D. N.D. 23533.66    25163.76   anti-MM-107 23794.78    25325.03    24193.78    24890.49    anti-miR-10319523.82*** 20822.32*** 19520.48*** 20822.43***

Also observed was a significant increase in the number of smalladipocytes and a decrease in large adipocytes (See Tables 37 and 38;values are normalized to the total cell number).

TABLE 37 DIO mice: anti-miR-103 increases the small adipocyte number anddecreases large adipocyte number SC V anti-MM-107 anti-miR-103anti-mm-107 anti-miR-103 1 0.0000 0.0000 0.0000 0.0000 2 0.0490 0.06800.0308 0.0641* 3 0.1194 0.1392 0.0576 0.1171* 4 0.1057 0.1386*** 0.10330.1200 5 0.1015 0.1239 0.1054 0.1075 6 0.0949 0.0918 0.0985 0.1053 70.0873 0.0845 0.0781 0.0837 8 0.0619 0.0639 0.0870 0.0850 9 0.05940.0501 0.0671 0.0648 10 0.0443 0.0522 0.0556 0.0431** 11 0.0410 0.03930.0574 0.0400* 12 0.0348 0.0333 0.0474 0.0329 13 0.0276 0.0296 0.04380.0340 14 0.0227 0.0188 0.0256 0.0186 15 0.0223 0.0162 0.0172 0.0209 160.0183 0.0122 0.0222 0.0112*** 17 0.0217 0.0100* 0.0220 0.0137 18 0.01550.0073 0.0144 0.0087 19 0.0166 0.0058* 0.0181 0.0046** 20 0.01660.0050** 0.0128 0.0051* 21 0.0110 0.0035* 0.0100 0.0075 22 0.0099 0.00370.0096 0.0046* 23 0.0059 0.0023 0.0081 0.0026* 24 0.0057 0.0008** 0.00600.0017 25 0.0033 0.0000 0.0014 0.0000 26 0.0016 0.0000 0.0007 0.0000 270.0016 0.0000 0.0000 0.0000 28 0.0005 0.0000 0.0000 0.0000 n = 6 foranti-mm-107; n = 7 for anti-miR-103

TABLE 38 Ob/ob mice: anti-miR-103 increases small adipocyte number anddecreases large adipocyte number SC V anti-mm-107 anti-miR-103anti-mm-107 anti-miR-103 1 0.0000 0.0006 0.0000 0.0000 2 0.0524 0.0860**0.0518 0.0767** 3 0.0965 0.1275** 0.0862 0.1016** 4 0.1005 0.1302***0.0878 0.1118** 5 0.0927 0.1129** 0.0868 0.1000 6 0.0900 0.0958 0.08710.1044** 7 0.0886 0.0883 0.0858 0.0922 8 0.0697 0.0687 0.0741 0.0786 90.0601 0.0592 0.0672 0.0735 10 0.0555 0.0451** 0.0571 0.0524 11 0.04840.0384* 0.0452 0.0442 12 0.0388 0.0313 0.0478 0.0397 13 0.0282 0.02500.0438 0.0256*** 14 0.0299 0.0239 0.0390 0.0252*** 15 0.0307 0.0154***0.0255 0.0167* 16 0.0243 0.0139** 0.0224 0.0128** 17 0.0185 0.0112**0.0191 0.0139* 18 0.0178 0.0097** 0.0163 0.0100*** 19 0.0160 0.0083**0.0134 0.0087* 20 0.0125 0.0065* 0.0126 0.0058** 21 0.0091 0.0010***0.0103 0.0020*** 77 0.0083 0.0003*** 0.0084 0.0028*** 23 0.00740.0003*** 0.0071 0.0008*** 24 0.0042 0.0003** 0.0051 0.0006*** 25 0 0 00 26 0 0 0 0 27 0 0 0 0 28 0 0 0 0 n = 4 for anti-mm-107; n = 5 foranti-miR-103

Comparing the decrease in fat pad size measured by CT with the averagedecrease in adipocyte size showed that anti-miR-103 mice hadapproximately 10-20% more adipocytes than anti-mm-107 controls. Toexplore whether this could be attributed to changes in the preadipocytedifferentiation, stromal-vascular fraction (SVF) was isolated from bothV and SC fat of wildtype mice, and differentiation was induced in thepresence of either anti-miR-103 or anti-mm-107. After 8 days in culture,anti-miR-103 transfected cells contained more mature adipocytes than thecells from anti-mm-107 (FIG. 7D), indicating that the absence of miR-103enhances adipocyte differentiation in a cell autonomous fashion.Quantification of adipocyte number by high content imaging demonstratedapproximately 2 and 2.5-fold increases of differentiated adipocytes inthe anti-miR-103 treated SVF derived from V or SC fat, respectively (seeTable 39). Conversely, Ad-107/GFP-mediated miR-107 over-expression ledto 3.7-fold decrease in the number of differentiated adipocytes comparedto Ad-GFP control infected SVF (See Table 39).

TABLE 39 anti-miR-103 treatment increases differentiated adipocytesRelative number of differentiated cells SC V anti-mm-107 1.00 1.00anti-miR-103 1.75*** 2.51** ad-GFP N.D. 1.00 ad-107/GFP N.D. 0.28***

The negative regulation of miR-103 on preadipocyte differentiation wasfurther corroborated by gene expression analysis of adipocytedifferentiation markers Apt, and PPAR-gamma. Both markers exhibitedincreased mRNA levels in differentiated SVF in which miR103/107 wassilenced with anti-miR-103 compared to the anti-mm-107 control (seeTables 40).

TABLE 40 Adipocyte differentiation markers increase following inhibitionof miR-103/107 AP2 Relative PPARγ Relative Gene Expression GeneExpression 0 h 24 h 48 h 96 h 0 h 24 h 48 h 96 h Mock 0.96 3.80 12.6237.16 0.99 1.69 2.15 5.68 anti- 0.96 3.80 14.92 57.24 0.99 1.71 2.127.36 mm-107 anti- 0.96 3.85 19.31 92.78*** 0.99 1.91 2.92* 9.34* miR-103

Example 9 miR-103-Mediated Glucose Uptake

Smaller adipocytes are associated with increased insulin sensitivity inhuman and rodent models. To explore if insulin-stimulated glucose uptakein adipocytes was affected by miR-103 inhibition, primary adipocyteswere isolated from either anti-miR-103, or control treated ob/ob mice,and insulin-stimulated D-¹⁴C-glucose uptake was measured in vitro.

In one study, primary adipocytes were isolated from 7 month old ob/obmice treated with PBS or anti-miR-103 (2 injections of 15 mg/kg each).Anti-miR-124 or anti-mm-107 was used as a control anti-miR. Mice weresacrificed 6 days after injection following a 15 hour fast, and theprimary subcutaneous (SC) or visceral (V) adipocyte fractions werepreincubated for 10 minutes with or without 20 nM insulin, and then foran additional 1 hour with 1 mM ¹⁴C-labeled glucose. Anti-miR-103improved insulin-stimulated glucose uptake in adipocyte cells, relativeto PBS or anti-miR-124 treatment, indicating an increase in insulinsensitivity. See Table 41. Glucose uptake after stimulation with 20 nMinsulin was significantly higher in the anti-miR-103 adipocytes comparedto the controls (anti-mm-107 or PBS) (Table 41).

TABLE 41 Anti-miR-103 improves insulin-stimulated glucose uptake (FIG.7h) 14C-labeled glucose uptake in primary adipocytes SC SC V V anti-anti- anti- anti- V mm-107 miR-103 mm-107 miR-103 PBS No Insulin 1.001.12 1.00 1.63 0.82 20 nM Insulin 1.27 1.78 1.29 2.61 1.05 SC: p < 0.01in no insulin, anti-miR-103 relative to anti-mm-107 SC: p < 0.001 in 20nM insulin, anti-miR-103 relative to anti-mm-107 V: p < 0.001 in noinsulin, anti-miR-103 relative to anti-mm-107 V: p < 0.01 in 20 nMinsulin, anti-miR-103 relative to anti-mm-107

Furthermore, adiponectin levels, which positively correlate with theinsulin sensitivity, were increased in anti-miR-103 treated ob/ob mice(Table 42), and decreased in C57Bl/6 mice injected with ad-107/GFP.

TABLE 42 Anti-miR-103 increases adiponectin levels in ob/ob miceTreatment Strain Adiponectin ug/ml anti-mm-107 ob/ob 6.20 anti-miR-103ob/ob 8.11 ad-GFP C57Bl/6 8.98 ad-107/GFP C57Bl/6 6.79

Together, these data demonstrate that silencing of miR-103/107 increasesinsulin sensitivity in adipocytes.

Example 10 miR-103-Mediated Lipoprotein Lipase Hydrolase Activity

LPL hydrolase activity in the fat of C57Bl/6 or ob/ob mice treated withPBS or anti-miR-103 was measured using an enzymatic assay. An increasein LPL hydrolase activity in the anti-miR-103 treated mice indicated anincrease in insulin sensitivity. See Table 43.

TABLE 43 Anti-miR-103 treatment increases LPL activity c57bl/6 ob/obanti-mm-107 0.34 0.22  anti-miR-103 0.38 0.31*

Increased insulin sensitivity results in improved insulin resistance.Accordingly, provided herein are methods for increasing insulinsensitivity, thus improving insulin resistance, by inhibiting theactivity of miR-103 and or miR-107.

Example 11 Effects of miR-103 Inhibition Mice Lacking the caveolin1 Gene

Cav1 is the principal protein of caveolae, distinct nonionicdetergent-insoluble, lipid- and cholesterol-enriched vascularinvaginations at the plasma membrane. Cav1 activates insulin signalingmost likely by stabilizing caveolae and its associated IR. Specifically,peptides corresponding to the scaffolding domain derived from Cav-1 and-3, potently stimulate insulin receptor kinase activity toward insulinreceptor substrate-1 (IRS-1). Cav3 overexpression augmentsinsulin-stimulated phosphorylation of IRS-1 in 293T cells and increaseshepatic IR phosphorylation in response to insulin stimulation, therebyimproving overall glucose metabolism of diabetic mice. Cav1 null (Cav1KO) mice are phenotypically normal on a chow diet. However, when placedon high fat diet they develop insulin resistance due to diminished IRsignaling, as evidenced by a 90% decrease in total fat IR proteinlevels. We investigated if the activity of insulin signaling correlatedwith miR-103/107 mediated changes in Cav1 expression. In adipocytes ofob/ob mice, silencing of miR-103/107 using anti-miR-107 resulted inincreased Cav1 protein levels (FIG. 8C), augmented IRb expression aswell as enhanced pAkt levels compared to anti-mm-107 treated mice (FIG.8C). In contrast, wild-type mice in which ad-107/GFP was injected intothe peritoneal fat 8 days prior to the analysis exhibited a reduction inCav1 expression and decreased IRb and pAKT levels (FIG. 8B; relativeCav1 expression of 0.4 following ad-107/GFP injection v. ad-GFPinjection). Since overexpression of miR-107 in the liver by recombinantadenovirus led to hepatic insulin resistance and impaired glucosetolerance, downstream molecular insulin signaling events in thoseanimals were studied. Protein levels of Cav1 and pAKT levels werediminished in the liver of wildtype mice infected with ad-107/GFP, withno changes observed in IRb protein levels (FIG. 8A). This result is inagreement with the phenotypic findings showing that overexpression ofmiR-103 can induce hepatic insulin resistance and data from Cav1 KOmice, which do not exhibit reduced IRb levels in the liver but havereduced IRb and pAkt levels in adipocytes. Lastly, in order to show thatmodulation of Cav1 expression is responsible for the increase in insulinsignaling upon miR-103/107 silencing, high-fat fed obese mice or Cav1 KOmice were treated with anti-miR-103 or anti-mm-107 (15 mg/kg anti-miR,once per day intraperitoneally, for 2 consecutive days) to study theactivation of insulin signaling following insulin stimulation. Whereassilencing of miR-103/107 in fat of high-fat fed obese wild-typelittermates of the CAV1 KO mice led to increased expression of IRb,phosphorylated IRb and phospho-Akt compared to anti-mm-107 treated mice,no activation of insulin signaling was observed in the fat of high-fatfed obese Cav1 KO mice that were treated with anti-miR-103 (FIG. 8D).Together, these data demonstrate that miR-103/107 regulates insulinsensitivity through a caveolin-mediated process.

Example 12 Experimental Methods

Statistical analysis All bars show mean±STD, except Table 10 where barsshow mean±STE. Significance was calculated using students t-test(p<0.05; p<0.01; p<0.001). Throughout the examples, unless otherwiseindicated, statistical significance is indicated in the Tables:*=p<0.05; **=p<0.01; ***=p<0.001.RNA isolation and Northern blotting analysis Total RNA was isolatedusing the Trizol reagent (Invitrogen). 5-30 μg RNA was separated at 15 Won 14% polyacrylamide gels as described Krutzfeldt et al., Nature, 2005,438, 685-689.Real Time PCR 2 μg of total RNA was used for cDNA preparation withrandom hexamer primers using Super Script III Reverse Transcriptase(Invitrogen). Steady state mRNA expression was measured by quantitativereal-time PCR using the LightCycler 480 SYBR Green Master I Mix (Roche)with a Mx3005P Real Time PCR System (Stratagene). Transcript levels werenormalized to GAPDH or 36B4. Primer sequences for real-time PCRs areavailable on request. mRNA levels were measured using the TaqManmicroRNA Assays for miR-103, mir-107, or U6 (Applied Biosystems) and PCRresults were normalized to U6 levels.Assay of luciferase activity Mouse or human 3′ UTR sequences werePCR-amplified with specific primers, followed by attB adapter PCR, andcloned in the pDONR221 entry vector using BP Clonase (Invitrogen). Thepositive clones were then further cloned behind the stop codon of thefirefly luciferase in the dual renila/firefly Luciferase pEM393destination vector. HEK-293 cells were cultured in 24-well plates andeach well was transfected with 100 ng of the final construct togetherwith either PBS, or 50 nmol of either control or si-103 double-strandsiRNA (Sigma) in quadruplicates. Cells were harvested and assayed 42-48h after transfection using the Dual-Luciferase Reporter Assay System(Promega). Results normalized to the renilla luciferase control andexpressed relative to the average value of the control PBS.Animals All animal models were maintained in a C57BL/6 background on a12-h light/dark cycle in a pathogen-free animal facility. Six-eightweek-old wt, or leptin-deficient (ob/ob), or 12 weeks old high fat diet(DIO) mice fed for 8 weeks with 60% fat (Pvolimi Kliba AG) were injectedin the tail-vein with either PBS, anti-miRs, ad-GFP, or ad-107/GFP (asindicated). Anti-miRs were administered at doses of 15 mg per kg bodyweight in 0.2 ml per injection on 2 consecutive days. Mice were injectedwith adenoviruses at 5×10⁹ plaque-forming units (PFU) in 0.2 ml PBSthrough the tail vein.Generation of recombinant adenovirus The recombinant adenovirus used toexpress miR-107 and GFP (Ad-107/GFP) was generated by inserting the PCRamplified miRNA precursor sequence with primers:5′-AATACCCGCATGGAAGCAGGCTAA-3′ (SEQ ID NO: 17) and5′-AACATGTCTCAAGGAGAGGACGGT-3′ (SEQ ID NO: 18) sinto a GFP expressingshuttle vector Ad5CMV K-NpA. Ad-GFP (ViraQuest), which does not containa transgene was used as a control.Adenovirus fat injection Ad-GFP or ad-107/GFP was injected in theperitoneal fat at a concentration of 1×10⁹ pfu in 40 μl PBS followingsurgical exposure.Computer Tomography Subcutaneous and visceral fat pads were scannedusing an animal CT-Scanner (LaTheta). Images were corrected and analyzedusing the LaTheta Software.Isolation of stromal-vascular (SV) fraction and primary adipocytesPrimary adipocytes and (SV) fraction from subcutaneous and visceral fatwere prepared as described reviously (Hansen et al., Mol. Endocrinol.,1998, 12, 1140-1149 and Tozzo et al., Am. J. Physiol., 1995, 268,E956-964. Adipocyte differentiation was induced with insulin,dexamethasone, isobutylmethylxanthine and rosiglitazone when SV cellswere 80% confluent (Tozzo et al.). Cells were treated using anti-miRs ata concentration of 5.5 μg/during the induction period on days 2 and 3.Automated analysis of adipocyte differentiation Differentiated cellswere fixed with 5% formaldehyde prior to staining with BODIPY for lipiddroplets, Hoechst for nuclei and Syto60 for cytosolic staining(Invitrogen). 25 pictures per well were taken with an automatedmicroscope imaging system (CellWorx). Pictures were analyzed using CellProfiler Software.Glucose uptake [¹⁴C] spiked glucose uptake with or without 20 nM insulinstimulation was measured as described (Tozzo et al.).Adipocyte size Hemotoxylin and eosin staining of 10 μm slices 5%paraformaldehyde fixed adipose tissue was performed according tostandard procedures (for example, Chen and Farese, J. Lipid. Res., 2002,43, 986-989), and images were analyzed using Cell Profiler Software. Atleast 2000 adipocytes were measured per animal to determine adipocytesize.Glucose, Insulin, Cholesterol, TGs and NEFA measurements Blood glucosevalues were measured using an automated glucose monitor (GlucometerElite, Bayer). Insulin was measured from plasma using Sensitive RatInsulin RIA Kit (Linco). Cholesterol and TAGs were measured with Choi,or Trig/GB reagents respectively with c.f.a.s. as standard(Roche/Hitachi). NEFA were quantified with NEFA-HR(2) R1/R2 Set (Wako).Glucose, Insulin, and Pyruvate Tolerance Tests Glucose, insulin orpyruvate tolerance tests were performed by i.p. injection of eitherglucose (2 g/kg of body weight in saline); insulin (0.75 unit/kg bodyweight); or pyruvate (2 g/kg of body weight in saline) respectively,after overnight fast (as indicated in the figures) for glucose andpyruvate, or 6 h fast for insulin. Blood glucose levels were measuredbefore (time=0) and 15, 30, 60, and 120 min after injection.Cell culture, infection, and transfection Hepal-6, 3T3-L1, or HEK293cells were maintained in growth medium Dulbecco's modified Eagle'smedium (Invitrogen) containing 4.5 g/liter glucose supplemented with 10%FBS and penicillin/streptomycin. Hepal-6 and 3T3-L1 were kept oncollagen-coated plates. Nepal-6 were infected with ad-GFP, or ad-107/GFPat 1:1000 dilution of 5×10¹⁰ PFU virus prep in growth medium for 36 h.HEK293 cells were transfected with anti-miRs at concentration of 5.5μg/ml in growth medium, or with PBS, si-103, or si-141 usingLipofectamine 2000 (Invitrogen).Western blotting and antibodies Cells were washed with ice cold PBS andextracted in lysis buffer (10 mM Tris-HCl, pH 8.0, 140 mM NaCl, 1%Triton X-100, 1 mM EDTA, and protease inhibitor cocktail (Roche)), andHalt phosphatase inhibitors (Thermo Scientific) at 4° C. Proteins wereseparated by 8-12% SDS-PAGE, transferred on nitrocellulose filters, anddetected with the following antibodies: mouse monoclonal anti-y-tubulin(Sigma-Aldrich), rabbit polyclonals anti-insulin receptor b subunit(C-19):sc-711 (IRb); anti-p-insulin receptor b subunit(Tyr1162/1163):sc25103 (p-IRb); anti-Caveolin 1 (N20):sc-894; andanti-GM103 (B10):sc-55591 (Santa Cruz Biotechnology); anti-p-AKT,anti-AKT, anti-p-S6BP; anti-p-GCK3 (Cell Signaling).Sucrose density gradient fractionation and insulin stimulation Ad-GFP,or ad-107/GFP infected Hepal-6 cells were serum starved for 12 h inDulbecco's modified Eagle's medium without fetal bovine serum,stimulated or not with 500 nM insulin in growth medium for 15 min.,scraped in ice cold PBS and resuspended in 1.5 ml homogenization buffercontaining 250 mM sucrose, 4 mM HEPES pH 7.4, and protease and Haltphosphatase inhibitors (Thermo Scientific). Cell suspension was douncedin tight douncer for 25 times, and the perinuclear supernatant (PNS)after 10 min at 1000 rpm was loaded from the top on 0.4-2 M continuoussucrose density gradients (for example, Ort et al., Eur. J. Cell Biol.,2000, 79, 621-630), and centrifuged with Beckman ultracentrifuge for 18h at 25000 rpm (100000 g) on 4° C. For the flotation gradientexperiments, the PNS was mixed 1:1 with 85% sucrose, and 1 ml of the mixwas loaded from the bottom on discontinuous sucrose gradient to thefinal 5% (2 ml), 30% (5 ml), and 42.5% (1 ml) sucrose and centrifuged 19h at 39000 RPM in SW41 rotor using Beckman ultracentrifuge at 4° C. 0.5ml fractions were collected from the top, precipitated with 1.5 volumesof ethanol overnight on −80° C., washed with 70% ethanol and resuspendedin 2×SDS containing loading buffer.

The foregoing description of the specific embodiments so fully revealsthe general nature of the invention that others can, by applying currentknowledge, readily modify and/or adapt for various applications suchspecific embodiments without undue experimentation and without departingfrom the generic concept, and, therefore, such adaptations andmodifications should and are intended to be comprehended within themeaning and range of equivalents of the disclosed embodiments. Althoughthe invention has been described in conjunction with specificembodiments thereof, it is evident that many alternatives, modificationsand variations will be apparent to those skilled in the art.Accordingly, it is intended to embrace all such alternatives,modifications and variations that fall within the spirit and broad scopeof the appended claims.

1.-121. (canceled)
 122. A method comprising administering to a subject acompound comprising modified oligonucleotide having a nucleobasesequence at least 90% complementary to the nucleobase sequence ofmiR-103 or miR-107, wherein the subject has at least one metabolicdisorder or at least one condition associated with a metabolic disorder.123. The method of claim 122, wherein at least one metabolic disorder isselected from pre-diabetes, diabetes, metabolic syndrome, obesity,diabetic dyslipidemia, hyperlipdemia, hypertension,hypertriglyceridemia, hyperfattyacidemia, hypercholesterolemia, andhyperinsulinemia.
 124. The method of claim 122, wherein at least onecondition associated with a metabolic disorder is selected from anelevated glucose level, elevated gluconeogenesis, insulin resistance,impaired glucose tolerance, and excess body fat.
 125. The method ofclaim 122, comprising measuring the blood glucose level of the subject.126. The method of claim 122, comprising administering at least oneadditional therapy, wherein the at least one additional therapy is aglucose-lowering agent or a lipid-lowering agent.
 127. The method ofclaim 122, wherein the modified oligonucleotide consists of 7 to 12linked nucleosides.
 128. The method of claim 122, wherein the modifiedoligonucleotide consists of 12 to 30 linked nucleosides.
 129. The methodof claim 122, wherein the nucleobase sequence of the modifiedoligonucleotide is 100% complementary to the nucleobase sequence ofmiR-103 and is 100% complementary to the nucleobase sequence of miR-107.130. The method of claim 122, wherein the nucleobase sequence of miR-103is SEQ ID NO: 1 and the nucleobase sequence of miR-107 is SEQ ID NO: 2.131. The method of claim 122, wherein the modified oligonucleotidecomprises at least one modified sugar.
 132. The method of claim 131,wherein the modified sugar is independently selected from a2′-O-methoxyethyl sugar, a 2′-fluoro sugar, 2′-O-methyl sugar, and abicyclic sugar moiety
 133. The method of claim 122, wherein the modifiedoligonucleotide comprises at least one modified internucleoside linkage.134. A method comprising contacting a cell or tissue with a compoundcomprising a modified oligonucleotide having a nucleobase sequence atleast 90% complementary to the nucleobase sequence of SEQ ID NO: 1 or 2wherein: a. the cell or tissue is an insulin resistant cell or tissue;b. the cell or tissue has decreased sensitivity to insulin; c. the cellis an undifferentiated adipocyte cell or the tissue comprisesundifferentiated adipocyte cells.
 135. The method of claim 134 whereinthe cell or tissue is a liver, fat, or skeletal muscle cell or tissue.136. A method comprising: determining the amount of miR-103 or miR-107in a sample from a subject, wherein an increased level of miR-103 ormiR-107, relative to a control sample, indicates that the subject is inneed of treatment with a compound comprising a modified oligonucleotideat least 90% complementary to miR-103 or miR-107.
 137. The method ofclaim 136 wherein the sample is selected from a liver sample and anadipose tissue sample.
 138. The method of claim 136 wherein the subjecthas at least one metabolic disorder.
 139. The method of claim 138,wherein at least one metabolic disorder is selected from pre-diabetes,diabetes, metabolic syndrome, obesity, diabetic dyslipidemia,hyperlipdemia, hypertension, hypertriglyceridemia, hyperfattyacidemia,hypercholesterolemia, and hyperinsulinemia.
 140. A method comprisingadministering to a subject a compound comprising modifiedoligonucleotide having a nucleobase sequence at least 90% complementaryto the nucleobase sequence of miR-103 or miR-107, wherein the subject,prior to administration of the compound, was determined to have anincreased level of miR-103 or miR-107.
 141. The method of claim 140,wherein the subject has at least one metabolic disorder.
 142. The methodof claim 141, wherein at least one metabolic disorder is selected frompre-diabetes, diabetes, metabolic syndrome, obesity, diabeticdyslipidemia, hyperlipdemia, hypertension, hypertriglyceridemia,hyperfattyacidemia, hypercholesterolemia, and hyperinsulinemia.